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ABSTRACT 
XLαs is a NH2-terminal splice variant of the stimulatory G-protein α-
subunit Gsα. Both are encoded by the imprinted Gnas locus. Similar to Gsα, XLαs 
can couple 7-TM receptors to adenylate cyclase in cultured cells. Previously, a 
knock-out mouse specific for the Gnasxl transcript was generated (Gnasxlm+/p-) 
(PLAGGE et al. 2004). This mouse model exhibits a lean, hypermetabolic 
phenotype with elevated sympathetic nervous system (SNS) activity (XIE et al. 
2006). Changes in phenotype between neonatal and adult stages (e.g. mortality; 
failure to thrive as neonates vs. healthy but hypermetabolic adults) are not yet 
fully understood. More recently a conditional gene trap knock-out mouse line 
(XLlacZGT) was established. Immunohistochemistry, XGal and 
immunofluorescence data were collected to document the changes in 
expression pattern of XLαs and determine possible signalling pathways affected 
by lack of XLαs in the brain; histological analysis of the lacZ-containing genetrap 
line revealed new sites of XLαs expression.  
A comparison of neonatal and adult brain expression patterns revealed 
that the lateral hypothalamus (LH), dorsomedial hypothalamus (DMH), arcuate 
nucleus (Arc), locus coeruleus and ventrolateral medulla express XLαs in both 
stages; the laterodorsal tegmental nucleus, hypoglossal and facial nucleus 
(motor nuclei important for feeding) express XLαs only in neonates; and 
expression in the amygdala and preoptic area are only found in adult brain.  
Colocalisation studies in the brain for XLαs, neuropeptides and other 
markers related to regulation of food intake and energy expenditure. Orexin 
partly colocalised with XLαs in the LH and DMH (22% orexin neurons XLαs 
positive); tyrosine hydroxylase/dopaminergic neurons colocalised with XLαs in 
the Arc (60% TH neurons XLαs positive); and phosphorylated S6, a component 
of the leptin signalling pathway, colocalised with XLαs in the Arc (30% XLαs 
neurons pS6 positive). MCH and CRF did not colocalise with XLαs. Changes in 
pS6/S6K1 and the indicators of ghrelin signalling in knock-out Arc neurons did 
not reach statistical significance.  
Analysis of the lacZ-genetrap line at neonatal stages revealed that XLαs is 
also expressed in spinal cord and peripheral tissues e.g. skeletal muscle, tongue 
muscle and blood vessel smooth muscle cells. Expression in muscle tissues, 
including blood vessel smooth muscle cells is silenced in adults, but the spinal 
cord remains positive for XLαs. 
XLαs expression pattern changes in the brain and peripheral tissues 
concur with changes in phenotype seen between neonatal and adult mice. pS6 is 
a good indicator of S6K1 activity, which influences leptin and insulin signalling. 
A decrease of S6K1 activity in Gnasxlm+/p- mice might explain their leptin 
sensitivity (Frontera et al. in prep). XLαs colocalises with orexigenic peptides – 
including orexin and NPY/AgRP neurons (Frontera et al. in prep) – in the 
hypothalamus; however, the function of XLαs in energy expenditure and SNS 
activity remains elusive. 
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1.1. GENOMIC IMPRINTING 
1.1.1. WHAT IS GENOMIC IMPRINTING? 
Offspring inherit two copies of an allele, one from each parent, for any 
given gene. However, it has been established that the parental genomes do not 
always contribute equally to gene expression. Genomic imprinting is an 
epigenetic phenomenon that is defined as the parent-of-origin-specific silencing 
of an allele. It is the result of a complex interaction of mechanisms, which create 
control regions within a gene locus for the implementation of genomic 
imprinting (in specific ways for specific genes). This phenomenon has only been 
observed in eutherian/placental mammals, marsupials and plants.  
There are approximately 100 known imprinted genes in humans and 
mice (some conserved, others not) although there is now evidence to suggest 
there are many more than this that have yet to be described fully (GREGG et al. 
2010). These are located in imprinting regions throughout the genome, many in 
clusters (for example the Gnas locus), but others are single imprinted genes 
isolated from any other imprinted gene (Figure 1.1). Imprinted genes have a 
variety of functions (some examples are outlined in Table 1.1). A comprehensive 
database of known imprinted genes in mice has been compiled (WILLIAMSON et 
al. 2011). Many methods have been used to try and identify genomically 
imprinted genes within the mouse and human genomes, including genome-wide 
analyses and surveys as well as transcriptome sequencing (BABAK et al. 2008). 
There are a wide variety of imprinting effects that can occur if these imprinted 
genes are expressed incorrectly, these include behavioural abnormalities, 
growth defects and lethality (PETERS and BEECHEY 2004).  
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Figure 1.1. Imprinted genes in the Mouse Genome from Mouse Book 
From the MRC Harwell Mousebook (WILLIAMSON et al. 2011) 
A schematic of the mouse chromosomes that have imprinted genes, showing the maternally expressed 
genes (red), the paternally expressed genes (blue), the maternally expressed small nucleolar RNAs and 
microRNA gene (red dot) and paternally expressed nucleolar RNAs (blue dot).  
Yellow blocks indicate regions of abnormal imprinting phenotypes with maternal duplication or paternal 
duplication. 
This text box is where this thesis contained the following third party 
copyrighted material; 
 
Williamson CM, Blake A, Thomas S, Beechey CV, Hancock J, 
Cattanach BM, and Peters J (2012), MRC Harwell, Oxfordshire. 
World Wide Web Site - Mouse Imprinting Data and References – 
http://www.har.mrc.ac.uk/research/genomic_imprinting/ 
 
Composite map 
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Function Imprinted genes 
Transporters 
Slc22a2, Slc22a3, Slc38a4, Copg2, 
Tssc5, Obph1 
Ubiquitin- related pathways Ube3, Usp29 
Cell cycle control Zac1(Plagl1), Cdkn1c 
Transcription Zim1, Mash2 
G-Protein-coupled receptor 
signalling 
Gnas, Calcr, Htr2a 
Intracellular signalling cascades Asb4, Rasgrf1, Grb10, Gnas 
Creatine synthesis Gatm 
Pre- and post-natal growth and  
development development 
Ins1, Ins2, Igf 2, Igf 2r, Rasgrf1, 
Grb10,  Gnas 
Table 1.1. Some examples of imprinted genes and their functions (PETERS and BEECHEY 2004) 
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1.1.2. THE EVOLUTION OF GENOMIC IMPRINTING 
Imprinting makes genes more vulnerable to mutation. If a mutation occurs on 
the allele which is not silenced then the effects of the mutation will appear 
immediately, as there is no possibility of a compensatory effect from the 
parental allele which is silenced. There are several possible routes of evolution 
for genomic imprinting. One is the parental-conflict hypothesis (WILKINS and 
HAIG 2003). This theory for the evolution of genomic imprinting is based upon 
the idea that the paternal and maternal genomes each want different things for 
their potential offspring. The father’s genome wants to promote resource 
acquisition from the mother in embryonic/neonatal offspring carrying his 
alleles, while the maternal allele wants to limit the acquisition of a particular 
offspring so that the resources available to her can be distributed equally to all 
of her offspring (CHARALAMBOUS et al. 2007; CONSTANCIA et al. 2004). In some 
cases genes that are maternally imprinted promote the acquisition of resources 
(i.e. paternally expressed transcripts such as the Gnasxl transcript).  When these 
paternally expressed genes are disrupted they tend to result in adult 
phenotypes of hypermetabolism and leanness (XIE et al. 2006).  The opposite 
can also be true, maternal disruption of the paternally-imprinted genes can 
result in opposite phenotypes, producing offspring that are obese or overgrown 
(e.g. Grb10) in adulthood with reduced energy expenditure (CHEN et al. 2005; 
SMITH et al. 2007). However, not all imprinted genes fit this theory for example, 
there are maternally expressed genes that have a positive influence on nutrient 
acquisition while some imprinted genes do not affect postnatal growth.  
Transposable elements are segments of DNA which are mobile and use 
the cellular machinery to replicate (ZAMUDIO and BOURC'HIS 2010). 
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Approximately half of the genomes of mice and humans are made up of 
transposable elements. It is necessary to control these transposable elements at 
a transcriptional level in order for the mammalian genome to tolerate their 
presence. DNA methylation, a mechanism that controls gene expression, might 
have originally evolved at the promoters of transposable elements to silence 
their transcription (YODER et al. 1997).  If these transposable elements were 
inserted within or close to the promoters of genes they might have been 
affected by the silencing of the transposable element. It might then have been an 
advantage to maintain the silencing of the gene in order to control the 
expression level of that gene. 
Recent research has shown genomic imprinting in mice has a complex 
pattern (WOLF et al. 2008). The imprinting is not just on the maternal or 
paternal allele but can also manifest as partial imprinting, where the expression 
level of the gene is reduced on one allele but not completely removed. Genomic 
imprinting can also be tissue-specific with some genes expressing biallelically in 
some tissues while only expressing from a single allele in another tissue, for 
example Gnas (WILKINS and HAIG 2003). There is also evidence to suggest that 
many more genomically imprinted genes have yet to be discovered (WOLF et al. 
2008). 
1.1.3. EPIGENETIC CONTROL OF GENOMIC IMPRINTING 
There are several epigenetic modifications that can control genomic 
imprinting, such as DNA methylation, histone modification and siRNAs. DNA 
methylation in mammals is targeted to CpG dinucleotides. The group of 
enzymes called DNA methyltransferases (Dnmts) are responsible for the 
transfer of a methyl group onto the DNA. These enzymes are essential for 
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viability and fertility. There are several types of Dnmt: Dnmt1 is the most 
abundant in mammalian cells and is responsible for the maintenance of 
methylation after DNA replication. It has been found that homozygous deletion 
of Dmnt1 in mice results in embryonic lethality (LI et al. 1992). Dnmt3a and 
Dnmt3b work in conjunction to establish methylation patterns by de novo 
methylation. Knock-outs of these Dnmts result in male sterility and embryonic 
lethality.  
Dnmt3-like (Dnmt3L) cannot mediate methylation on its own, but is a co-
factor of Dnmt3a and is involved in de novo methylation. Dnmt3L is essential for 
maternal methylation establishment. Loss of Dnmt3L results in male sterility 
and biallelic expression of genes which are normally silenced on the maternal 
allele (ZAMUDIO and BOURC'HIS 2010).  
Imprinted genes contain differentially methylated regions of DNA 
(DMRs). These areas have DNA methylation, which differs between the maternal 
and paternal allele and results in silencing of the methylated allele.  Methylation 
is erased in the embryo then re-established in early development in the 
appropriate way for the sex of the offspring – this would be maintained 
throughout life (CONSTANCIA et al. 1998).  
DNA methylation occurs by the addition of a methyl group to the 5 
position on a cytosine residue. It is particularly prevalent in areas of DNA with a 
high cytosine guanine percentage (CpG islands). This is known as CpG 
methylation.  
Methylation can prevent the expression of a transcript, as in the Gnas 
locus, where areas of methylation silence the maternal or paternal allele 
(depending on the location of the methylation). The maternal allele is 
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methylated on the Gnasxl promoter, while Gnas imprinting is not caused by a 
DMR, but is possibly due to transcription of Gnas exon 1A blocking the 
transcription through the Gnas exon. It has been shown that disruption of Gnas 
exon 1A results in biallelic expression of Gsα in all tissues (Figure 1.2) 
(WILLIAMSON et al. 2004; WILLIAMSON et al. 2006). 
In pre-implantation embryos the parental methylation is almost 
completely erased in the somatic cells of the embryo, imprinted genes maintain 
their methylation (REIK 2007; REIK and WALTER 2001). The paternal genome is 
actively demethylated, while the maternal genome passively loses methylation. 
The passive loss of methylation occurs when Dnmt1 is excluded from the 
nucleus of the cell and so cannot maintain the methylation pattern on new 
strands of DNA created during replication (MERTINEIT et al. 1998).  
The imprint marks are erased in the primordial germ cells (PGCs) of the 
offspring and then re-established in the correct pattern for the sex of that 
offspring (ROSSANT 1993). The de-methylation of both male and female PGCs is 
completed by embryonic day (E) 14. Re-methylation begins at E16 in the male 
PGCs (BRANDEIS et al. 1993; KAFRI et al. 1992). For oocytes, their arrested 
development at E13.5 halts re-methylation, which is not restarted until after 
birth, during oocyte growth periods and when there is a high level of Dmnt 
available (MERTINEIT et al. 1998).  
Imprinted genes have, within their gene locus, control areas for the 
correct imprinting of a gene. Imprinting control regions (ICR) are areas along 
the locus which are important for correct DNA methylation. Nesp deletion in the 
Gnas locus results in a disruption of the ICR (CHOTALIA et al. 2009). There are 
also differentially methylated regions (DMRs) located on the loci. The Gnas locus  
    Chapter 1. Introduction 
28 
 
Figure 1.2. Schematic of the complex Gnas locus 
The Gnas locus is a complex imprinted locus on mouse chromosome 2. There are five main transcripts 
expressed from this locus (2 non-coding and 3 coding). From the main Gnas transcript the G-protein alpha 
subunit, Gsα, is produced. This protein is expressed biallelically in most tissues but is imprinted in some 
tissues, being expressed only from the maternal allele. The second transcript is derived from the Gnasxl 
exon 1, expression from this transcript is only from the paternal allele and can result in two proteins. The 
main protein is XLαs; this is an extra-large version of Gsα. This protein is identical to Gsα apart from the 
extra large first exon, splicing onto exons 2 through 12. The second protein expressed from this transcript 
is XLN1. This is a truncated form of XLαs, This protein splices onto exons 2, 3 then N1 which results in the 
truncation due to a stop codon in the N1 exon. It has been indicated that splicing can occur onto exon A20.   
The imprinting of the gene locus is controlled by imprinting control regions (indicated in purple). There 
are three imprinting control regions on the Gnas locus, two on the maternal allele across the Gnasxl 
promoter and a second across exon 1A. The third is expressed from the paternal allele across the Nesp 
exons. The DNA methylation in these regions prevents expression from the allele.  
Adapted from (PLAGGE et al. 2004) 
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has several DMRs. These are located at specific positions on the locus to achieve 
silencing of the appropriate allele (e.g. the Nespas DMR on the maternal allele; 
Gnas exon 1A on the maternal allele (Figure 1.2)).Methylation is essential for 
correct imprinting of genes but the way in which these imprinting methylation 
marks are established is not fully understood. There have been several 
suggestions for when the DMRs are established in offspring. The first is that the 
marks are erased in the offspring and re-established in accordance with the sex 
of the embryo (CONSTANCIA et al. 1998).  
DNA methylation is one of the mechanisms by which imprinting occurs, 
and these methylation marks can be used to identify imprinted genes. DMRs 
occur at specific sites on the genome and prevent transcription (PETERS and 
BEECHEY 2004) (Figure 1.2). There is evidence to show that transcription 
through the DMRs is essential for germ line methylation marks to be established 
(CHOTALIA et al. 2009). Another mechanism, known to have a role in the 
establishment of the imprinting marks of genes, is known as histone 
modification. This is likely to have an instructive role in the establishment of 
imprints (FERGUSON-SMITH 2011).  
1.1.4. FUNCTIONS OF IMPRINTED GENES. 
Many imprinted genes have been associated with embryonic 
development but more recent research has determined that some imprinted 
genes have a function in postnatal development (CHARALAMBOUS et al. 2007; 
CONSTANCIA et al. 2004; CURLEY et al. 2005; FRONTERA et al. 2008; GARFIELD et al. 
2011; KOZLOV et al. 2007; WILKINSON et al. 2007).  
Many of these imprinted genes continue to be expressed in adulthood –  
not only in the central nervous system (CNS) but also in peripheral tissues 
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associated with metabolism (CHARALAMBOUS et al. 2007; FRONTERA et al. 2008; 
WILKINSON et al. 2007).  
Dysfunctions of these imprinted genes can have serious implications 
resulting in abnormal development and usually severe phenotypes – many 
associated with embryonic lethality. There have been some disorders associated 
with imprinted genes in both mice and humans. Some of these include 
Beckwith-Wiedemann syndrome, Prader-Willi syndrome/Angelman syndrome 
and transient neonatal diabetes.  
1.1.5. DISORDERS INVOLVING IMPRINTED GENES 
Many human disorders occur as a result of genetic defects in imprinted 
genes. These include Beckwith-Wiedemann Syndrome (BWS), Prader-Willi 
syndrome (PWS), Angelman Syndrome (AS), and Albright’s Hereditary 
Osteodystrophy (AHO).  
PWS and AS are two rare genetic disorders associated with disruption of 
imprinted genes on human chromosome 15, in a 2 MB imprinted domain 
(LEDBETTER et al. 1981). Two of the imprinted genes in this cluster are magel2 
and Necdin.  PWS, associated with mutations in SNRPN, is defined by a 
phenotype of hypotonia, hypogonadism, hyperphagia (resulting in obesity), 
short stature and behavioural problems (psychosis, lying, stealing and 
aggressive behaviour) (CASSIDY et al. 1997). Neonates also exhibit difficulty 
feeding, defined as a failure to thrive in infancy (ROBERTSON 2005). PWS is 
commonly the result of a deletion of the SNRPN/SNURF first exon and promoter 
(ROBERTSON 2005). AS has a phenotype of mental retardation, speech 
impairment as well as behavioural abnormalities and is the result of the loss of 
maternally expressed UBE3A which is imprinted in the brain (ROBERTSON 2005). 
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Transient neonatal diabetes is associated with imprinted genes 
(PLAGL1/ZAC1 and HYMAI). These are located on human chromosome 6 
(ROBERTSON 2005). 
BWS is associated with disruption of human chromosome 11. It is known 
to affect growth. It has a phenotype of placental and embryonic overgrowth, 
macroglossia, examphalos, and a predisposition to childhood tumours. IGF2 and 
CDKN1C are the two imprinted genes associated with BWS, with the two main 
causes being uniparental disomy and point mutations. Over-expressing IGF2 is 
associated with overgrowth while the deficiency of CDKN1C is more likely to 
cause abdominal wall defects (WALTER and PAULSEN 2003). 
Neurological defects associated with imprinting disorders include those 
seen in AS (NICHOLLS 2000).  
Imprinting also has a role to play in early development of the embryo as 
well as other functions such as placental development (GEORGIADES et al. 2001). 
It has been suggested that genomic imprinting has a role to play in the social 
behaviour of mice in the bonding of the mother with her offspring, as well as 
influencing adult social interactions (ISLES et al. 2006). 
1.2. THE COMPLEX IMPRINTED GNAS LOCUS 
1.2.1. TRANSCRIPTS OF THE GNAS LOCUS 
The imprinted Gnas locus, located on mouse distal chromosome two, 
encodes five distinct transcripts: Gnas, Gnasxl, Gnas1A, Nespas and Nesp. These 
encode several proteins (Figure 1.2). The locus is highly conserved between the 
mouse and human genome, thus it is possible to study human disorders in GNAS 
with mouse models and several mouse models have been established to study 
the locus. 
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The Gnas transcript of the Gnas locus codes for the stimulatory alpha- 
subunit (Gsα) of the G-protein signalling complex. It is associated with the βγ 
subunit and can stimulate adenylyl cyclase (AC) to produce the second 
messenger cAMP (Figure 1.3). This transcript is biallelically expressed in most 
tissues (HAYWARD et al. 1998a; HAYWARD et al. 1998b). However, in some tissues 
(for example the renal proximal tubules, anterior pituitary, ovary, thyroid gland, 
and paraventricular nucleus of the hypothalamus) it is imprinted and expressed 
solely from the maternal allele (Figure 1.2) (CHEN et al. 2010; GERMAIN-LEE et al. 
2002; GERMAIN-LEE et al. 2005; HAYWARD et al. 2001; MANTOVANI et al. 2002). In 
adipose tissues there is evidence for transient imprinting of Gsα (CHEN et al. 
2010; CHOTALIA et al. 2009; WILLIAMSON et al. 2004). Homologous knock-out of 
Gsα is always embryonically lethal (CHEN et al. 2005; GERMAIN-LEE et al. 2005; YU 
et al. 1998). This is indicative of the importance of Gsα in development. XLαs, the 
protein derived from the Gnasxl exon, like other α-subunits, binds to the plasma 
membrane through post translational lipid modifications as well as binding to 
the G-protein βγ-complex (UGUR and JONES 2000). It has been located in cells 
with constitutive and regulated protein secretion pathways (KEHLENBACH et al. 
1994) and is also known to be a cholera toxin substrate (UGUR and JONES 2000).  
XLαs is identical to the Gsα protein except for its start exon where the 
Gnas exon 1 (47 amino acids) is replaced by the significantly larger Gnasxl exon 
(347 amino acids; Figure 1.4) (KEHLENBACH et al. 1994; LI et al. 2000) (Figure 
1.4). The expression of this protein has been shown to be restricted mainly to 
neuroendocrine tissues (KEHLENBACH et al. 1994; PASOLLI et al. 2000) with some 
expression in adipose tissue at neonatal day 4 (PLAGGE et al. 2004). Similarly to 
Gsα, in vitro studies have shown stimulation of AC, however, in vivo this has not  
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Figure 1.3. Stimulatory G-Protein Stimulation of cAMP 
(A) The inactive G-protein complex, with the alpha subunit (Gsα or XLαs) in its GDP bound conformation 
(B) When an agonist (Ag) binds to the G-protein coupled 7-transmembrane receptor (R) the GDP is 
replaced by a GTP. This leads to a conformational change and activation of the alpha subunit which 
dissociates from the beta/gamma subunit.  
(C) The GTP-bound alpha-subunit, now in its active form, can now interact with the adenylyl cyclase (AC) 
which increases the production of the second messenger cyclic AMP (cAMP).  
(D) Binding of GTPase activating proteins (GAP) stimulates the GTP hydrolysis activity of alpha-subunits. 
This results in the alpha-subunit becoming inactive and rebinding to the beta/gamma subunit. 
Adapted from (PLAGGE et al. 2008) 
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Figure 1.4. The protein domains encoded in the Gnasxl and Gnas first exons.  
The αs and βγ binding portion of the exons are conserved between the Gnas and Gnasxl first exons. This 
allows XLαs to perform the same signalling role as Gsα. The XL-domain is specific to the Gnasxl exon 1. 
This domain contains a cysteine rich region (C) and a proline rich region (P) (Pasolli 2000). 
 
This text box is where this thesis contained the following third party 
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been clearly established (BASTEPE et al. 2002; KLEMKE et al. 2000; XIE et al. 2006). 
1.2.2. KNOCK-OUT MOUSE LINES OF THE GNAS LOCUS 
Several knock-out mouse lines have been generated which result in the 
heterozygous removal of Gsα. The Gnas exon 2 knock-out line could disrupt 
either the maternal allele (E2m-/+) or the paternal allele (E2+/p-) (YU et al. 1998). 
It was discovered that the E2 mutation would disrupt the alternative transcripts 
of the locus, Gnasxl and Nesp, as well as Gsα. The E2+/p- mice have narrow bodies, 
increased glucose tolerance, increased insulin sensitivity, decreased body 
weight and decreased serum leptin as well as poor suckling ability and 
inactivity (YU et al. 1998). The E2m-/+ mice have wide bodies, subcutaneous 
oedema and increased body weight as well as neurological defects and 
resistance to parathyroid hormone (PTH) (YU et al. 1998). 
A second mouse line was developed, which disrupts the first exon of Gnas 
with either maternal (E1m-/+) or paternal (E1+/p-) transmission, each resulting in 
different phenotypes (CHEN et al. 2005). E1+/p- mice have a normal phenotype as 
opposed to the lean phenotype seen in both the E2+/p- and the XLαs specific 
knock-out mice (PLAGGE et al. 2004; YU et al. 1998).  
Maternal transmission of the E1 mutation resulted in mice with 
increased body weight and a significant increase in adipose tissue but no change 
in lean mass. They also showed no difference in food intake but had a small, 
significant decrease in metabolic rate (CHEN et al. 2005). The neonatal mice 
showed subcutaneous oedema and 50% lethality shortly after birth; adults are 
obese and insulin resistant (CHEN et al. 2005). E1+/p- showed an opposite 
phenotype to the E2 paternal disruption mice, suggesting the E2+/p- phenotype 
is due to the removal of XLαs, which shares exons 2 through 12 with Gsα.  
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A point mutation in exon 6 of the Gnas locus, converting a valine to a 
glutamine, resulted in the Oedematous-Small line (Oed-Sml); maternal 
transmission of this point mutation results in subcutaneous oedema and obesity 
in adulthood (Oed), while paternal transmission results in growth retardation 
(Sml) (CATTANACH et al. 2000; KELLY et al. 2009; SKINNER et al. 2002). The Oed  
phenotype mirrors the phenotype of the Gnas knock-out line while the Sml 
phenotype is the same as the Gnasxlm+/p- mice (CHEN et al. 2005; XIE et al. 2006). 
A paternal knock-out (Gnasxlm+/p-) of the Gnasxl exon 1 removed XLαs, 
Alex (a protein generated from an alternate open reading frame of the Gnasxl 
transcript)   and the truncated XLαs isoform, XLN1, which is missing much of the 
functional domain downstream of exon 3, as exon 4 is replaced by the N1 exon 
(PLAGGE et al. 2004) (Figure 1.1). Gnasxlm+/p- mice show several physiological 
differences to wild type mice. They exhibit reduced adiposity due to increased 
energy expenditure, increased metabolic rate with increased lipid metabolism 
in adipose tissue, as well as increased glucose tolerance and insulin sensitivity 
(XIE et al. 2006). Neonatal mice have difficulties suckling and inertia as well as 
severe lethality, however these are overcome in adult survivors (PLAGGE et al. 
2004; XIE et al. 2006). Brown adipose tissue has increased mitochondrial 
content in Gnasxlm+/p- (XIE et al. 2006). They are thought to be lean due to an 
increase in lipid mobilization and oxidation however there are some changes in 
expression of genes that regulate metabolism in other tissues, such as an 
increase of Glut4 in muscles which might contribute to the insulin sensitivity 
(XIE et al. 2006). There are several indicators that suggest XLαs is involved in 
sympathetic nervous system activity regulation including increased urine 
norepinephrine levels. In male mice there is an increase in urine epinephrine 
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suggesting an increase in activity of the adrenal medulla; there is also an 
increase in sympathetic nervous system (SNS) controlled gene expression in 
adipose tissue which would result in increased lipolysis (XIE et al. 2006). 
In adult Gnasxlm+/p- mice, there is an increase in energy expenditure 
(these mice eat more food per body weight than their wild type counterparts 
but remain lean) (XIE et al. 2006). They also exhibit hypoleptinaemia which 
contributes further to the idea of XLαs’ involvement in the SNS (XIE et al. 2006) 
along with the finding that XLαs is expressed in the sympathetic trunk of the 
central nervous system (PASOLLI and HUTTNER 2001; PLAGGE et al. 2004). The 
increased glucose tolerance and decreased insulin levels seen in Gnasxlm+/p- 
mice is not likely to be related to an impairment of the secretion of insulin by 
the β cells. This hypoleptinaemia is caused by the low lipid stores in white 
adipose tissue (WAT). Insulin sensitivity might be due to increased insulin 
clearance but this is quite likely a secondary effect to a decrease in tissue 
triglyceride content which is a result of chronically increased lipid oxidation and 
energy expenditure (CHEN et al. 2009a). There may also be a contribution to 
hypoleptinaemia from a decrease in the expression of hepatic lipogenic genes 
(XIE et al. 2006).  
The fact that Gsα-knock-out and XLαs-knock-out mice have opposite 
metabolic phenotypes (Gsα being obese and XLαs being lean) suggests that 
these two proteins, although almost identical, act in distinct pathways in the cell 
to control energy (XIE et al. 2006). There is a very specific distribution of XLαs 
expression in the postnatal brain tissue (PLAGGE et al. 2004). There has been 
little information collected about its distribution within the adult mouse brain. 
Changes in the expression pattern of XLαs/Gnasxl might account for the change 
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in phenotype from pre-weaning to post-weaning in Gnasxlm+/p- mice and this is 
currently under investigation. 
1.2.3. DISORDERS ASSOCIATED WITH THE GNAS LOCUS  
In humans, mutations of GNAS result in several severe phenotypes. The 
first is Albright hereditary osteodystrophy (AHO). This disorder is a result of 
mutations in Gnas that can be paternally or maternally inherited and result in a 
50% reduction in the expression of Gnas. The disorder exhibits as mental 
retardation and subcutaneous ossification. This subcutaneous ossification is 
also observed in mice (HUSO et al. 2011; SAKAMOTO et al. 2009). 
Maternal transmission of Gnas mutations results in AHO with the 
addition of hormonal resistance is several tissues, including the thyroid, kidney 
and gonads, as a result of the loss of imprinted Gnas. This is called pseudo-
hypoparathyroidism type-Ia (PHP-Ia). Hormone resistances include parathyroid 
hormone signalling in kidney and thyroid stimulating hormone (GERMAIN-LEE et 
al. 2002; LEVINE et al. 1983; WEINSTEIN et al. 2001). 
PHP-Ib is caused by the loss of the methylation on the maternal allele at 
exon 1A on the Gnas locus. This would silence the expression of Gsα in tissues 
that have monoallelic expression of Gsα. The phenotype associated with Gsα 
mutations is characterised by renal PTH resistance (JÜPPNER et al. 2006), a mild 
TSH resistance and in some cases AHO-like symptoms (LIU et al. 2003; 
MANTOVANI et al. 2007).  
1.3. CNS REGULATION OF ENERGY HOMEOSTASIS 
With several imprinted genes having an impact on neonatal feeding 
behaviours and being expressed in areas of the brain which control food intake 
regulation and energy expenditure, it is interesting to investigate the control of 
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energy homeostasis by these imprinted genes.  
One of the fastest growing medical problems in the western world is 
obesity. This is defined as a body mass index (BMI) above 30. Obesity is 
associated with many other health problems, being a predicting factor for 
diseases such as type 2 diabetes mellitus and heart disease. To tackle the 
growing number of overweight individuals it is important to understand how 
energy homeostasis is controlled. It is well established that having a higher 
calorific intake than energy expenditure is how people become overweight. 
Having a clear picture of how the body processes nutrient signals and how they 
might be manipulated to manage weight is currently an important area of 
research. 
Energy homeostasis is a finely tuned balance of many complex and 
interacting signalling pathways. To maintain this homeostasis, energy 
expenditure and food intake must be balanced to avoid a negative energy 
balance (i.e. decreased calorific intake compared to the calories burned) 
resulting in body weight loss, or – perhaps more importantly for medical 
researchers today – a positive energy balance (i.e. increased calorific intake 
compared to energy burned) resulting in body weight gain and, if left 
unchecked, obesity. Although many pathways have been established as having a 
role in energy homeostasis, the exact mechanisms and functions of each in these 
complex and interacting pathways have yet to be clarified.  
Many of the pathways that control energy balance involve neuropeptides 
in the brain that are activated by nutrient signalling from the gut via nerves 
such as the vagus. One of the best-known regulators of energy metabolism is 
leptin signalling. This will be discussed further in Chapter 7. 
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1.4. AIMS OF THE PHD 
This project set out to investigate several aspects of Gnasxl expression 
patterns.  
Firstly, to establish a suitable position for placement of a gene trap into 
the intron, after the Gnasxl exon 1, splice variants of Gnasxl-derived proteins 
were analysed.  
Secondly, to investigate the possible causes of a phenotypic change from 
neonatal to adult phases of development, the expression pattern of XLαs was 
analysed in the brain of neonatal mice and compared to the expression pattern 
of XLαs in adult mouse brain. This analysis of XLαs expression pattern was 
continued in peripheral tissues of neonatal and adult mice.  
Finally, the project addressed the significance of XLαs in signalling 
pathways and the importance of XLαs removal. This was investigated through 
colocalisation studies and immunoblotting.  
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CHAPTER 2. MATERIALS AND METHODS 
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2.1. CHEMICALS AND REAGENTS 
CD1 (wild type mice) were obtained from Charles River, UK. 
Electrophoresis grade reagents for PAGE gels and Western blotting were 
purchased from National Diagnostics except the broad-spectrum protein ladder, 
which was purchased from Fermentas. For histology, normal donkey serum was 
obtained from Sigma or Vector Laboratories. Vectastain Elite kits, normal goat 
serum and normal rabbit serum were purchased from Vector Laboratories. 
Histoclear was obtained from National Diagnostics and the TritonX100 and 
Eukitt hard-mounting medium were from Fluka. From Sigma was purchased 
PFA, PBS tablets, Tris, sucrose, sodium citrate and DAB tablets. From Thermo 
Scientific were obtained the Superfrost and Polylysine slides and the Shandon 
Cyromatrix. Fluorogel mounting medium was purchased from Electron 
Microscopy Sciences. For Western blotting, Pierce  BCA protein assay kits, 
Amersham ECL Plus Western blotting detection system and Amersham Hybond-
P PVDF membrane were purchased from GE Healthcare (through Thermo 
Scientific). The PhosSTOP phosphatase inhibitor tablets were purchased from 
Roche. Protease inhibitors, PMSF, Kodak fixative and developer solutions as well 
as Kodak X-Ray film were provided by Sigma. Reagents for PCR reactions were 
obtained from Qiagen (HotStar Taq) or Promega (Go Taq Hotstart Polymerase). 
TOPO cloning kits were bought from Invitrogen along with the Alexa 
Fluorophore- (AF-) conjugated secondary antibodies. Restriction enzymes were 
purchased from Promega, Fermentas and New England Biolabs. For Southern 
blotting and in situ hybridisation DNA and RNA probe labelling kits were 
obtained from Roche, along with blocking reagent and the alkaline phosphatase-
conjugated anti-DIG-Fab fragments. The ProbeQuant G-50 Sephadex columns 
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and Amersham Hybond N+ nylon membrane were obtained from GE Healthcare.  
DEPC, single stranded DNA from salmon testes, phenol: chloroform: isoamyl 
(25:24:1), chloroform: isoamyl (24:1), agarose, LB broth, ampicillin, agar, 
Tween20, NBT and BCIP were all purchased from Sigma. The DNA extraction kit 
was bought from Geneflow. The 1 kb DNA ladder was obtained from New 
England Biolabs. Antibodies were purchased from Santa Cruz, Jackson 
ImmunoResearch Laboratories, Abcam, Cappel, Cell Signalling Technology, 
Invitrogen, Millipore, Lifespan Biosciences, Acris Antibodies and Alpha 
Diagnostics. 
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2.2. BUFFERS AND SOLUTIONS 
2.2.1 TISSUE COLLECTION 
Fixative stock. 4 % (w/v) paraformaldehyde (PFA); 1 x PBS. This was heated to 
50°C for up to 1 hour until dissolved then aliquoted into 50 mL tubes and stored 
at -20°C. 
2.2.2. HISTOLOGY 
Cryoprotectant Sucrose. 30% (w/v) sucrose; 1 x PBS. Sterile filtered and stored 
at 4 C. 
10x Tris-Buffered Saline (TBS). 100 mM Tris-HCl, pH7.5; 150 mM NaCl. This 
solution was diluted to 1 x concentration with ddH2O for washing steps. To 
make Tween TBS (TTBS), 0.1% (v/v) Tween20 (Sigma) was added to 1 x 
dilution of TBS stock. This solution can be stored at room temperature.  
10x PBS stock.  50 PBS tablets (Sigma) were dissolved in 1 L of ddH2O and then 
autoclaved. This gave the following concentrations of the tablet components: 0.1 
M phosphate buffer; 2.7 mM KCl2; 1.37 M NaCl. This stock was diluted with 
ddH2O to 1 x concentration for washing and antibody solutions. For Tween PBS 
(TPBS) 0.1% (v/v) Tween20 was added to 1 x dilution of the stock. This solution 
can be stored at room temperature.  
1 M Sodium Citrate for Antigen Retrieval. 147.1 g sodium citrate was diluted 
in 0.5 L ddH2O. This was diluted to 10 mM for antigen retrieval protocols. 
DAB Colour Substrate. 1 DAB tablet (Sigma) was dissolved in 15 mL 1 x PBS. 
This was sterile filtered and stored as 500 µL aliquots at -20°C. Before use 
aliquots were thawed (one aliquot per slide) and 1.67 µL 30% H2O2 (Final 
concentration 0.1% (v/v)) was added. This produces a brown colour substrate; 
to change the colour of the precipitate metal salts can be added (nickel 
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chloride). 
50% Nickel Chloride. 50% (w/v) nickel chloride was dissolved in ddH2O. Long 
term storage was at -20°C but it was stored at room temperature for shorter 
periods. This solution was added in a 1:100 dilution to thawed DAB aliquots. 
This produces a black/purple colour precipitate. 
Vectastain Elite ABC Solution. 2% (v/v) solution A; 2% (v/v) solution B; PBS. 
500 μL was prepared per slide to be stained (i.e. 10 μL A; 10 μL B; 480 μL PBS) 
Normal Serum for Blocking. 10% (v/v) normal serum (donkey, rabbit or goat; 
Sigma or Vector Laboritories); 1 x PBS. 
Antibody Dilution Solution. 10 % (v/v) normal serum (donkey, rabbit or goat); 
0.25% (v/v) TritonX100; 1 x PBS 
ISH Blocking Solution. 1 x PBS; 20% (v/v) sheep serum (Sigma); 5% (w/v) milk 
powder; 0.05% (v/v) Tween20. 
Cryoprotectant. 50 mM phosphate buffer; 30% (w/v) sucrose; 1% (w/v) 
polyvinylpyrolidone; 30% (v/v) ethylene glycol; ddH2O 
XGal Solution for Detection of lacZ in Tissues. 0.1 % (v/v) XGal; 2 mM MgCl2; 
0.01% (v/v) Na-deoxycholate; 0.02 % (v/v) NP-40; 5 mM potassium ferric 
cyanide; 5 mM potassium ferrous cyanide; 0.02 M NaH2PO4; 0.08 M Na2HPO4; 
H2O. Potassium ferrous cyanide and potassium ferric cyanide were made up as 
fresh stocks before the XGal solution was prepared. The final XGal solution was 
pre-warmed to 37 C before applying to tissues. 
0.1 M Phosphate Buffer. 0.02 M NaH2PO4; 0.08 M Na2HPO4 
2.2.3. PAGE GELS 
RIPA Lysis Buffer. 25 mM NaPO4, pH 7.5; 25 mM NaF; 25 mM β-
Glycerolphosphate; 100 mM NaCl; 5 mM EGTA; 0.5 % (w/v) Deoxycholate; 0.5 
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% (w/v) NP-40 (Igepal CA 630); 0.1 % (w/v) SDS; 0.01 % (w/v) Sodium azide. 
This solution was stored at 4 C. Before use in lysates PMSF (1:1000), protease 
inhibitors (1:100) and phosphatase inhibitors (1:10) were added to the 
required amount of RIPA lysis buffer.  
20 % SDS stock. 20 % SDS (w/v); ddH20 
PMSF stock. Final concentration of 0.5 M PMSF dissolved in DMSO. This was 
used at 1:1000 (0.5 mM) in protein lysates and stored at 4°C for up to 1 month. 
Protease Inhibitor Stock. 104 mM 4-2-(aminoethyl)benzenesulphonyl fluoride; 
80 μM aprotinin; 4 mM bestatin; 1.4 mM E-64; 2 mM leupeptin; 1.5 mM 
pepstatin A in DMSO. To be used at 1:100 dilution 
Phosphatase Inhibitor Stock (PhosSTOP). 1 PhosSTOP tablet (Roche) 
dissolved into 1 mL ddH2O. This was used at a 1:10 dilution in protein lysates. 1 
PhosSTOP tablet contains 5.6 % sodium molybdate; 3.7 % Sodium 
orthovanadate; 0.4 % catheridine. 
10% APS (10 mL). 1 g APS dissolved in 10 mL ddH2O. This was stored as 500 μL 
aliquots, after thawing it was stored on ice while making PAGE gels and 
discarded at the end of the experiment.  
5 x SDS-PAGE Electrophoresis buffer. 125 mM Tris base; 1.25 M Glycine; 0.5% 
SDS (w/v). 
2x Laemmli buffer for SDS-PAGE gels. 100 mM Tris-HCl, pH 6.8; 20 % (v/v) 
glycerol; 4 % SDS (w/v); 200 mM DTT; 0.2% (w/v) bromphenol blue.  
Transfer buffer. 25 mM Tris, pH 8.3; 192 mM Glycine; 20% (v/v) MeOH. This 
solution was pre-cooled to 4°C for several hours before use in transfers. 
Stripping buffer. 100 mM -mercaptoethanol; 2 % (w/v) SDS; 62.5 mM Tris-
HCl pH 6.7. 
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10% Resolving Gel. 10 % (v/v) Accugel (30% stock; 29:1 
Acrylamide:Bisacrylamide); 390 mM 1 M Tris-HCl, pH 8.8; 0.1 % (w/v) SDS. For 
polymerisation of the gel to occur 0.1 % APS and 0.04 % TEMED are added to 
the mixture. For native-PAGE gels SDS was omitted from the recipe and 
replaced with ddH2O. 
Stacking Gel. 5 % Accugel (30 % stock; 29:1 Acrylamide:Bisacrylamide);  100 
mM Tris-HCl, pH 6.8; 0.1 % SDS. For polymerisation of the gel to occur 0.1 % 
(v/v) APS and 0.1 % (v/v) TEMED are added to the mixture. For native-PAGE 
gels SDS was omitted from the recipe and replaced with ddH2O. 
Ponceau S Staining Solution (1 L): 10 g Ponceau S; 30 g Trichloroacetic acid; 1 
L ddH2O.  
Developer Solution (1 L). 218 mL Kodak developer solution (Sigma) made up to 
1 L with ddH2O. This solution was kept in the dark to avoid degradation. 
Fixative Solution (1 L). ). 218 mL Kodak fixative solution (Sigma) made up to 1 
L with ddH2O. This solution was kept in the dark to avoid degradation. 
2.2.4. SOUTHERN BLOTTING AND IN SITU HYBRIDISATION 
Hybridisation Buffer for Southern Blotting and in situ hybridisation. 5 x SSC; 
1 x blocking reagent; 0.1 % (w/v) N-Lauroylsarcosine; 0.02 % (w/v) SDS. This 
solution was stored at -20 C. Salmon sperm DNA may be added to reduce 
background staining from probes.  
10x blocking reagent. 5 g blocking reagent (Roche). made to 50 mL with DIG 
buffer 1. This stock was stored at -20 C.  
DIG synthesis mix stock. 2mM dATP; 2mM dCTP; 2mM dGTP; 1.3 mM dTTP; 0.7 
mM DIG-11-dUTP, alkali-labile; pH 7.0 
NBT stock sol. 75 mg/mL in 70 % Dimethylformamide. This was aliquoted into 
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1 ml tubes and kept at -20°C. For colour reaction 45 μL NBT was added per 10 
mL DIG buffer 3. 
BCIP stock sol. 50 mg/ml in 70% Dimethylformamide. This was aliquoted into 1 
ml tubes and kept at -20°C. For colour reactions 35 μL BCIP was added per 10 
mL DIG buffer 3. 
0.25 M HCl Solution for Gel preparation before Southern Blotting (2 L). 42 
mL 37 % HCl; ddH2O 
Neutral solution for Gel preperation before Southern Blotting (2 L). 1 M 
ammonium acetate in ddH2O [154 g NH4COOH; ddH2O].  
Denaturing Solution for Gel preperation before Southern Blotting (2L). 0.5 M 
NaOH; 1.5 M NaCl in ddH2O [40 g NaOH; 175.3 g NaCl; ddH2O] 
DIG Buffer 1. 0.1 M Maleic acid; 0.15 M NaCl; pH 7.5. This solution was 
dissolved on a hot plate and autoclaved before use. 
DIG Buffer 3. 0.1 M Tris-HCl, pH 9.5; 0.1 M NaCl; 0.05 M MgCl2 
2.2.5. ELECTROPHORESIS 
TAE (50x) buffer for Gel Electrophoresis. 2 M Tris base; 1 M acetic acid; 50 mM 
EDTA, pH 8.0. Diluted to 1 x for gel electrophoresis and agarose gel preparation.  
Agarose gel preparation. 0.8, 1.2 or 2% gels were prepared by dissolving the 
appropriate percentage w/v agarose into the required volume of 1x TAE for the 
size of gel needed (50 mL, 100 mL or 200 mL). This mixture was heated in the 
microwave until all the agarose had dissolved. 1 μL ethidium bromide per 50 
mL of agarose gel was added and the gel was poured into a gel tray to set.  
2.2.6. CLONING 
Luria-Bertani (LB) medium. 1 % (w/v) Tryptone; 0.5 % (w/v) Yeast extract; 1 
% (w/v) NaCl. The solution was autoclaved and cooled to 55 C and 50 g/mL 
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ampicillin was added. This was stored at 4 C.  
LB Agar Plates. Prepared as for LB medium but 15 g/L agar was added before 
autoclaving. After cooling to 55 C, 50 μg/mL ampicillin was added and the 
LB/agar mix poured into 10 cm plates. These were allowed to air dry and then 
stored at 4 C. 
TE buffer. 10 mM Tris, pH 8.0; 1 mM EDTA 
TENS buffer. 10 mM Tris, pH 8.0; 1 mM EDTA; 0.1 M NaOH; 0.5% (w/v) SDS. 
S.O.C. medium. 2 % (w/v) Tryptone; 0.5 % (w/v) Yeast extract; 10 mM NaCl; 
2.5 mM KCl; 10 mM MgCl2: 10 mM MgSO4; 20 mM glucose 
1x TAE buffer for gel electrophoresis. 40 mM Tris; 20 mM acetic acid; 1 mM 
EDTA.  
Tail Lysis Buffer. 100 mM Tris; 5 mM EDTA; 200 mM NaCl; 0.2 % (w/v) SDS. 
dNTPs. 2 mM dATP, 2 mM dTTP, 2 mM dGTP, 2 mM dCTP. 
Ampicillin Stock. 50 mg/ml ampicillin. This was used at a 1:1000 dilution. 
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2.3. MICE 
Mice carrying the global Gnasxl mutation (strain: XL3G5) (PLAGGE et al. 
2004) were maintained on a CD1 out-bred genetic background (Charles River, 
UK) via crosses of female mutation carriers to wild type males, resulting in 
phenotypically normal Gnasxlm-/p+ offspring. For analysis of the Gnasxl-deficient 
phenotype, male mutation carriers were crossed with wild type CD1 females, 
resulting in Gnasxlm+/p- offspring. 
The conditional gene trap line – XLlacZGT – was generated in the 
University of Liverpool Transgenic Unit. Founder chimera mice were bred to 
Flpe-transgenic mice (RODRIGUEZ et al. 2000) to remove the frt-flanked 
neomycinr-cassette, which can cause unexpected disruption of transcripts. In 
following generations, XLlacZGT female mice were crossed with CD1-
background males to maintain the line with loss of the Flpe-transgene. The 
XLlacZGT line has a mixed background of 129/C57BL/6J/CD1. Cre crosses were 
carried out with Nestin-Cre (TRONCHE et al. 1999) and CMV-Cre (SCHWENK et al. 
1995) females and XLlacZGT males to generate mice lacking Gnasxl in specific or 
all tissues, respectively.  
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CHAPTER 3. ANALYSIS OF EXON A20 SPLICING IN 
PROTEINS DERIVED FROM THE GNASXL TRANSCRIPT: 
XLΑS VS.XLN1 
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3.1. INTRODUCTION 
3.1.1. ALTERNATIVE SPLICING IN GNASXL: XLN1, EXON A20 AND EXON 3 
XLN1 is a truncated form of the paternally expressed, extra-large variant 
of the stimulatory G-protein-signalling alpha subunit XLαs (Figure 1.2). This 
protein is found in neural tissue, expressed mainly in the brain stem and the 
hypothalamic area; it is also found in the pituitary and adrenal medulla, and is 
formed of the Gnasxl domain, the shared Gnas exons 2 and 3 and the XLN1-
specific exon N1 (CRAWFORD et al. 1993; PASOLLI et al. 2000);  splicing onto exon 
N1 results in a premature stop codon. The mRNA produced has a 
polyadenylated (poly A) tail that results in the termination of transcription; thus 
it does not splice onto the functional exons 4 through 12 (CRAWFORD et al. 1993). 
XLN1 protein has no known function, and as it lacks the functional exons of the 
full-length XLαs protein, a function seems unlikely. It might, however, be the 
case that the protein acts as an antagonist to Gsα and/or XLαs by preventing or 
limiting binding to receptors thus interfering with the signalling of the full-
length functional proteins. XLαs/XLN1 has been detected in the rat embryonic 
brain from embryonic day 10 onwards (PASOLLI and HUTTNER 2001). In rat brain, 
XLN1 has been detected as a proportion of protein detectable from the Gnasxl 
transcript by an antibody that is specific for the N-terminal region of the full-
length XLαs protein that is determined by Gnasxl exon 1 (PASOLLI and HUTTNER 
2001; PASOLLI et al. 2000).  It has also been observed that Gnasxl exon 1 can 
splice directly onto Gnasxl exon A20 – a small 95 bp exon downstream of the 
large Gnasxl exon 1 – in humans and in mice (Figure 1.2); however, there has 
not been a systematic or quantitative analysis of splicing onto exon A20 in 
either species (HAYWARD et al. 1998a; HOLMES et al. 2003).  
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It has been shown that there is alternative splicing of the 45 bp exon 3 in 
the full-length Gsα protein (KOZASA et al. 1988). This alternative splicing does 
not affect functionality of Gsα (LEVIS and BOURNE 1992; MATTERA et al. 1989).  
This would also apply to any other transcripts splicing onto exons 2 through 12 
in the same manner as Gs , including XLαs and Nesp.  
3.1.2. AIMS 
The aim of this work was to carry out a systematic analysis of exon A20 
splicing in the mouse to determine when it is included in splicing (XLN1 and/or 
the full-length XLαs), and what this might mean in terms of protein composition, 
as previous data collected from humans discovered a frame-shift when exon 
A20 was included in these proteins (HAYWARD et al. 1998a). 
If the inclusion of exon A20 into a protein results in a frame-shift, and 
probable non-functionality of the protein, it was thought this might be an 
interesting area to insert a gene trap cassette to establish an XLαs conditional 
knock-out mouse line.  The localisation of an exon, which results in splicing in 
the endogenous locus in this region of the Gnas locus and in a non-functional 
protein, is an interesting possibility for insertion of the conditional gene trap 
cassette. Placing the gene trap in a similar position would eliminate the 
uncertainty of splicing ability that would be associated with inserting the gene 
trap further into the intron. The fact that the protein produced from this splicing 
would appear to be non-functional is important, as the removal of the A20 exon 
should not produce a phenotype. 
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3.2. MATERIALS AND METHODS 
3.2.1. TISSUE COLLECTION 
Wild type mice were killed by Schedule One procedure and relevant 
tissues were quickly removed and frozen down on dry ice. Hypothalami were 
separated from the rest of the brain tissue by dissection for analysis of this 
brain region. It is particularly important the tissues are frozen down 
immediately to maintain RNA integrity. Tissues were stored at -80°C and used 
for RNA extraction. 
3.2.2. RNA EXTRACTION 
RNA was extracted from 40 mg hypothalamic tissue samples using the 
Stratagene RNA extraction kit following the protocol for tissue extraction. This 
included homogenization of tissue samples with 600 µL lysis buffer containing 
4.2 µL β-Mercaptoethanol. Homogenate was added, 700 μL at a time, to a pre-
filter spin-cup in a 2 mL receptacle tube and centrifuged for 5 minutes. The 
filtrate was added to an equal volume of 70% EtOH and mixed thoroughly. From 
the filtrate/EtOH mixture, 700 µL was transferred to an RNA-binding spin-cup 
and centrifuged for 1 minute, the filtrate was discarded and the rest of the 
mixture added to the spin-cup and centrifuged for 1 minute.  
If RT-PCR was to be performed on the RNA extracts, 600 µL 1 x low salt 
buffer was added to the spin-cup and centrifuged for 1 minute. The cup was 
retained and replaced in the receptacle tube (the filtrate was discarded), 50 µL 
RNAse-free DNAse digestion buffer and 5 µL reconstituted RNAse-free DNAse I 
was pipetted onto the fibre matrix and incubated for 15 minutes at 37°C. 600 µL 
1 x high salt wash buffer was added to the spin-cup and centrifuged for 1 
minute. The filtrate was discarded and the spin-cup replaced in the receptacle 
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tube. 600 µL 1 x low salt wash buffer was added and the tube centrifuged for 1 
minute. Again the spin-cup was retained and the filtrate discarded. 300 µL 1 x 
low salt buffer was added and the tube centrifuged for 2 minutes. The spin-cup 
was transferred to a fresh 1.5 mL tube and 30 µL elution buffer was added to 
the fibre matrix of the spin-cup, incubated for 2 minutes at room temperature 
and centrifuged for 1 minute. The elution step was repeated, giving a final 
volume of 60 μL eluate. These RNA extracts were stored at -80°C.  
3.2.3. REVERSE TRANSCRIPTION-PCR (RT-PCR) 
For each sample 1 μg total RNA was required. Hexamer stock (0.6 μL of a 
500 ng/μL) was added and the volume made up to 13.7 μL with RNAse-free 
water. This was incubated at 65°C for 5 minutes then cooled slowly to room 
temperature (20°C). To each reaction 2 μL 10x AffinityScript™ RT buffer; 2 μL 
100 mM DTT; 0.8 μL 10 mM dNTP mix; 0.5 μL RNAse inhibitor (20U); and 1 μL 
AffinityScript™ Multiple Temperature Reverse Transcriptase (Stratagene) were 
added. The reaction was mixed gently, incubated at 25°C for 10 minutes; 42°C 
for 1 hour; 70°C for 15 minutes and cooled to 37°C. 1 μL RNAseH was added and 
the reactions were incubated at 37°C for 20 minutes. The cDNA obtained was 
stored at -20°C. 
PCR reactions consisted of 1 µL cDNA, 22 µL ddH2O, 3 µL PCR buffer, 3 µL 
dNTPs, 0.5 µL forward primer, 0.5 µL reverse primer and 0.25 µL Taq 
polymerase. PCR reactions were run on the following thermocycler programme: 
heated lid at 111°C, 15 minute denaturation at 95°C, this was followed by 30 
cycles of 45 seconds at 95°C (denaturation), 45 seconds at 56°C (annealing) and 
1 minute at 72°C (extension). PCR products were stored at 4°C until required. 
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3.2.4. LIGATION AND CLONING INTO COMPETENT E. COLI 
Equimolar amounts of supercoiled, uncut plasmid (~50 ng) and PCR 
products were used in a total volume of 25 μL along with 12.5 μL H2O; 1 x 
Ligation buffer; 0.2 mM dNTP, 1U SmaI restriction enzyme; 1 U T4 DNA 
Polymerase; and 3U T4 DNA ligase. This was left at room temperature 
overnight. One third of the reaction was transformed into competent E. coli 
(Strain: DH5 ). Bacteria were grown on LB + Ampicillin (Amp) plates at 37 C 
overnight. 
3.2.5. CLONING OF PCR PRODUCTS USING THE TOPO TA CLONING® KIT 
(INVITROGEN)  
A TOPO TA Cloning  kit was used to clone PCR products into competent 
bacterial cells.  Two LB + Amp plates per cloning reaction to be performed were 
pre-warmed to 37 °C. 4 μL amplified PCR product to be cloned into bacteria was 
added to 1 μL salt solution (1.2 M NaCl; 0.06 M MgCl2) and 1 μL 10 ng/μL pCR  
2.1-TOPO vector and incubated at room temperature for 5 minutes. To 
transform the vector into bacterial cells, 2 μL of the TOPO TA cloning ® reaction 
mixture was added to one vial of thawed, one-shot TOP10 cells and incubated 
on ice for 30 minutes. The TOP10 cells were then heat-shocked for 30 seconds 
at 42°C and immediately placed on ice. 250 μL SOC medium was added to the 
TOP10 cells in a mini-culture tube. This was left at 37 C for 1 hour with 
constant agitation. These were then plated out in 50 μL and 200 μL aliquots 
onto the pre-warmed LB + Amp plates and incubated at 37 C overnight.  
3.2.6. PREPARATION OF BACTERIAL MINI-CULTURES 
 Individual colonies were selected from cloning experiment LB + Amp 
plates and grown overnight in individual mini-culture tubes containing 2 mL LB 
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+ Amp broth at 37 C with constant agitation. After overnight incubation these 
were stored at 4 C and could be used to re-grow colonies of interest if 
necessary. 
3.2.7. TENS MINI-PREP FOR EXTRACTION OF DNA FROM BACTERIAL MINI-
CULTURES 
Overnight bacterial mini-cultures were tipped into 1.5 mL tubes and 
spun in the centrifuge for 30 seconds at full speed. The supernatant was 
discarded, leaving a small amount (~50 μL) in the centrifuge tube for 
resuspension of the pellet. 300 μL of TENS buffer was added to lyse cells. 
Samples were placed on ice for 5 minutes. 150 μL of 3 M sodium acetate, pH 5.0, 
was added and mixed immediately by inverting. The samples were returned to 
ice for 5 minutes then centrifuged at maximum speed for 5 minutes. The 
supernatant was transferred to a separate tube containing 900 μL 100% EtOH, 
mixed and placed at -20°C for 30 minutes. Samples were spun for 5 minutes and 
the supernatant was removed. Pellets were washed twice with 700 μL 70% 
EtOH with a 1 minute spin. The EtOH was removed and the pellets allowed to 
dry for 10 minutes at 37°C then resuspended in 30 μL 1 x TE + RNAseA. These 
were stored at 4°C. 
3.2.8. DETERMINATION OF COLONIES CONTAINING PCR PRODUCT INSERTIONS BY 
ETBR AGAROSE GEL ELECTROPHORESIS 
Mini-prep DNA was digested using restriction enzymes to cut out the 
PCR product insert; 5 μL digested mini-prep DNA was run on 2% agarose gels 
containing EtBr. Colonies that were deemed to contain fragments of interesting 
size after visualisation on the gel doc were sent for sequencing by DBS 
Genomics (University of Durham). Sequences were returned and compared to 
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the full-length sequence to determine exon splicing of the fragment using NCBI 
BLAST.  
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3.3. RESULTS 
3.3.1. ANALYSIS OF ALTERNATIVE SPLICING OF GNASXL EXON A20 IN FULL-
LENGTH XLΑS AND XLN1 PROTEIN 
Using RT-PCR the splice variants of each of the different cDNA variations 
produced from the Gnasxl exon 1 were analysed. Alternative splicing of Gnas 
exon 3 is known to exist in the Gsα protein (KOZASA et al. 1988). This was taken 
into account when the splice variants were being analysed as alternative 
splicing of exon 3 would result in products differing in size by 45 bp, therefore 
at least two products were expected for each primer combination to be used. 
Unique sequences were selected as primers: a single forward primer for the 
Gnasxl domain (XL-FL1) was designed along with reverse primers for exon N1 
(XLN1-R6) showing splicing in XLN1 protein and, as a positive control for full-
length XLαs, a reverse primer for exon 5 (Exon5-R1) (Appendix Table 1). These 
pairings were expected to result in markedly different fragment sizes of 357 bp 
and 312 bp for the XL-FL1/XLN1-R6 combination and 468 bp and 423 bp for the 
XL-FL1/Exon5-R1 combination resulting from the alternative splicing of exon 3 
(Figure 3.1 A; Table 3.1). This would allow the use of both reverse primers in 
the same PCR with the XL-FL1 forward primer. However, test PCRs for the 
individual reverse primers with the XLαs-specific forward primer resulted in 
exon N1 fragments which were larger than expected but distinguishable from 
the exon 5 control pairing (Figure 3.1 B and 3.2 A; Table 3.1).  
To establish the cause of these larger than expected fragments, PCR was 
performed using the XLN1-R6 and Exon5-R1 reverse primers with the XL-FL1 
forward primer as before. The separate bands for each combination were cut 
out of 2% agarose gels and the PCR product extracted. The extracted products
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Figure 3.1. PCR products expected and observed in PCR for alternative splicing in XLN1 protein.  
(A) Schematic of expected alternative splicing of exon 3 using Gnasxl-specific forward primer (XL-FL1) in 
PCRs with reverse primers for exon N1 (N1-R6) and exon 5 (Exon5-R1).  
(B) Schematic of observed fragments for alternative splicing of exon A20 and exon 3 in XLN1 and XLαs full 
length respectively. There was no alternative splicing of exon 3 in XLN1 protein but this was replaced with 
alternative splicing of A20. In full-length XLαs protein there was only alternative splicing of exon3. 
(C) Fragments expected from A20 (A20-F1) and Nesp2 (Nesp2-F1) forward primers. These were used to 
assess the splicing of A20 in full-length XLαs and Nesp.  
Arrows indicate location of primers. 
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Table 3.1. Expected and observed fragments for alternative splicing of Gnasxl Exon A20 and Gnas 
Exon 3.  
Values indicate the size of a PCR product containing the exons on the left (A20 or exon3) when the PCR 
primer pairings along the top are used. 
U – unexpected; O – observed; E – expected; N – not observed. 
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Figure 3.2. PCR of cDNA from hypothalamic lysates revealed unexpected alternative splicing of 
Gnasxl exon A20.  
(A) PCR using XLN1 (XLN1-R6) and Exon 5 (Exon5-R1) reverse primers with the Gnasxl exon 1 (XL-FL1) 
forward primer resulted in PCR products of unexpectedly similar size.  
(B) RT-PCR products showing alternative splicing of exon A20 in the XLN1 transcript but not in the full-
length XLαs or Nesp proteins using forward primers for Gnasxl (XL-FL1), Nesp exon 2 (Nesp 2-F1) and 
exon A20 (A20-F1) in combination with reverse primers for XLN1 (XLN1-R6) and Exon 5 (Exon5-R1). 
Bands from each combination of forward and reverse primer were sent for sequencing. Where 
combinations of primers resulted in more than one band, these were extracted, cloned and sequenced 
separately. 
(A-B) DNA ladder is 100 bp ladder and product sizes are indicated below the associated lanes. 
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 were cloned in separate cloning reactions into competent E. coli cells. 
Between 10 and 15 colonies from each reaction were selected to be grown in 
mini-culture and mini-prep DNA was collected from them. Colony mini-prep 
DNA was digested with appropriate restriction enzymes and colonies deemed 
positive for the extracted PCR product were sent for sequencing (Figure 3.3). 
Using the TOPO TA cloning kit more positive clones were produced compared to 
standard ligation into pBluescript SK (-). BLAST analysis of the returned 
sequences established that there was consistent alternative splicing of Gnasxl 
exon A20 in the XLN1 protein but no alternative splicing of exon 3 (Figure 3.1 B, 
Table 3.1).  Further analysis with forward primers in the A20 exon itself and the 
Nesp2 exon was used to assess splicing in all transcripts (Appendix Table 1). 
Exon A20 is not included in either of these proteins on a regular basis (Figure 
3.1 B-C and 3.2 B). The alternative splicing of exon A20 into XLN1 also produced 
a frame-shift resulting in a premature stop codon in exon 2, further truncating 
the XLN1 protein (Figure 3.4). 
3.3.2. SUMMARY 
In summary the following combinations of splicing were observed. XLN1 
always contained exon 3 and could be plus or minus exon A20. Full-length XLαs 
rarely contained exon A20, and could be plus or minus exon 3. Nesp was always 
minus A20 and contained exon 3.  In conclusion, if splicing of exon A20 occurs 
then exon 3 is always spliced.  
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Figure 3.3. Restriction digest of mini-prep DNA to check for PCR product insertion. 
Representative image of restriction enzyme analysis of mini-prep DNA for PCR product (XL-FL1 and 
Exon5-R1) insertion into plasmid. The gel shows mini-prep DNA made from two separate bands with the 
same primer combination. Only one does not contain the PCR insert. Restriction digests run on a 2% 
agarose gel.  
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Figure 3.4. Amino acid sequence resulting from splicing of exon A20.  
The inclusion of exon A20 into either XLN1 or the full length XLαs protein would result in a frame-shift 
that had been previously described in humans (HAYWARD et al. 1998a) and a premature stop codon in 
exon 2. Gnasxl exon1 - Black; Gnasxl exonA20 - Blue; exon2 - red; * - stop codon 
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3.4. DISCUSSION 
3.4.1. ALTERNATIVE SPLICING OF GNASXL EXON A20 
The alternative splicing of the Gnasxl exon A20 in the XLN1 protein of mice 
is in concurrence with the data collected for human XLN1 (HAYWARD et al. 
1998a), but has never been fully documented in mice – although this splicing 
has been detected using FANTOM clones (HOLMES et al. 2003). The implications 
of this splicing have never been fully understood. It has now been shown that 
the inclusion of exon A20 would cause a severe truncation of any protein it 
might be spliced into. It has also been established in this project that splicing of 
exon A20 is regularly observed only in the XLN1 protein and not in the full-
length XLαs. Given the phenotype observed in Gnasxlm+/p- mice, this is 
unsurprising considering the serious implications of the premature termination 
codon in exon 2, which would result in the further truncation of both the XLN1 
protein and in full-length XLαs. It has been suggested that XLN1 might interfere 
with cAMP signalling. The further truncation of the XLN1 protein, with the 
addition of exon A20 occurring on a regular basis, indicates it is unlikely to have 
a function in vivo.  
3.4.2. PLACEMENT OF THE XLLACZGT GENE TRAP  
The data obtained from the analysis of exon A20 splice variants were used 
in another project within our laboratory. This project established a conditional 
knock-out mouse line by insertion of a gene targeting cassette into the locus, 
which allowed the deletion of XLαs in specific or all tissues when crossed with 
specific Cre-recombinase- (Cre-) carrying mice. However, the established 
method of simply flanking the Gnasxl exon 1 with lox sites could not be applied 
due to the Nespas/Gnasxl ICR situated in this region of the locus (Figure 1.2). It 
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was therefore necessary to develop a novel targeting strategy that would insert 
a gene targeting cassette in a position which could disrupt the protein 
expression of XLαs but would not disturb the regulatory regions of the Gnasxl 
exon 1. A function for XLN1 was deemed to be more unlikely than previously 
thought due to the regular inclusion of exon A20 in XLN1 and the resulting 
truncation of the protein. The exon A20 position in the locus was deemed to be 
ideal for placement of a gene trap cassette as splicing spontaneously occurs at 
this location and inclusion of exon A20 was thought to be unimportant in 
transcripts. 
 The gene trap cassette deleted approximately 950 bp, which covered an 
area downstream of the Gnasxl exon, across the A20 exon and within the intron 
(Figure 3.5 A). This was replaced with a lox flanked cassette containing a frt-
flanked neomycin and a cassette which consisted of an exon 2 splice acceptor 
site and a lacZ cassette with a polyA tail, flanked by two different pairs of lox 
sites (loxP and lox2272) in a head-to-head orientation (Figure 3.5 B). The 
bacterial gene lacZ produces the protein βGalactosidase. This is the enzyme 
which converts lactose into the monosaccarides, glucose and sucrose; it can be 
used as a reporter of gene expression under the control of specific promoters – 
in this case Gnasxl. The gene trap cassette was inserted into the gene locus in an 
inactive orientation with the exon 2 splice acceptor site in a position where 
Gnasxl exon 1 could not splice onto it allowing XLαs to be produced normally in 
carrier mice (Figure 3.5 C). To avoid interference with expression the frt-
flanked neo cassette was removed by crossing with Flpe mice (Figure 3.5 D). 
Crosses of male gene trap carrier mice with female Cre-expressing mice result 
in inversion of the gene trap cassette. Litters were born in the expected 
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Figure 3.5. Schematic of gene targeting strategy for insertion and inversion of the gene trap cassette 
into Gnas gene locus.  
(A) Shows a simplified scheme of the Gnas locus focussing on the Gnasxl domain indicating Gnasxl exon 
A20 (A20) location downstream of Gnasxl exon 1 (Gnasxl). 
(B) Indicates the structure of the gene-targeting cassette flanked by Lox2272 and LoxP containing a frt-
flanked neomycin cassette (Neo), a lacZ cassette and an exon 2 splice acceptor site (Ex2 SA). The arrow 
indicates the direction of the cassette orientation opposing the normal direction of splicing. 
(C) The gene trap cassette inserted into the locus at the position of the A20 exon  
(D) The Neo cassette could potentially cause some problems with the correct expression of the full-length 
XLαs protein in the active gene trap so it was removed by crossing with Flpe mice. 
(E) Crossing with Cre mice resulting in the non-permanent inversion of the LacZ-Ex2 SA cassette into the 
inactive orientation with the Lox2272 sites so there are three lox sites on one side of the gene trap and one 
on the other side of the cassette 
(F) Crossing with Cre mice resulting in the non-permanent inversion of the LacZ-Ex2 SA cassette into the 
active orientation with the LoxP sites so there are three lox sites on one side of the gene trap and one on 
the other side of the cassette. 
(G) After inversion with the Lox sites deletion occurs at the two excess sites with the opposite lox site in 
order to lock the gene trap cassette into the active orientation. 
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Mendelian ratio. Only mice expressing the gene trap on the paternal 
allele along with Cre would have the required inversion and activation of the 
gene trap. This could occur between either of the pairs of lox sites (Figure 3.5 E 
and Figure 3.5 F).   
The gene trap cassette is locked in to the active orientation by deletion 
between the two identical lox sites, leaving only an incompatible pair of lox sites 
flanking the gene trap cassette (Figure 3.5 G). This produces the XL-βGal fusion 
protein, in which XLαs functionality is lost, but βGalactosidase activity is 
retained in place of the XLαs full-length protein as the Gnasxl exon 1 splices onto 
the splice acceptor site on the inverted and active gene trap. 
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CHAPTER 4. GNASXL EXPRESSION: A COMPARATIVE 
STUDY OF CHANGES BETWEEN NEONATAL AND ADULT 
DEVELOPMENTAL STAGES I. THE CENTRAL NERVOUS 
SYSTEM 
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4.1. INTRODUCTION 
4.1.1. PREVIOUSLY DESCRIBED GNASXL EXPRESSION PATTERN IN THE CNS 
The Gnasxl expression pattern has previously been described in brain 
tissue of neonatal wild type mice using in situ hybridisation at neonatal day 4 
(PLAGGE et al. 2004). These data describe expression in many regions important 
for the control of energy metabolism and sympathetic outflow including areas of 
the raphe nuclei, reticular area of the medulla, the laterodorsal tegmental 
nucleus (LDTg), and the locus coeruleus (LC) (PLAGGE et al. 2004). However, 
there has been no systematic analysis of the adult expression pattern of Gnasxl 
in mouse brain. 
A specific phenotype change in feeding behaviour was observed between 
neonatal and adult stages of development in Gnasxlm+/p- mice. It was 
hypothesised that this could be related to an expression pattern change in 
nuclei in the brain which innervate muscles required for correct feeding 
(orofacial motor nuclei). It was also of interest to fully analyse the expression 
pattern across the adult brain to investigate possible causes of the adult 
phenotype of increased SNS outflow (XIE et al. 2006). The regions of interest 
and their functions are described in the following sections. 
4.1.2. THE HYPOTHALAMUS 
The hypothalamus is located at the base of the brain on both sides of the 
third ventricle, below the thalamus, and between the optic chiasm and the 
midbrain (Figure 4.1). It is essential for homeostatic regulation and has 
functions in regulating hunger, thirst, sexual and mating behaviours, pleasures 
and the fight or flight response. It receives signals from many regions of the 
brain including the limbic system. The hypothalamus is divided into sub-regions
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Figure 4. 1. Schematic of the hypothalamus in a coronal section of adult mouse brain. 
Diagram showing the main areas of the hypothalamus; these include: the lateral hypothalamus (LH), the 
dorsomedial hypothalamus (DMH), the Arcuate nucleus (Arc) and the ventrolateral hypothalamus (VMH). 
The third ventricle (3V) demarks the midline of the brain, and the median eminence (ME) bridges the base 
of the 3V. 
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including: the lateral hypothalamus (LH); dorsomedial hypothalamus (DMH); 
ventromedial hypothalamus (VMH); arcuate nucleus (Arc); the paraventricular 
nucleus (PVN); and the preoptic area (POA). 
4.1.2.1. The Arcuate Nucleus of the Hypothalamus 
The Arc is an elongated nucleus – located on the ventral side of the brain 
and lateral to the third ventricle – containing subpopulations of neurons with 
differing roles including those involved in feeding and satiety (WILLIAMS et al. 
2001). One population of neurons expresses both neuropeptide Y (NPY) and 
agouti-related protein (AgRP), while proopiomelanocortin (POMC-) and 
cocaine- and amphetamine-regulated transcript (CART-) expressing neurons 
occupy a second separate population (BROBERGER et al. 1998; ELIAS et al. 1998; 
HAHN et al. 1998; KRISTENSEN et al. 1998). These populations of neurons have 
opposite effects on food intake and have inhibitory effects on each other under 
the influence of leptin (NPY/AGRP neurons are orexigenic while POMC/CART 
neurons are anorexigenic) (Figure 4.2) (ELIAS et al. 1999). The Arc has many 
connections to other regions of the hypothalamus (LH, DMH, VMH and PVN) 
with information travelling in both directions regarding nutrient status 
(WILLIAMS et al. 2001). Molecules relaying energy status to the brain can be 
detected by the Arc in the third ventricle, which contains cerebrospinal fluid 
(CSF) (ELMQUIST et al. 1998). This region of the brain is also known to be 
GABAergic (VONG et al. 2011). 
At the base of the third ventricle, connecting the two sides of the Arc, is 
the median eminence. This region is important for nutrient sensing; it is 
generally considered to be outside the blood-brain barrier and allows peptide 
hormones, like leptin, ghrelin and glucose, access to the Arc
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Figure 4.2. Schematic of leptin signalling influencing energy homeostasis through the Arc.  
Leptin released from the white adipose tissue (WAT) has stimulatory effects on proopiomelanocortin 
(POMC)-expressing neurons which are anorexigenic and inhibit food intake and increase energy 
expenditure. Leptin has an inhibitory effect on neuropeptide Y (NPY)-/agouti-related protein (AgRP)-
expressing neurons. NPY-/AgRP-expressing neurons promote food intake and inhibit energy 
expenditure. NYP/AgRP neurons also have an inhibitory effect on POMC neurons. 
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 (BROADWELL and BRIGHTMAN 1976).  
4.1.2.2. The Lateral and Dorsomedial Hypothalamic Nuclei 
The LH/DMH region contains two distinct populations of neurons. One 
population expresses the neuropeptide orexin (also called hypocretin) while the 
other contains the neuropeptide melanin-concentrating hormone (MCH) 
(ABIZAID et al. 2006). These are both known to play roles in food intake 
regulation and energy homeostasis (ABIZAID et al. 2006; F. BRISCHOUX 2001). 
These populations will be discussed in greater detail in Chapter 7.  
There are also many projections to this area from the NPY neurons in the 
Arc with reciprocal projections from orexin and MCH neurons, which contain 
NPY receptors (ELIAS et al. 1999; HU et al. 1996). Projections from the POMC 
neurons in the Arc have also been established to have an effect on orexin and 
MCH neurons in the LH (ELIAS et al. 1999). When this nucleus is stimulated, food 
intake is increased; in opposition to this, destruction of the LH results in weight 
loss and a decrease in food intake (NAMBU et al. 1999; WILLIAMS et al. 2001). 
Glucose-sensitive neurons are abundant in this region of the hypothalamus 
(BERNARDIS and BELLINGER 1996). 
Moving further dorsal, the DMH has connections to the PVN, POA, LH and 
brainstem (ARMSTRONG 2004; YOSHIDA et al. 2009; ZHANG et al. 2011). Warm- 
sensing neurons in the POA have inhibitory effects on the DMH, controlling body 
temperature through brown adipose tissue (BAT) non-shivering thermogenesis 
via the sympathetic nervous system (SNS) (FAN et al. 2007). It is possible that 
the DMH and the PVN interact to control food intake and energy expenditure 
(CHRISTOPHE 1998). This region has been established as expressing XLαs in brain 
at neonatal day four along with the LH (PLAGGE et al. 2004). 
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4.1.2.3. The Paraventricular Hypothalamus 
The PVN is located at the top of, and lateral to, the third ventricle. This 
region is important not only for integrating many energy homeostatic signals 
but also for SNS outflow. Many neurotransmitters are found in this region that 
are related to energy homeostasis including NPY, alpha-melanocyte-stimulating 
hormone ( -MSH), serotonin (5-HT), galanin, noradrenaline (NA) and opioid 
peptides (WILLIAMS et al. 2001). The PVN has corticotropin-releasing hormone 
(CRH) projections to the pituitary controlling the secretion of ACTH  resulting in 
the secretion of cortisol  (SIMMONS and SWANSON 2009).  
4.1.2.4. The Ventromedial Hypothalamus 
The VMH is located directly dorsal to the Arc in the hypothalamus. This 
area is known to inhibit food intake; however, lesioning of the region results in 
hyperphagia and body weight increases (STELLAR et al. 1954). This region has 
projections to and from the PVN, LH and DMH (ARMSTRONG 2004).  
4.1.2.5. The Preoptic Area 
The POA receives noradrenaline projections from the LC along with 
adrenergic projections from the ventrolateral medulla (ASTON-JONES 2004b). The 
ventrolateral POA has a role in sleep and waking (LU et al. 2000). In the POA are 
warm-sensing neurons and this area of the brain has been implicated in the 
control of BAT thermogenesis in response to cold (BOULANT and HARDY 1974). 
The POA is thought to have an inhibitory input onto the DMH and raphe pallidus 
(RPa). When the warm-sensing POA neurons are inhibited by GABA – released 
in response to skin cooling – the DMH and RPa neurons are disinhibited and 
thermogenesis proceeds (MCALLEN 2004; MORRISON and NAKAMURA 2011). MnPO 
neurons are required for BAT thermogenesis (MORRISON and NAKAMURA 2011). It 
has been shown that two separate populations of neurons in the POA project to 
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the DMH and RPa (YOSHIDA et al. 2009). The bed nucleus of the stria terminalis 
(BST) is formed of a fibre bundle which connects the amygdala with other 
regions of the brain. 
4.1.2.6. The Suprachiasmatic Nucleus 
The suprachiasmatic nucleus (SCh) is the body’s internal clock. This 
nucleus projects both directly and indirectly to many nuclei in the brain 
including the DMH and PVN. This suggests that the SCh is not only important for 
wakefulness but other processes which fluctuate over the period of a day 
including SNS outflow (ARMSTRONG 2004; VRANG et al. 1997).  
4.1.3. THE AMYGDALA 
The amygdala is a nucleus located in the temporal lobe of the brain and is 
a part of the limbic system (CAMPBELL 2002). It is composed of several sub-
regions: the basolateral complex, the centromedial nucleus (CeA) and the 
cortical nucleus (AMUNTS et al. 2005). There are several known functions of the 
amygdala. It is involved in arousal, emotion and fear responses as well as 
hormonal secretions. It is central to the creation and storage of memories as 
well as the recognition of emotions in facial expressions of other individuals 
(CAMPBELL 2002).  
The amygdala has connections to the hypothalamus and it has been 
observed that stimulation or disruption of this area results in changes in feeding 
and drinking behaviours (MIÑANO et al. 1992). There are two major routes to the 
hypothalamus from the amygdala. The first is the stria terminalis: a compact 
bundle of fibres that originates from the medial, central and basomedial nuclei 
of the amygdala (MIGUELEZ et al. 2001). The second route is the ventral 
amygdalo-hypothalamic pathway; this arises from the piriform complex and 
Chapter 4. Gnasxl Expression Pattern I: CNS 
77 
basolateral nucleus providing a diffuse network of efferent and afferent 
connections to the hypothalamus (MIGUELEZ et al. 2001). Hyperphagia occurs in 
rats given bilateral lesions at the postero-ventral border of the amygdala. 
Electrical stimulation of this region stops or greatly reduces food intake (HAN 
and JU 1990). Depending on the region of the amygdala there are varying 
numbers of GABA-expressing neurons: there is a high density in the CeA, but 
surrounding areas are less densely populated (VONG et al. 2011). Some diseases 
for which the amygdala has been investigated include: Alzheimer’s disease, 
autism, schizophrenia, and bipolar disorder (CAMPBELL 2002). The amygdala 
receives projections which originate in the LC, NTS, and the ventral medulla 
(CLAYTON and WILLIAMS 2000; FALLON and MOORE 1978; ZARDETTO-SMITH and GRAY 
1990; ZARDETTO-SMITH and GRAY 1995). 
4.1.4. THE BRAIN STEM  
4.1.4.1. The Raphe Nuclei (Figure 4.3) 
The raphe nuclei are serotonergic and the main supplier of 5-HT to the 
brain. Clear links have been established between these nuclei and the medial 
POA (BERTON and NESTLER 2006; HOLLAND and GOADSBY 2009). These nuclei also 
have feedback projections to the SCh, indicating they have a role in circadian 
rhythms. These nuclei also receive efferent fibres from the NTS (NIEUWENHUYS et 
al. 2008).  
There are several raphe nuclei and of particular interest are the raphe 
pallidus (RPa) and the raphe obscurus (ROb). The RPa has many MC4R-
expressing neurons and receives projections from the POMC-expressing 
neurons of the Arc (LEI et al. 2008). It has also been established that the RPa 
neurons project to the sympathetic preganglionic neurons of the 
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Figure 4.3. Schematic of the pons region of the adult mouse brain in a coronal section 
Diagram of the pons region of the brain indicating the locus coeruleus (LC), the motor trigeminal nucleus 
(Mo5), the raphe pallidus (RPa), the laterodorsal tegmental nucleus (LDTg), and the subcoeruleus (SubC). 
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intermediolateral layer of the spinal cord (IML) (BACON et al. 1990; LOEWY and 
MCKELLAR 1981) and have implications in the control of BAT 
thermogenesis(BAMSHAD et al. 1999; MORRISON 2001a; MORRISON 2001b). The 
RPa receives afferent signals from the periaqueductal grey (PAG), PVN, DMH, 
LH, POA, the CeA, MnPO, Gi and the parvocellular reticular nucleus (HERMANN et 
al. 1997; HOSOYA 1985). It is possible that the RPa is constantly under GABAergic 
inhibition from the POA in the control of heart rate and BAT thermogenesis 
(MCALLEN 2004). The ROb has implications in the control of SNS outflow and 
autonomic motor outflow controlling the hypoglossal nerve (PEEVER et al. 2001). 
4.1.4.2. The Locus Coeruleus (LC) and the Laterodorsal Tegmental Nucleus 
(LDTg) (Figure 4.3) 
The LC is known to be important in alertness as well as stress response 
and is the main noradrenergic centre of the brain. It is located in the pons, 
dorsal to the ventricle. It has close proximity to the LDTg to which it is thought 
to have connections. These nuclei have a role in alertness and stress but their 
complete functional roles remain elusive.  
Many neurotransmitters involved in alertness and stress are contained 
in the LC, including GABA, galanin, NPY, vasopressin, neurophysin, neurotensin, 
vasoactive intestinal peptide and atrial natriuretic factor (ASTON-JONES 2004a). 
Orexin stimulates the LC by decreasing the resting potassium conductance 
(HAGAN et al. 1999; HORVATH et al. 1999; IVANOV and ASTON-JONES 2000) – 
evidence that the LC is important for arousal and waking as these are affected 
by orexin (ASTON-JONES and BLOOM 1981a; SAKURAI 2007). There is also evidence 
that GABA inhibits the LC during sleep – further showing that this nucleus is 
involved in alertness and wakefulness (ASTON-JONES and BLOOM 1981a; ASTON-
JONES and BLOOM 1981b).  
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Many receptors are found in the LC; these include leptin receptor (LepR) 
(HAY-SCHMIDT et al. 2001) as well as orexin receptors (SUNTER et al. 2001) and 
corticotropin-releasing hormone (CRH) receptors (MORIN et al. 1999). Although 
the presence of receptors does not always correspond to effects on the nucleus, 
it has been shown that CRH and serotonin have inputs to the nucleus (ASTON-
JONES 2004b). 
The LC has far-reaching projections in the brain as well as from many 
regions of the brain. Specific inputs have been observed from the medial POA 
(RIZVI et al. 1992) and the PAG (ENNIS et al. 1991). The LC is known to have 
projections to the POA (DUBOIS et al. 2006), the amygdala (CLAYTON and WILLIAMS 
2000; FALLON and MOORE 1978) and the wall of the PVN (CUNNINGHAM and 
SAWCHENKO 1988). 
LC neurons projecting to the spinal cord regulate sensory perception 
(FRITSCHY and GRZANNA 1990), as do LC neurons projecting to  the brainstem 
(FRITSCHY and GRZANNA 1990; LEVITT and MOORE 1979). Interestingly, the LC’s 
activity appears to be controlled by circadian rhythms produced by the SCh 
(ASTON-JONES et al. 2001). The SCh projects indirectly to LC via the DMH (ASTON-
JONES et al. 2001).  
The area surrounding the LC which includes the subcoeruleus (SubC) 
also has many inputs including the NTS (ENNIS and ASTON-JONES 1989a; ENNIS 
and ASTON-JONES 1989b; MANTYH and HUNT 1984; VAN BOCKSTAELE et al. 1996; 
WALLACE et al. 1989), the dorsal horn of the spinal cord (CECHETTO et al. 1985; 
STANDAERT et al. 1986) and the CeA (ASTON-JONES et al. 1986; VAN BOCKSTAELE et 
al. 1996). This region includes the A7 noradrenergic nucleus.  
There is little functional data describing the LDTg. It is thought that the 
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nucleus has functions in controlling stress responses and alertness and the main 
studies into the region have been investigating this involvement. 
The LDTg is a cholinergic nucleus with connections to the ventral 
tegmental area (VTA), which stimulates the limbic system (BLAHA et al. 1996; 
KIMURA et al. 1981; MESULAM et al. 1983; SHUTE and LEWIS 1967). The LDTg 
receives stimulatory innervations from orexin-expressing neurons and 
therefore has implications for sleep and wakefulness (BURLET et al. 2002; PEYRON 
et al. 1998). GABAergic and glutamatergic neurons have been detected in the 
nucleus contained in separate populations (CLEMENTS and GRANT 1990; WANG 
and MORALES 2009). Glutamate neurons are located in the rostral part of the 
nucleus, while the GABA-expressing neurons are in the caudal part (WANG and 
MORALES 2009). Ghrelin receptor (GHSR) and CRH-expressing neurons have also 
been identified in the neurons of this nucleus (ALON et al. 2009; ZIGMAN et al. 
2006). The nucleus has projections to the thalamus, hypothalamus, substantia 
nigra, ventral tegmental nucleus and cortex. There are three known populations 
of neurons in the region: the first is the cholinergic neurons involved in both 
wakefulness and REM sleep (EL MANSARI et al. 1989); the second is involved in 
REM sleep only (EL MANSARI et al. 1989); and the third group are involved in 
wakefulness only (KAYAMA et al. 1992). The removal of XLαs in this nucleus has 
previously been suggested as a cause of the lethargy of XLαs-deficient mice 
(PLAGGE et al. 2004). 
4.1.4.3. The Nucleus of the Solitary Tract (NTS) (Figure 4.4) 
The NTS carries and receives vicsceral signals of sensation and taste 
from the facial, glossopharengeal and vagus nerves. This nucleus is long:  
stretching almost the entire length of the medulla oblongata, starting above the 
Chapter 4. Gnasxl Expression Pattern I: CNS 
82 
  
Figure 4. 4. Schematic of the medulla oblongata region of the mouse brain in a coronal section 
Diagram of the medulla oblongata showing the main nuclei of the region including the nucleus of the 
solitary tract (Sol), the reticular area (IRt and Gi), the ambiguus nucleus (Amb), and the raphe nuclei (ROb 
and RPa) 
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central canal in the posterior brain stem and becoming more laterally 
positioned as it moves anterior. Medial NTS neurons are responsible for 
processing gastrointestinal vagal afferent signals coming from food intake and 
stimulation of the stomach and gut (HAYES and COVASA 2006; SCHWARTZ 2002; 
VRANG et al. 2003; WILLING and BERTHOUD 1997). In addition to nutrient signals, 
the NTS is also known to process afferent signals from the cardiovascular and 
respiratory systems (TAYLOR et al. 1999). The NTS, as part of the hindbrain 
circuitry, is likely to mediate the size of food intake inhibition signals (GRILL and 
HAYES 2009). Meal size is determined by gastrointestinal signals acting on the 
brainstem. This CNS system relays important information about nutrient status 
of the periphery to the brain. The main input of this system is through the NTS, 
which then relays information to other regions in the brain. It has been 
suggested that leptin acts upon the NTS through projections from the 
hypothalamus (SCHWARTZ 2002). However, it has been shown that the NTS 
possesses its own LepR and that leptin injection into the NTS reduces food 
intake (GRILL et al. 2002; MÜNZBERG et al. 2004). POMC-expressing neurons 
found in the NTS have a different role in signalling than the POMC-expressing 
neurons in the Arc (PERELLO et al. 2007). NTS neurons project to the 
hypothalamus but these neurons do not include those expressing POMC (GRILL 
2006; GRILL and HAYES 2009; SCHWARTZ 2002). 
4.1.4.4. Gigantocellular Reticular Nucleus of the Medulla (Gi) (Figure 4.4) 
This nucleus is made up of giant neuronal cells and innervates the caudal 
hypoglossal nucleus by exciting the hypoglossal nerve. It is known to respond to 
glutamatergic stimuli. The diffuse region has inputs from the PAG, PVN, CeA and 
the parvocellular reticular nucleus (LOEWY et al. 1981). It is known to mediate 
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cardio-inhibition (SU et al. 1991). This nucleus innervates the neurons in the 
IML (LOEWY et al. 1981). 
4.1.4.5. Ambiguus Nucleus (Figure 4.4) 
The ambiguus nucleus (Amb) is located in the lateral part of the medulla 
and gives rise to the branchial efferent fibres of the vagus nerve. The external 
formation contains cholinergic preganglionic parasympathetic neurons for the 
heart. It acts with the dorsal motor nucleus of the vagus nerve to decrease 
cardiac activity in response to fast increase in blood pressure. The Amb strongly 
innervates the soft palate (STRUTZ et al. 1988).  
4.1.4.6. Orofacial Motor Nuclei 
The three orofacial motor nuclei – the motor trigeminal nucleus (Mo5), 
the hypoglossal (12N) and the facial nucleus (7N) – receive projections 
containing neurotransmitters and neuromodulating substances, which have 
both excitatory and inhibitory effects (TRAVERS 2004). Although the three nuclei 
are defined by individual characteristics, they have a co-ordinated influence on 
the stimulation of facial muscles during many behaviours including feeding, 
grooming and respiration (TRAVERS 2004). 
The noradrenergic A7 and A5 cell groups are the main sources of 
noradrenaline to the Mo5 (GRZANNA et al. 1987; VORNOV and SUTIN 1983) (Figure 
4.3). This nucleus is one of the important orofacial nuclei in the brainstem 
controlling facial muscles. 
The 12N extends the length of the medulla located close to the midline 
below the central canal and is important for the control of the tongue (TRAVERS 
2004). Many of the neurons in this nucleus express MCH1R (SAITO et al. 2001). 
The nucleus has been found to be a receiver of cholinergic and noradrenergic 
innervations (ALDES et al. 1992; CONNAUGHTON et al. 1986). It is known that the 
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SubC projects to the 12N and the SubC projections fall into the 12N in the same 
pattern as the noradrenergic neurons that are known in this region (TRAVERS 
2004). 
The 7N is involved in the control of facial muscles which are essential for 
suckling in neonates. Deletion of XLαs in this nucleus had previously been 
suggested as a possible cause of the suckling deficiency in the Gnasxlm+/p- 
neonates (PLAGGE et al. 2004). The 7N is another nucleus in which XLαs was 
shown to be highly expressed in neonatal tissue (PLAGGE et al. 2004). 
4.1.5. SPINAL CORD 
The spinal cord is the relay centre between peripheral tissues and the 
brain. There are many different types of neurons in separate populations in the 
spinal cord including the intermediolateral layer (IML), which contains 
sympathetic preganglionic neurons (SPNs) involved in SNS outflow to the 
periphery, including the adrenal glands (BACON and SMITH 1988). The ventral 
part of the spinal cord contains motor neurons (VMNs). 
4.1.6. AIMS 
To date, there has been no systematic analysis of Gnasxl expression in the 
brain in adult mice. As a comparison to the previously described neonatal 
expression pattern (PLAGGE et al. 2004), the aim of this project was to provide a 
comprehensive overview of staining in one-day old mice and adult tissue. 
Previously, neonatal staining was performed on four-day old mice using in situ 
hybridisation (PLAGGE et al. 2004). It was necessary to compare the two in a 
systematic way using more than one histological technique and to document 
changes between the two phases of development that might account for the 
phenotypic change that was previously described in Gnasxlm+/p- mice (PLAGGE et 
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al. 2004; XIE et al. 2006) and to establish any areas of the brain in which 
deletion of XLαs might result in the increased SNS outflow that has been 
described in Gnasxlm+/p- mice (XIE et al. 2006).  
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4.2. MATERIALS AND METHODS 
4.2.1. TISSUE COLLECTION 
For neonatal histology WT, Nestin-Cre/+; +/XLlacZGT and CMV-Cre/+; 
+/XLlacZGT brains were collected and placed in 4% PFA overnight and then 
placed in 30% sucrose until required. For adult histology WT, Gnasxlm+/p- and 
CMV-Cre/+; +/XLlacZGT mouse brains were collected by perfusion as described 
below. 
4.2.2. ADULT MOUSE PERFUSION  
Mice were deeply anaesthetised with an intraperitoneal (i.p.) injection of 
pentobarbitone. Once the mouse was deemed to be brain-dead, the chest was 
cut open and the right atrium of the heart punctured to allow blood to drain 
from the circulatory system. Mice were perfuse-fixed by injection of PBS then 
4% PFA in PBS into the left ventricle of the heart.  Relevant tissues were 
dissected out and the tissues placed in 4% PFA for appropriate times of fixation 
depending on technique (several minutes for XGal staining; overnight for 
cryosectioning). Tissues were transferred to 30% sucrose for 24-48 hours at 
4°C to dehydrate and cryoprotect them. Tissues could then be processed for 
sectioning. 
4.2.3. SECTIONING OF TISSUES 
4.2.3.1. Cryosectioning 
Perfuse-fixed tissues were mounted in Shandon Cryomatrix (Thermo 
Scientific) and serial frozen sections were cut using a Leica CM1950 cryostat 
(14 or 25 µm) onto SuperFrost* Plus slides (Thermo Scientific) in sets of ten. 14 
and 25 µm sections were used for immunofluorescence and 
immunohistochemistry and required antigen retrieval (see below) for staining 
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to be clearly observed. These were used to visualise strongly-stained areas with 
immunohistochemistry and for colocalisation studies with 
immunofluorescence.  
4.2.3.2. Microtome Sectioning 
Tissues were mounted onto the Leica 2000R microtome stage, 
cryoprotected with 30% sucrose in PBS and allowed to freeze fully using dry ice. 
Serial sections of 80 µm were collected into 24-well plates filled with 
cryoprotectant (6 sections per well). These sections were used for 
immunohistochemistry only and did not require an antigen retrieval step. 
Thicker sections were used to visualise weakly-stained areas of tissue. 
4.2.3.3. Vibratome Sectioning 
After perfusion and brief fixation in 4% PFA, whole brains were washed 
four times in 1 x PBS for 10 minutes then trimmed back to create a flat surface 
for mounting. The cut edge was dried slightly then glued to the chuck with 
cyanoacrylate gel. The chuck and tissue were then fixed into the vibratome and 
submerged in PBS. Slices were cut at 300-500 μm using high vibration speeds 
and low cutting speeds. Cut sections were placed in 4% PFA in a 12-well plate 
for 5 minutes, washed twice with 1 x PBS, then used in XGal staining protocols. 
4.2.4. ANTIBODIES  
For immunohistochemistry the following primary antibodies were used: 
goat anti-XLαs (M14) (Santa Cruz; sc-18993; 1:200). The following secondary 
antibodies were used: Vectastain Elite biotin-conjugated rabbit anti-goat 
(Vector Laboratories; PK6105; 1:200) and Affinipure  donkey anti-goat Biotin 
conjugated (Jackson ImmunoResearch Laboratories; 705-065-147; 1:3000). 
For immunofluorescence the following primary antibodies were used: 
goat anti-ChAT (Millipore; AB144P; 1:100), chicken anti-βGalactosidase 
Chapter 4. Gnasxl Expression Pattern I: CNS 
89 
(Abcam; ab9361; 1:500), and rabbit anti-βGalactosidase (Cappel; 55976; 
1:2000). The following secondary antibodies were used: DAPI (Invitrogen; 
1:1000), donkey anti-chicken Dylight 594 (Jackson ImmunoResearch 
Laboratories; 703-515-155; 1:3000), donkey anti-rabbit AF594 (Invitrogen; 
A21207; 1:1000) and donkey anti-goat AF488 (Invitrogen; A11055; 1:1000). 
4.2.5. ANTIGEN RETRIEVAL 
Sections were incubated with 10 mM sodium citrate (Sigma) at 60°C by 
heating in a microwave for 45 seconds. Sections were allowed to cool in solution 
for 1 minute before continuing with staining protocols. 
4.2.6. VECTASTAIN ELITE KIT FOR IMMUNOHISTOCHEMISTRY (APPENDIX 4) 
14-80 µm sections were treated for antigen retrieval if necessary (see 
above) and washed three times in PBS for 5 minutes. A quenching step (1 
minute in a solution of 0.03% H2O2 in 100% MeOH) was included to remove the 
endogenous horse radish peroxidise-like activity in blood vessels. Sections were 
washed three times for 5 minutes with PBS and incubated in 10% normal serum 
(Sigma or Vector Laboratories) in PBS for 1 hour at room temperature. These 
were transferred into primary antibody diluted in 10% normal serum in PBS 
overnight at 4°C. Sections were washed three times for 5 minutes in PBS and 
incubated with a biotin-conjugated secondary antibody in 10% normal serum in 
PBS for 1 hour at room temperature. After the secondary antibody was applied 
to sections, the avidin-biotin complex (ABC) solution was prepared. Sections 
were washed three times for 5 minutes and incubated with ABC solution from 
the Vectastain Elite Kit (Vector Laboratories) for 30 minutes at room 
temperature followed by washes in PBS and incubation with 3,3'-
diaminobenzidine (DAB; Sigma) solution containing nickel chloride (1:100 
Chapter 4. Gnasxl Expression Pattern I: CNS 
90 
dilution of 50% w/v stock). After washing with PBS and ddH2O, sections were 
dehydrated with 70% EtOH, 90% EtOH, twice with 100% EtOH and finally 
cleared twice with Histo-clear™ (National Diagnostics) before being mounted 
with Eukitt® quick hardening mounting medium (Fluka).  
80 μm free-floating microtome sections were carried through the above 
solutions in 24-well plates. After completion of the staining they were mounted 
from PBS onto polylysine slides (Thermo Scientific) and allowed to air-dry over 
night before being put through the dehydrating EtOH series and mounting with 
Eukitt®. 
4.2.7. IMMUNOFLUORESCENCE (IF) 
14 µm cryostat sections were treated for antigen retrieval (see above) 
then washed three times for 5 minutes with PBS, incubated for one hour with 
500 µL blocking serum (10% donkey serum (Sigma); 1x PBS) then incubated in 
500 µL primary antibodies diluted in blocking serum containing 0.25% 
TritonX100 (Fluka) overnight at 4°C. Primary antibody solutions were removed 
and the slides were washed three times for 15 minutes in PBS, incubated in 500 
µL of a solution of secondary antibodies diluted in blocking serum containing 
0.25% TritonX100. Antibody solutions were discarded and the slides washed 
three times in PBS for 15 minutes. Slides were mounted with Fluorogel 
(Electron Microscopy Sciences), allowed to air-dry, sealed and stored at 4°C. 
4.2.8. XGAL STAINING 
Whole mount tissues or 14 µm cryostat sections were fixed briefly with 
4% PFA before being incubated with a pre-warmed solution (37°C) of XGal 
overnight at 37°C. Whole mount tissues were then fixed and stored in 4% PFA 
in PBS and cryostat sections were dehydrated and mounted with Eukitt®. 
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4.2.9. IN SITU HYBRIDISATION  
4.2.9.1. Linearization of Probe 
Using RNAse-free conditions, 10-20 μg of the plasmid containing the 
insert of more than 1 kbp was linearised by digestion with a 5’-overhang 
producing restriction enzyme that cuts at the 5’-end of the insert. This was run 
on a 1% agarose gel from which the linearised plasmid was extracted. 
4.2.9.2. Gel Extraction (Geneflow) 
Using RNAse-free conditions, gel fragments of the expected molecular 
weight were excised from the agarose gel. Gel pieces were weighed and equal 
volumes of binding buffer were added to the gel pieces. These were incubated at 
65 C for 5-10 minutes with gentle vortexing at intervals until the agarose had 
dissolved. Equal volumes of binding buffer were added and then incubated at 
room temperature for 1 minute. The mixture was then added to a spin column 
supplied with the Geneflow kit and allowed to stand for 1 minute. The spin 
column was centrifuged for 1 minute and the flow-through discarded. 500 μL of 
wash solution I was added to the column. The column was centrifuged for 15 
seconds and the flow-through discarded. This step was repeated. The column 
was spun for 1 minute to remove residual wash solution and then the column 
was transferred to a new 1.5 mL centrifuge tube. 30 μL of elution buffer was 
added onto the membrane in the column and it was incubated for 2 minutes at 
room temperature. Finally, the column was spun and the probe collected in the 
new tube. The extracted plasmid was EtOH precipitated and resuspended in a 
small volume to get a concentration of ~0.5-1.0 μg/μL.  
4.2.9.3. EtOH Precipitation 
To the sample from which DNA was to be extracted, either equal volumes 
of isopropanol (if sample buffers contained high salt levels) or 0.1 volume 
sodium acetate pH5.0 and 2.5 volumes EtOH (if buffers contained low salt 
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levels) were added. This was inverted until white strands of DNA could be seen 
precipitating out of the solution. This was centrifuged for 30 seconds to form a 
DNA pellet. The supernatant was removed and discarded and the DNA pellet 
was washed twice with 70% EtOH, centrifuging in between and removing the 
supernatant. The DNA pellets were air-dried at 37 C for 5-10 minutes and 
resuspended in an appropriate volume of 1 x TE with RNAse.  
4.2.9.4. DIG-labelling of Antisense RNA Probe by In Vitro Transcription  
The following components were incubated at 37°C for 2 hours: 12.5 μL 
RNAse-free water; 4 μL 5x transcription buffer; 2 μL 10x DTT; 2 μL 10x DIG-
RNA labelling mix; 0.5 μL RNAse inhibitor (1 U/μL); 3μl (this is approximately 1 
μg) linearised template plasmid; and 1 μL T7 RNA polymerase (1 U/μL). After 2 
hours the following components were added to the reaction mix: 23 μL RNAse-
free water; 5 μL 10x RNAse-free DNAse buffer; and 2 μL RNAse-free DNAse. This 
was incubated at 37°C for a further 30 minutes. To estimate final probe 
concentration 1 μL was removed from the reaction mixture and put into 20 μL 
50% formamide. 
4.2.9.5. Purification of DIG-Labelled RNA Probe 
ProbeQuant G-50 Micro Sephadex Column (GE Healthcare) resin was 
resuspended and placed in a 2 mL support tube. This was spun at 735 g for 1 
minute. Flow-through was discarded and the column returned to the support 
tube. 50 μL of in vitro transcription reaction was added to the column and spun 
again at 735 g for 1 minute; the flow-through contained the DIG-labelled RNA 
probe. For the gel estimation of concentration, 1 μL was removed and added to 
20 μL 50% formamide. To the probe, 2 μL of RNAse inhibitor was added and it 
was stored at -20°C.  
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4.2.9.6. Gel Estimation of Probe 
Before and after purification, probe samples were run on 1 % agarose 
gels with the λHinDIII and 1 kb DNA ladders (New England Biolabs) for 
comparison. Probe band strength was compared to bands of known DNA 
concentration in the ladders to determine the concentration of the probes.  
4.2.9.7. Hybridisation of Adult Brain Sections 
14 µm frozen sections were dried at 50°C. These were post-fixed in cold 
4% PFA/PBS for 20 minutes then washed twice in PBS, followed by two 15-
minute carbethoxylation washes in active 0.1% DEPC/PBS. The sections were 
equilibrated in DEPC-treated 5 x SSC for ~10 minutes, then pre-hybridised in 
hybridisation buffer (50% Formamide, 5 x SSC and 40 μg/mL salmon sperm 
DNA [heat denatured for 10 minutes]) for 2 hours at ~58°C. Hybridisation was 
carried out in the same buffer containing 0.4 μg/mL DIG-labelled RNA probe; 
slides were covered in parafilm and sealed in an airtight box overnight at 58°C. 
Parafilm was removed from slides and sections washed in: 2 x SSC at room 
temperature for 30 minutes; 2 x SSC at 65°C for 1 hour; 0.2 x SSC at 65°C for 1 
hour; PBS/0.05% Tween20 at 65°C for 10 minutes; and PBS/0.05% Tween20 
(Sigma) at room temperature for 10 minutes. Sections were blocked for 2 hours 
at room temperature with ~400 μL per slide blocking serum (0.05% Tween20, 
5% sheep serum, 0.5-5% milk powder; 1 x PBS) and then incubated with the 
same solution containing alkaline phosphatase-conjugated anti-DIG-Fab 
fragments (Roche; 11093274910; 1:5000) at 4°C overnight. Sections were 
washed three times in TPBS for 30 minutes at room temperature, equilibrated 
for 5 minutes in alkaline phosphatase buffer (100 mM Tris-HCl, 100 mM NaCl, 
50 mM MgCl2, pH 9.5) and incubated with 400 μL of the same alkaline 
phosphatase buffer containing 45 μL NBT and 35 μL BCIP (for stocks see buffer 
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and solutions) per 10 mL alkaline phosphatase buffer overnight, in the dark, at 
room temperature. The reaction was stopped with PBS and post-fixed in 4% 
PFA/PBS for 20 minutes. Slides were washed with ddH2O, dehydrated (with 2 
minute incubations with 70%, 90%, 100%, 100% EtOH), cleared twice in Histo-
clear™ for 2 minutes and mounted with Eukitt®. 
4.2.10. IMAGING 
Epifluorescence images were taken using a Zeiss Axioskop 40 
microscope and Axioskop vision v4.6 software. Confocal images were taken 
using a Leica SP2 confocal microscope. Bright field images were taken using a 
Leica mz16 microscope for overview and whole mount images; higher 
magnification bright field images were taken using an inverted Leica DM IRB or 
an upright Leica Leitz DM RB microscope. 
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4.3. RESULTS 
4.3.1. TISSUE PROCESSING FOR HISTOLOGY 
The first method used to analyse the brain expression pattern of Gnasxl-
derived proteins, was an antibody against a Gnasxl exon 1-encoded peptide. This 
antibody detects both XLαs and the truncated neural-specific XLN1 protein but 
not Gsα. The specificity of the antibody was tested in the Gnasxlm+/p- mouse line 
along with a wild type sibling, under the same conditions, showing that the 
antibody was specific for the Gnasxl-derived proteins XLαs and XLN1 (Figure 
4.5).  In histology it is not possible to distinguish between the expression of 
these two proteins, and any expression described as XLαs protein would include 
both XLαs full-length and the truncated XLN1 in brain sections. The second 
method of detection used was XGal staining for the detection of XL- Gal fusion 
protein (XL- Gal) in Cre/+; +/XLlacZGT gene trap mice described in Chapter 3. 
The fusion protein was expressed in tissues where XLαs had been removed by 
crossing with specific Cre-expressing mice, for example Nestin-Cre (TRONCHE et 
al. 1999) or CMV-Cre (SCHWENK et al. 1995). Nestin-Cre is regarded as a brain-
specific Cre-deleter, while CMV-Cre is an early embryonic general Cre-deleter.  
Sections were made of neonatal and adult wild type brains at 14 or 80 
μm for detection of XLαs protein in immunohistochemistry. Neonatal Nestin-
Cre/+; +/XLlacZGT whole brains were used in XGal staining for XL-βGal and then 
sectioned on a freeze microtome at 80 μm after cryoprotection and dehydration 
in 30 % sucrose. Adult CMV-Cre/+; +/XLlacZGT brains were sectioned at 500 μm 
on a vibratome before being stained for the fusion protein with XGal. 
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Figure 4.5. Control staining for XLαs in a Gnasxlm+/p- adult brain and a wild type littermate 
(A) Gnasxlm+/p- mouse brain probed using anti-XLαs antibody showing no staining in the hypothalamus. 
(B) Wild type sibling of the mouse in (A) showing clear staining of the hypothalamus. These tissues were 
stained using the anti-XLαs antibody at the same time under the same conditions. 
14 µm coronal cryostat sections; 500 µm scale bar 
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4.3.2. GNASXL EXPRESSION IN THE NEONATAL HYPOTHALAMUS IS MAINTAINED 
AND BECOMES MORE WIDESPREAD IN ADULT TISSUE. 
In the hypothalamus of neonatal tissue, expression of XLαs was observed 
in the LH, DMH and PVN (Figure 4.6 A). There was a small amount of staining in 
the Arc at neonatal day 1 (Figure 4.6 A). All of this staining was reproducible 
with XGal staining for XL- Gal fusion protein in neonatal Nestin-Cre/+; 
+/XLlacZGT mice (Figure 4.7 A and C). No XLαs was detected in the VMH with 
either mouse line (Figure 4.6 A; Figure 4.7 C). There was also clear staining in 
the POA of both wild type and Nestin-Cre/+; +/XLlacZGT mice (Figure 4.6 C; 
Figure 4.7 A). The SCh was positive for XLαs and XL- Gal (Figure 4.7 D). Blood 
vessel staining in neonatal tissue was not expected but was consistently 
observed with XGal staining in neonatal Nestin-Cre/+; +/XLlacZGT mice (Figure 
4.7). 
In adult tissue, the hypothalamic expression pattern remains largely the 
same as neonatal brain with more widespread staining in each of the nuclei that 
express XLαs. The LH, DMH and PVN all have more widespread staining (Figure 
4.8; Figure 4.9 A and B). The Arc continues to develop after neonatal day 1 and 
in adult mice many neurons in this nucleus express XLαs in wild types as shown 
with IHC (Figure 4.8 A and C); in CMV-Cre/+; +/XLlacZGT mice there were few 
XL- Gal-positive neurons in the Arc (Figure 4.9 A; Figure 4.10 A). The SCh 
continues to be stained at adult stages of development with increased 
expression (Figure 4.8 D; Figure 4.9 D; Figure 4.10 A). The XLαs expression in 
the POA is also expanded in adults and can be defined as the BSTMA, LSV, ADP, 
MnPO; this staining can be confirmed with both IHC for XLαs (Figure 4.11) and 
XGal for XL- Gal fusion protein (Figure 4.10 A). Expression in the amygdala 
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Figure 4.6. Neonatal expression of XLαs protein in the hypothalamus 
(A) Neonatal wild type brain stained for XLαs protein showing the lateral hypothalamus (LH), the 
dorsomedial hypothalamus (DMH) and the arcuate nucleus (Arc). The amygdala does not show any XLαs 
expression at this stage.  
(B) XLαs expression in the neonatal paraventricular nucleus (PVN). 
(C) Neonatal wild type brain stained for XLαs protein showing the preoptic area (POA). 
500 µm scale bars; 80 µm free floating coronal microtome sections 
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Figure 4.7. Sections of neonatal Nestin-Cre/+; +/XLlacZGT mice stained for XL-βGal with XGal 
(A) Sagittal section of the neonatal brain stained for XL-βGal fusion protein using XGal showing the 
ambiguus nucleus (Amb), subcoeruleus (SubC), locus coeruleus (LC), facial nucleus (7N), motor 
trigeminal nucleus (Mo5), noradrenergic A7 nucleus (A7), dorsomedial hypothalamus (DMH), lateral 
hypothalamus (LH) and the preoptic area (POA).  
(B) Sagittal section of neonatal brain stained for XGal showing the hypoglossal nucleus (12N), 
gigantocellular reticular nucleus (Gi) and the subcoeruleus (SubC). 
 (C) Neonatal Nestin-Cre/+; +/XLlacZGT coronal brain section stained for XL-βGal fusion protein with 
XGal showing the DMH. 
(D) Coronal section of Neonatal Nestin-Cre/+; +/XLlacZGT anterior brain stained for XLαs showing the 
suprachiasmatic nucleus (SCh). 
Red arrows indicate blood vessel staining; scale bars are 500 µm; crosses were performed with male 
XLlacZGT-carrying mice and female Nestin-Cre mice; 80 µm freeze microtome sections. 
 
Chapter 4. Gnasxl Expression Pattern I: CNS 
100 
 
Figure 4.8. Adult hypothalamus stained for XLαs protein in wild type mice 
(A) Overview of XLαs expression in the adult hypothalamus of wild type brain showing the amygdala 
(Amy), lateral hypothalamus (LH), zona incerta (ZI), dorsomedial hypothalamus (DMH) and arcuate 
nucleus (Arc) express XLαs. The ventromedial hypothalamus does not express XLαs. 3V third ventricle. 
(B) Magnified image of amygdala expression of XLαs. Axonal staining can be clearly seen in this nucleus. 
(C) Magnified image of Arc and VMH 
(D) Expression of XLαs in the anterior hypothalamus of an adult wild type mouse showing XLαs is 
expressed in the paraventricular nucleus of the hypothalamus (PVN) and the Suprachiasmatic nucleus 
(SCh) 
14 µm coronal cryostat sections; 500 µm scale bars 
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Figure 4.9. XGal staining for XL-βGal fusion protein in the hypothalamus of adult CMV-Cre/+; 
+/XLlacZGT brain  
(A) XL-βGal expression in the hypothalamus of the adult XLlacZGT brain is not as strong as in IHC stained 
wild type brains but the DMH and Arc are clearly stained. The Arc staining was not as widespread as in 
IHC stained wild type brains.  
(B) In the Amygdala (Amy) the XL-βGal staining is much reduced in adult brain compared to wild type 
Amy staining of XLαs. 
(C) XL-βGal in the paraventricular nucleus of the hypothalamus (PVN) is less strong than in wild type 
brain.  
(D) XL-βGal staining in the suprachiasmatic nucleus (SCh) is strong. 
500 µm coronal vibratome sections; 500 µm scale bars 
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Figure 4.10. Sagittal sections of the adult CMV-Cre/+; +/XLlacZGT mouse brain stained for XL-βGal 
fusion protein with XGal 
(A) Anterior part of the adult brain showing XL-βGal expression in the preoptic area (POA), 
suprachiasmatic nucleus (SCh), arcuate  nucleus (Arc), lateral hypothalamus (LH) and the dorsomedial 
hypothalamus (DMH).  The anterior commisure (ac) is not stained for XL-βGal. 
(B) Hindbrain sagittal section showing staining of the subcoeruleus (SubC), gigantocellular nucleus (Gi) 
and the hypoglossal (12N).  
500 µm Sagittal vibratome sections; 500 µm scale bars 
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Figure 4.11. Adult XLαs expression pattern in the preoptic area of wild type mice. 
(A) Posterior preoptic area shows expression in the anterodorsal preoptic nucleus (ADP) and the A14 
noradrenergic neurons in this region. The anterior commisure (aca) does not express XLαs protein. 
(B) The anterior preoptic area shows XLαs in the ADP, lateral septal nucleus (LSV) and bed nucleus of the 
stria terminalis (BSTMA; BSTVA). The medial preoptic nucleus (MnPO), aca and the ventral pallidum (VP) 
do not express XLαs.   
14 µm coronal cryostat sections; 500 µm scale bars 
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develops in adult tissue (Figure 4.8 A and B). This nucleus is detected in CMV-
Cre/+; +/XLlacZGT mice with XGal staining for XL- Gal; however, this is reduced 
compared to the staining seen in adult wild type mice (Figure 4.9 B). This 
finding concurs with the 90% reduction in expression levels seen by qPCR 
(KRECHOWEC et al. 2012). Adult brain sections did not show staining of blood 
vessels. This will be discussed further in Chapter 5. 
4.3.3. GNASXL EXPRESSION IN THE BRAINSTEM IS ALTERED IN ADULT TISSUE 
COMPARED TO NEONATAL TISSUE 
In neonatal wild type tissue, areas expressing XLαs protein include the 
raphe nuclei (RPa, ROb; Figure 4.12 A and B) and the Gi (Figure 4.12 B).  The 
Amb also stains for XL- Gal fusion protein (Figure 4.12 D). The orofacial motor 
nuclei (7N and 12N) are strongly positive in both wild type and Nestin-Cre/+; 
+/XLlacZGT mice (Figure 4.7 A and B; 4.12 A and C.).  
In adult medulla oblongata, the Gi stains for XLαs and XL- Gal (CMV-
Cre/+; +/XLlacZGT) (Figure 4.13 A and D; Figure 4.10 B) as does the RPa (Figure 
4.13 E.). The orofacial motor nuclei (7N and 12N) could not be detected in adult 
tissue with IHC for XLαs in wild type mice (Figure 4.13 C.) and Gnasxl 
expression was barely detectable with in situ hybridisation (Figure 4.14.); 
however, these nuclei were clearly detectable with XGal staining in 500 µm 
vibratome sections (Figure 4.10 B; Figure 4.14 A and B). Adult-specific staining 
was observed in the rostral part of the NTS, which was detected with IHC 
(Figure 4.13 A and B) and XGal (Figure 4.15 C).  
In the neonatal pons the LC and LDTg nuclei were strongly positive for 
XLαs in wild type mice as well as XL- Gal in Nestin-Cre/+; +/XLlacZGT mice 
(Figure 4.16). In both mouse lines the SubC expressed the respective XL
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Figure 4.12. Neonatal expression of Gnasxl in the medulla oblongata  
(A) XLαs expression in the hypoglossal (12N) and raphe obscurus (ROb) of wild type neonatal mice is 
strong  
(B) XLαs expression in the gigantocellular reticular nucleus (Gi) and the ROb of wild type mice  
(C) XL-βGal fusion protein expression in the 12N and Gi of Nestin-Cre/+; +/XLlacZGT mice stained with 
XGal  
(D) XGal staining of XL-βGal fusion protein expression in the Gi and ambiguus nucleus (Amb) in Nestin-
Cre/+; +/XLlacZGT mice 
(A-B) 25 µm coronal cryostat sections; 500 µm scale bars 
(C-D) 80 µm coronal cryostat sections; 500 µm scale bars 
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Figure 4.13. XLαs expression in the medulla oblongata of adult wild type mice 
(A) Overview of XLαs protein expression in the medulla oblongata including the nucleus of the solitary 
tract (NTS), the gigantocellular reticular nucleus (Gi) and the hypoglossal (12N). 500 µm scale bar. 
(B) Magnification of the NTS indicating cells and axonal staining. 200 µm scale bar. 
(C)  Magnification of the 12N showing no expression of XLαs using IHC. 500 µm scale bar. 
(D) Magnification of the Gi. This image shows clear XLαs expression in neurons and the axonal projections 
from these neurons. 20 µm scale bar. 
(E) XLαs is expressed in neurons and axons of the raphe pallidus (RPa). 200 µm scale bar. 
14 µm coronal cryostat sections 
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Figure 4.14. in situ hybridisation staining of Gnasxl expression in the hypoglossal of adult wild type 
mice 
Expression of Gnasxl was barely detectable by in situ hybridisation in the hypoglossal (12N). This 
indicates that Gnasxl expression is reduced in adult mice. Confirming the lack of expression detected with 
the XLαs antibody in the 12N in wild type mice. 
14 µm coronal cryostat section; 500 µm scale bar 
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Figure 4.15.  XL-βGal expression in the orofacial motor nuclei of adult CMV-Cre/+; +/XLlacZGT brains 
(A) In the facial nucleus (7N) XL-βGal is expressed in a diffuse pattern. There is also expression in the raphe 
pallidus (RPa).   
(B) XL-βGal fusion protein is expressed in the hypoglossal nucleus (12N).  
(C) Staining in the medulla is seen in the 12N and the nucleus of the solitary tract (NTS). The NTS staining is 
weak compared to the staining of  XLαs adult staining in wild type mice. 
(D) In the pons the motor trigeminal nucleus (Mo5) is diffusely stained for XL-βGal fusion protein. The 
subcoeruleus (SubC) can also be seen. 
500 µm coronal vibratome sections; 500 µm scale bars   
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Figure 4.16. Neonatal Gnasxl expression pattern in the Pons 
(A) XLαs expression in the laterodorsal tegmental nucleus (LDTg) and the locus coeruleus (LC) of wild 
type mice.  
(B) XLαs expression pattern in the anterior pons peduncle (PTg) and the SubC of wild type mice. 
(C) XL-βGal fusion protein expression in the PTg and the SubC of Nestin-Cre/+; +/XLlacZGT mice 
(D) XL-βGal fusion protein expression in the PTg, SubC, A7 and Mo5 of Nestin-Cre/+; +/XLlacZGT mice 
80 µm coronal freeze microtome sections; 500 µm scale bars 
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proteins (Figure 4.16). The Mo5 orofacial motor nucleus was also strongly 
positive for XL- Gal in Nestin-Cre/+; +/XLlacZGT neonates (Figure 4.7 A; Figure 
4.16 D). 
In the adult pons the expression pattern changed compared to neonates. 
The LC and SubC continued to express XLαs and XL- Gal (Figure 4.17; Figure 
4.10 B). However, the LDTg region no longer expressed Gnasxl in either mouse 
line (Figure 4.17 B). The positive staining of the Mo5 orofacial motor nucleus 
was reduced, being undetectable with IHC and IF but diffusely stained with XGal 
(Figure 4.17 A; Figure 4.15 D).  
4.3.4. XL- GAL EXPRESSION IN THE SPINAL CORD 
In CMV-Cre/+; +/XLlacZGT neonatal mouse spinal cord there was clear 
staining of XL- Gal fusion protein in the ventrolateral motor neurons (VMN) in 
the ventral part of the spinal cord. This clearly colocalised with a marker for 
cholinergic neurons: choline acetyl transferase (ChAT) (Figure 4.18 A and C). In 
the IML layer of the spinal cord there were many ChAT positive neurons; in this 
region ChAT denoted sympathetic preganglionic neurons (SPNs). These SPNs 
did not regularly colocalise with the few XL- Gal-expressing neurons in the IML 
that were observed (Figure 4.18 A and B). There were several XL- Gal-
expressing neurons in the vicinity of the ChAT-expressing neurons in the IML 
layer (Figure 4.18 A and B). 
In adult spinal cord, XL- Gal expression resulted in a more diffuse 
staining in the VMNs (Figure 4.19; Figure 20 A). There was still a considerable 
amount of colocalisation in this region between XL- Gal and ChAT in adult CMV-
Cre/+; +/XLlacZGT spinal cord (Figure 4.20 A). In the IML layer there were 
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  Figure 4.17. Staining in the adult wild type Pons 
(A) XLαs expression in the SubC of the pons. The motor trigeminal nucleus (Mo5) is not visibly stained 
with the IHC technique. 80 µm coronal freeze microtome section. 
(B) XLαs expression is observed strongly in the LC but no staining can be seen in the LDTg, a change from 
the neonatal expression pattern. 14 µm coronal cryostat section. 
500 µm scale bars 
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Figure 4.18. Confocal images of neonatal expression of XL-βGal fusion protein in the neonatal 
spinal cord of CMV-Cre/+; +/XLlacZGT mice  
(A) Overview staining of the neonatal spinal cord shows two distinct layers of ChAT expressing neurons. 
The white arrow indicates the ventromedial layer neurons where there is a significant amount of 
colocalisation. 200 µm scale bar 
(B) XL-βGal and ChAT staining in the intermediolateral layer of the spinal cord. White arrow indicates a 
colocalised cell. A green arrow indicates a singly stained ChAT cell. The red arrow indicates a singly 
stained XL-βGal neuron. Very few neurons express XL-βGal in this layer of the spine. (i) merged image (ii) 
XL-βGal only (iii) ChAT only. 
(C) XL-βGal fusion protein expression in the VMN neurons shows some colocalisation in these neurons 
with ChAT. A green arrow indicate (i) merged image (ii) XL-βGal only (iii) ChAT only 
(B-C) 20 μm scale bars  
14 µm sagittal cryostat sections 
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Figure 4.19. XGal staining for XL-βGal fusion protein expression in the spinal cord of adult CMV-
Cre/+; +/XLlacZGT mice 
(A) The XL-βGal fusion protein is expressed in the ventral motor neurons (VMNs) of the spinal cord. This 
tissue was dissected out, cut in half in a sagittal orientation and used in a whole mount staining protocol. 
500 µm scale bar 
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 Figure 4.20. Transverse section of adult spinal cord stained for ChAT and XL-βGal fusion protein 
in CMV-Cre/+; +/XLlacZGT mice 
(A) Overview image of adult transverse section of the spinal cord showing the VMN (white arrow) and 
the IML (green arrow). White square indicates the area magnified in (B-D). 200 µm scale bar. 
(B) ChAT single stained section in the IML.   
(C) βGalactosidase single stained section for XL-βGal fusion protein in the IML. 
(D) Merged image of B and C showing one colocalised cell in the IML (white arrow) 
(B-D) 20 µm scale bar 
25 µm sagittal cryostat sections 
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several XL- Gal-positive neurons; these were mostly singly-stained with the 
occasional ChAT colocalised neuron (Figure 4.20; Figure 4.21). There were 
many more SPNs expressing ChAT in the IML layer than XL- Gal-expressing 
neurons (Figure 4.18; Figure 4.20; Figure 4.21). Neurons in the VMN were 
detectable with XGal staining in adult tissue (Figure 4.19).  
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Figure 4.21. Horizontal section of CMV-Cre/+; +/XLlacZGT mouse spinal cord co-stained for XL-βGal 
fusion protein and the sympathetic preganglionic neuron marker choline acetyl transferase 
(A) βGalactosidase IF of horizontally sectioned adult spinal cord showing clear XL-βGal expression in the 
inter medial lateral layer. 
(B) Choline acetyl transferase (ChAT) expression in the same section. 
(C) Merged image of (A) and (B) showing that there is little XL-βGal and ChAT coexpression in the IML  
25 µm horizontal cryostat sections; 500 µm scale bar; red arrow indicates a single XL-βGal stained neuron; 
green arrow indicates a singly stained ChAT neuron; white arrow indicates a colocalised XL-βGal/ChAT co-
expressing neuron.  
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4.4. DISCUSSION 
4.4.1. EXPRESSION OF GNASXL IN REGIONS RESPONSIBLE FOR ENERGY 
HOMEOSTASIS 
 The hypothalamus is a well-described control centre for energy 
homeostasis. This is a region which has been described as having strong Gnasxl 
expression at neonatal day four (KRECHOWEC et al. 2012). This area of the 
hypothalamus continues to develop over the first neonatal days (BOURET et al. 
2004; BOURET and SIMERLY 2004). The hypothalamic regions of the brain remain 
positive for XLαs from neonatal day one to adult phases of development. The 
XLαs expression in the LH, DMH and Arc continues to develop over the first 
neonatal days and is therefore unlikely to contribute to the lethargy and poor 
suckling phenotype seen in neonates that continues past neonatal day four 
(PLAGGE et al. 2004).  
These regions show increased expression of XLαs in adult mice but this 
is unlikely to be the main contributing factor for the phenotypic difference 
between neonates and adults, although loss of XLαs in these neurons might have 
implications for the increased food intake and energy expenditure in adult mice. 
A region of adult-specific XLαs expression is the amygdala – a region 
important not only for emotions and memories but also reward seeking 
behaviours and energy balance (CAMPBELL 2002; MIÑANO et al. 1992). This region 
could have wide-ranging effects although the exact impact of XLαs deletion in 
this nucleus remains to be elucidated. The CeA has many projections into parts 
of the brain involved in the regulation of energy homeostasis including the 
hypothalamus (it has reciprocal projections to orexin neurons in the DMH) 
(MIGUELEZ et al. 2001; MIÑANO et al. 1992). 
Chapter 4. Gnasxl Expression Pattern I: CNS 
118 
4.4.2. GNASXL EXPRESSION IN REGIONS IMPORTANT FOR SNS OUTFLOW 
The brain is integral to the correct functioning of the SNS. Many regions 
of the brain known to be centres for SNS outflow express Gnasxl. The PVN in 
adult tissues expresses XLαs clearly in the periphery of the nucleus. Neurons in 
this area of the PVN have been established as GABAergic (VONG et al. 2011) and 
it is possible that these neurons have inhibitory effects on the neurons 
expressing Gsα in the centre of the PVN (CHEN et al. 2009b) or other neurons in 
this central region. Gnasxlm+/p- mice show increased sympathetic activity (XIE et 
al. 2006) and this nucleus is also a well-known centre for SNS outflow. XLαs–
expressing neurons might inhibit this in wild type mice – projecting onto the 
SNS mediating neurons in the centre of the nucleus. 
It is also interesting that the POA projects to the DMH to control BAT 
thermogenesis through the SNS by inhibiting neurons (MCALLEN 2004; MORRISON 
and NAKAMURA 2011). However, both of these areas are stained in adults and 
have high Gnasxl expression at the day of birth suggesting they are not 
responsible for any changes in phenotype that have been noted. Loss of POA 
neurons inhibiting the DMH might have an impact on body temperature. The 
POA also has links to the amygdala through the BST; all of these regions contain 
Gnasxl expression.  
The fact that XLαs expression continues to develop in these brain regions 
post-weaning indicates that this area is not a major contributor to the suckling 
behaviour of neonates observed from the day of birth, and therefore would not 
be a likely cause of the lethargy, feeding or mortality problems observed with 
the Gnasxlm+/p- neonatal mice (PLAGGE et al. 2004).    
The observation that XLαs-expressing and ChAT-expressing neurons are 
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in mainly separate populations in the IML of the upper spinal cord suggests that 
XLαs is unlikely to directly affect the SPNs in this region; however, it is 
reasonable to hypothesise that XLαs neurons, with their close proximity to 
SPNs, might have a regulatory function on these SPN neurons.   
Staining of the Amb was continuous throughout neonatal and adult 
developmental stages. This area is important for parasympathetic activity and it 
is possible that these XLαs-expressing neurons might act to inhibit SNS outflow, 
and deletion of XLαs in these neurons would result in the SNS over-activity seen 
in Gnasxlm+/p- mice (XIE et al. 2006).  
4.4.3. GNASXL EXPRESSION IN NUCLEI RESPONSIBLE FOR MUSCLE INNERVATION 
The orofacial motor nuclei (Mo5, 7N and 12N), with their strong XLαs 
expression even at neonatal day one that is reduced in adult tissue, could be 
important for the phenotype seen in neonatal mice. These regions are well-
developed at birth and are extremely important for efficient suckling as they 
control not only the facial muscles but also the tongue (TRAVERS 2004).  
It is interesting that the orofacial motor nuclei seem to be down-
regulated towards adulthood in terms of their contribution to feeding. XLαs 
expression in these nuclei might be necessary for control of facial muscles 
during neonatal suckling but might not be required for adult feeding 
behaviours. This could be an explanation for the recovery of normal feeding 
behaviour in surviving Gnasxlm+/p- adults, which have increased food intake 
relative to their body weight when compared to wild type littermates. The fact 
that these nuclei could not be detected with IHC in adults might be due to the 
sensitivity of the IHC technique not detecting low levels of full-length XLαs 
protein compared to the XGal detection of the XL- Gal and the poor affinity of 
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the XLαs antibody compared to the anti-βGalactosidase antibody. It is also 
possible that the insertion of the gene trap into the exon A20 region of the gene 
locus could have disrupted something that controlled this expression – possibly 
an enhancer element or a developmental control region that has not been 
described previously . Analysis of the expression levels in the gene trap-carrying 
mice (inactive or active) showed that they have a 90% reduction in expression 
of the XLαs full-length (inactive) or the XL-βGal fusion protein (active gene trap) 
(KRECHOWEC et al. 2012). A new gene trap mouse model is in the process of being 
created; this gene trap will be inserted in a region of the intron much farther 
from the Gnasxl exon 1 and will not result in disruption of the full-length XLαs in 
mice carrying the non-active gene trap. 
4.4.4. ALERTNESS AND SLEEP/WAKE NUCLEI EXPRESS GNASXL 
In regions of the brain important for alertness, wakefulness and sleep 
(LDTg, LC, Gi) there is clear staining in neonatal brain using both IHC and XGal 
staining at neonatal day one. These areas were also positive at neonatal day four 
(PLAGGE et al. 2004). Previously it had been suggested that deletion of XLαs in 
these nuclei might be the cause of the lethargy seen in neonatal Gnasxlm+/p- mice 
(PLAGGE et al. 2004).  In adult tissue the LDTg no longer expresses either full-
length XLαs or the XL- Gal fusion protein, although both the Gi and the LC 
continue to express XLαs strongly. The loss of XLαs in the LDTg could partly 
explain the recovery of the lethargy seen in these Gnasxlm+/p- adult survivors as 
this nucleus is important for alertness and wakefulness and is only expressed at 
neonatal stages of development. Deletion of XLαs in the Gi and/or the LC might 
have a role in the phenotype, which is shared by the two developmental stages. 
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4.4.5. ADULT-SPECIFIC AREAS OF STAINING 
The NTS, as a new area of adult-specific staining, is interesting: this 
region is the input centre in the brain for signals from the gut through the vagal 
nerve, transmitting satiety and hunger signals to the brain from the periphery 
(HAYES and COVASA 2006; SCHWARTZ 2002; VRANG et al. 2003; WILLING and 
BERTHOUD 1997). A disregulation of this nutrient-sensing system in Gnasxlm+/p- 
adult survivors might explain their increased food intake compared to their wild 
type siblings (XIE et al. 2006).  
The amygdala is important for emotions and memory retention as well 
as energy homeostasis. It has connections with many regions of the brain 
including the DMH and the POA. It is possible that these areas have not fully 
developed at birth and as there is no expression found in these nuclei on the day 
of birth in wild type mice they are unlikely to contribute to the knock-out Gnasxl 
phenotype in neonates. The loss of XLαs signalling in these nuclei in adulthood 
might have implications for food intake and nutrient sensing.  
4.4.6. DIFFERENCES BETWEEN ANALYSIS TECHNIQUES 
The differences seen between expression patterns of XLαs protein with 
IHC and XL-βGal fusion protein using XGal or IF for Galactosidase were 
interesting observations. There could be several possible explanations for this. 
Firstly, it could result from the insertion of the gene trap across the A20 region 
of the gene locus. There might be an enhancer or other control mechanism for 
expression in this location, which would be affected by the gene trap insertion. 
Secondly, it is possible that the two types of protein are processed differently in 
different regions of the brain in vivo. The shorter XL-βGal fusion protein could 
be quickly degraded in the amygdala and NTS. The cause of XL-βGal expression 
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detection in an area and no expression of XLαs full-length is likely to be a 
problem of antibody sensitivity. As we think these areas are down-regulated in 
adult brain it could be the case that the IHC detection of the full-length protein is 
not possible while the more sensitive XGal staining can still detect XL-βGal.  
4.4.7. CONCLUSIONS  
The Gnasxl expression pattern in the CNS alters from neonatal stages to 
adult stages of development (Table 4.1). Many regions of the brain maintain 
expression of Gnasxl while other regions are down-regulated or begin to 
produce Gnasxl once the brain is matured. Regions which strongly express 
Gnasxl on the day of birth but have down-regulated expression into adulthood 
appear to have functions which might explain not only the initial poor suckling 
phenotype observed in the neonatal mice but also why the surviving adult mice 
do not exhibit a feeding phenotype (Table 4.1).  
Many regions which maintain expression are involved in the control of 
energy homeostasis (food intake and energy expenditure) and/or SNS control. 
This is in concurrence with the phenotype of an over-activity of the SNS in 
Gnasxlm+/p- mice (XIE et al. 2006). 
New areas of Gnasxl expression in adult brain might be due to the 
continued development of the brain over the first weeks of life. These regions 
would be unlikely to have an effect on the neonatal phenotype but might have 
implications for the increased food intake and energy expenditure observed in 
adult survivor Gnasxlm+/p- mice (XIE et al. 2006). 
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Table 4.1. Table of Brain areas in neonatal and adult tissues which show Gnasxl expression
Neonatal and 
Adult staining 
Neonatal Specific 
staining 
Adult Specific 
Staining 
LH, DMH, PVN, Arc, 
VMN, IML, Mo5, 7N, 
12N, RPa, Gi, LC, 
SubC, Amb, SCh, 
POA 
LDTg NTS, Amygdala 
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CHAPTER 5. GNASXL EXPRESSION: A COMPARATIVE 
STUDY OF CHANGES BETWEEN NEONATAL AND ADULT 
DEVELOPMENTAL STAGES II. PERIPHERAL TISSUES 
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5.1. INTRODUCTION 
5.1.1. PREVIOUS GNASXL EXPRESSION ANALYSIS IN NEONATES 
XLαs expression has been partially described previously in peripheral 
tissues of both mice and rats using Northern blotting and in situ hybridisation 
(PASOLLI et al. 2000; PLAGGE et al. 2004).   These data indicated that XLαs was 
expressed not only in the brain but also in the heart, BAT, white adipose tissue 
(WAT), pancreas, pituitary gland, adrenal gland and kidneys (PASOLLI et al. 2000; 
PLAGGE et al. 2004). These tissues are all important for the maintenance of 
energy homoeostasis and some are derived from the neural crest of the embryo 
(adrenal medulla), thus their expression of XLαs is unsurprising as they would 
simply be modified neurons. There has been no systematic analysis of Gnasxl 
expression pattern in these peripheral tissues. 
5.1.2. THE PITUITARY GLAND 
The pituitary gland is located at the base of the brain in contact with the 
median eminence via a portal vein. It is formed of two parts – the 
neurohypophysis (neural part) and the adenohypophysis. The neurohypophysis 
is derived from the diencephalic tissue and consists of the neural lobe, the 
pituitary stalk and median eminence (ARMSTRONG 2004). The neural lobe is 
supplied with catecholamines from the dopamine neurons in the NTS and 
rostral periventricular (GARTEN et al. 1989; KAWANO and DAIKOKU 1987). The 
main hormones released from the neurohypophysis are oxytocin and 
vasopressin. As well as catecholamines, both GABA and serotonin have been 
found in this lobe of the pituitary probably regulating hormone release (FALKE 
1991). 
The adenohypophysis consists of three parts - the anterior lobe, the 
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intermediate lobe and the pars tuberalis (ARMSTRONG 2004). The anterior lobe 
surrounds all but the dorsal part of the pituitary. The intermediate lobe, which 
is derived from the neural crest, is innervated by dopamine (BJÖRKLUND et al. 
1973), serotonin (MEZEY et al. 1984) and GABA (TAPPAZ et al. 1983). This lobe is 
also known to produce POMC derived proteins including -MSH (ARMSTRONG 
2004).  
5.1.3. THE ADRENAL GLANDS 
The adrenal glands are located on the top of the kidneys and are 
endocrine glands. They release hormones in response to stress, for example 
they release corticosteroids such as cortisol and catecholamines such as 
epinephrine.  
The adrenal medulla is the body’s main source of the catecholamines: 
noradrenaline and adrenaline as well as some dopamine (TORTORA and 
GRABOWSKI 2003). They are stimulated through the thoracic spinal cord 
preganglionic fibres (MORRISON and CAO 2000). They release secretions directly 
into the blood. Medullary cells are derived from the neural crest, which means 
they are modified neuronal cells unlike the adrenal cortex, which is derived 
from the mesoderm. Norepinephrine released from the adrenal medulla 
activates the receptors in the vagal nerve, which in turn stimulates the NTS.   
5.1.4. MUSCLE TISSUE 
There are three main types of muscle tissue found in the body: skeletal 
muscle; smooth muscle; and cardiac muscle.  The latter two are not under 
conscious control whilst the first can be controlled consciously (limb control) or 
unconsciously (breathing). Smooth muscle is contained in organs such as the 
gastrointestinal tract and blood vessels. The heart (cardiac muscle) was 
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previously described as having Gnasxl expression in wild type mice in four-day 
old mice Northern blot analyses (PLAGGE et al. 2004). This muscle type is 
controlled by SNS outflow from the brain. Its function has important 
implications in blood pressure and heart rate through sympathetic activation.  
5.1.5. ADIPOSE TISSUE 
There are two forms of adipose tissue, WAT and BAT, named for their 
colour; WAT is colourless to the naked eye while BAT has a distinctive brown 
coloration due to the high density of mitochondria in this tissue. The lean 
Gnasxlm+/p- mice have very little adipose tissue (BAT or WAT) although it has 
been indicated that Gnasxl is expressed in neonatal BAT and WAT by Northern 
blot and RT-PCR (PLAGGE et al. 2004; XIE et al. 2006). 
WAT is located in the peritoneal cavity or subcutaneously (PAVELKA and 
ROTH 2010) and provides an important energy source in the form of 
triglycerides, which can be stored or metabolised depending on the energy 
status of an organism. Another important role of this tissue is its secretory 
function: WAT secretes leptin, along with other adipocytokines, as an indicator 
of adiposity (PAVELKA and ROTH 2010).  
There are several BAT deposits located around the body, the main one 
being in the interscapular region. BAT cells contain fat in many small vacuoles, 
as opposed to the single large fat vesicle which demarks WAT (HULL and SEGALL 
1966). BAT is important for non-shivering thermogenesis in the newborn 
mammal, although it is still present in adults. Non-shivering thermogenesis is 
induced by norepinephrine release and cold exposure. Several areas of the brain 
including the raphe pallidus, DMH and POA are involved in the SNS activation of 
non-shivering thermogenesis in BAT (CANNON and NEDERGAARD 2004). 
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Norepinephrine controls the cAMP production in BAT by binding to 3-
adrenergic receptors (a Gs-coupled receptor) to simulate cAMP production; it 
can also bind to α2-adrenergic receptors (Gi-coupled receptors) inhibiting 
adenylyl cyclase and reducing cAMP production thus inhibiting thermogenesis 
(CANNON and NEDERGAARD 2004).  
Heat is produced in the tissue by the uncoupling action of uncoupling 
protein 1 (UCP1), a BAT specific uncoupling protein, which is activated only in 
stimulated mature adipocytes and is the only uncoupling protein to mediate 
thermogenesis (CANNON and NEDERGAARD 2004). Other work has found an 
increase in UCP1 as well as an increased body temperature in adult Gnasxlm+/p- 
mice (XIE et al. 2006) (our unpublished data). It has also been observed that 
there is increased lypolysis in BAT and WAT of Gnasxlm+/p- mice, which is 
probably due to the global increase in SNS activity that is seen in these mice (XIE 
et al. 2006).  
5.1.6. AIMS 
The aim of this work was to confirm, on a histological level, the Gnasxl 
expression pattern in peripheral tissues using the XLlacZGT mouse line. For 
analysis of peripheral tissues crosses of Nestin-Cre (Nestin-Cre/+; +/XLlacZGT) 
and CMV-Cre (CMV-Cre/+; +/XLlacZGT) were performed with male XLlacZGT 
mice.  
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5.2. MATERIALS AND METHODS 
5.2.1. TISSUE COLLECTION 
Tissues were collected from neonatal and adult CMV-Cre/+; +/XLlacZGT 
and +/+; +/XLlacZGT mice as described in Chapter 4. 
5.2.2. XGAL WHOLE-MOUNT STAINING  
Protocols for immunofluorescence and whole mount staining with XGal 
were carried out as described in Chapter 4.  
5.2.3. ANTIBODIES 
Primary antibodies used for co-staining of XL- Gal and cellular markers 
in blood vessels were chicken anti-βGalactosidase (Abcam; 1:500; ab9361), 
mouse IgG2α anti-alpha Smooth Muscle actin (Sigma; 1:500; A2547) and rabbit 
anti-von Willebrand factor (Dako; 1:500; A0082).  
Secondary antibodies used were donkey anti-chicken Dylight™ 594 
(Jackson ImmunoResearch, 1:1000), Zenon direct labelling kit 488 (Invitrogen) 
and donkey anti rabbit AF488 (Invitrogen; 1:1000) 
5.2.4. DIRECT LABELLING OF PRIMARY ANTIBODIES 
Direct labelling was carried out according to the instructions for the 
mouse IgG2a AF488 kit. This consisted of the following steps: 1 µg antibody was 
pipetted into a 1.5 mL tube and 5 µL component A from the Zenon labelling kit 
was added, mixed carefully by pipetting and incubated in the dark for 5 
minutes. 5 µL Component B was added, mixed by pipetting and incubated in the 
dark for 5 minutes. The directly labelled antibody was used in 
immunofluorescence co-localisation experiments by addition to the secondary 
and DAPI incubation solution of the immunofluorescence protocol described in 
Chapter 4. 
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5.2.5. IMMUNOFLUORESCENCE  
This staining was carried out in the same way as described in Chapter 4. 
5.2.6. HISTOLOGY OF XGAL STAINED WHOLE MOUNT TISSUES. 
After XGal whole mount staining, tissues were prepared for microtome 
sectioning by dehydrating in an ethanol series and then incubating with 
Histoclear. Tissues were then embedded in paraffin, which was allowed to 
solidify before sectioning on a paraffin microtome at 7 µm. After mounting onto 
slides the sections could be rehydrated and counterstained with Eosin before a 
final dehydration and mounting with Eukitt® as described in Chapter 4.  
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5.3. RESULTS 
5.3.1. TISSUE COLLECTION FOR ANALYSIS OF XL- GAL EXPRESSION PATTERN IN 
THE PERIPHERAL TISSUES OF NEONATAL AND ADULT XLLACZGT MICE 
To analyse the expression pattern of Gnasxl in the peripheral tissues of 
mice, tissues were collected from neonatal day one and adult Cre/+; +/XLlacZGT 
mice. These were processed for XGal staining as described in the methods 
section of Chapter 4. Litters of neonates were collected after schedule one 
killing while adult tissues were collected after perfusion fixation. Controls were 
performed on +/+; +/XLlacZGT littermates of Cre/+; +/XLlacZGT mice. 
5.3.2. XL-βGAL IS EXPRESSED IN PERIPHERAL TISSUES  
In the neonatal pituitary gland of Cre/+; +/XLlacZGT mice, staining was 
seen in the intermediate layer of the adenophysis (Figure 5.1. A). In the neonatal 
adrenal gland the XL- Gal staining was limited to the medullary tissues (Figure 
5.1. B). Controls for the pituitary tissue determined that there was no 
βGalactosidase-like endogenous activity in this tissue (Figure 5.1. C). Both the 
intermediate layer of the pituitary and adrenal medulla expressed XL- Gal in 
adult tissue whole mount staining (Figure 5.2. A and B) and again in the 
pituitary of +/+; +/XLlacZGT mice there was no XGal staining (Figure 5.2. C).  
5.3.3. XL-βGAL EXPRESSION IN ADIPOSE TISSUE IS FOUND IN BLOOD VESSELS 
 In the WAT of CMV-Cre/+; +/XLlacZGT neonatal mice staining of 
blood vessels was observed (Figure 5.3. A). This staining was not present in the 
+/+; +/XLlacZGT sibling mice (Figure 5.3. C). In BAT tissue staining was seen in 
the blood vessels only (Figure 5.3. B). Both CMV-Cre/+; +/XLlacZGT mice and 
their +/+; +/XLlacZGT siblings have very little adipose tissue similar to the 
Gnasxlm+/p- phenotype (XIE et al. 2006).  
Chapter 5. Gnasxl Expression Pattern II: Peripheral Tissues 
132 
 
  
Figure 5.1. XL-βGal expression in whole mount neonatal tissues derived from the neural crest  
(A) In the pituitary gland of neonatal CMV-Cre/+; +/XLlacZGT mice XL-βGal expression is confined to the 
intermediate layer of the gland  
(B) XL-βGal expression in the adrenal gland of neonatal CMV-Cre/+; +/XLlacZGT tissue was limited to the 
adrenal medulla. No XGal staining of the adrenal cortex was observed (Staining performed by Stefan 
Krechowec). 
(C) The intermediate layer of the pituitary gland in neonatal +/+; +/XLlacZGT mice does not stain for the 
XL-βGal fusion protein with XGal. 
500 µm scale bars or as indicated 
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Figure 5.2. Whole mount XGal staining of adrenal and pituitary gland in adult mice 
(A) The adult pituitary gland maintains expression in the intermediate layer (green arrow) of CMV-Cre/+; 
+/XLlacZGT mice. 
(B) In adult CMV-Cre/+; +; +/XLlacZGT tissue XGal staining of XL-βGal is observed in the adrenal medulla 
(green arrow). The adrenal cortex does not express XL-βGal fusion protein. 
(C) In The adult pituitary gland of +/+; +/XLlacZGT mice no XL-βGal was detected in the intermediate layer. 
500 µm scale bars 
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Figure 5.3. XL-βGal fusion protein expression pattern analysis in adipose tissue of neonatal mice 
using XGal staining 
(A) White adipose tissue shows some expression of the XL-βGal fusion protein in blood vessels in CMV-
Cre/+; +/XLlacZGT mice in whole mount staining for XGal. Scale bar 500 µm 
(B) Brown adipose tissue showing XL-βGal fusion protein in blood vessels of Nestin-Cre/+; +/XLlacZGT 
neonatal mice in 7 µm paraffin sections. 20 µm scale bar. 
(C) +/+; +/XLlacZGT white adipose tissue in neonates shows no XL-βGal fusion protein expression with 
XGal staining in whole mount tissues. Scale bar 500 µm. 
Red arrows indicate blood vessel staining;  
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5.3.4. XL-βGAL EXPRESSION IN MUSCLES IS RESTRICTED TO NEONATAL TISSUE 
XL- Gal expression was identified in other neonatal muscle tissues, 
including the intercostal muscles (Figure 5.4 A) and the tongue (Figure 5.4 B). 
Control XGal staining in +/+; +/XLlacZGT neonatal mice for the intercostal 
muscles and tongue indicated that this was genuine staining as no XGal staining 
was observed in these tissues (Figure 5.5). In adult +/+; +/XLlacZGT mice, no 
XGal staining was observed in either the intercostal muscles or the tongue 
(Figure 5.6 A and B). 
In other tissues that had previously been described as Gnasxl-expressing 
using Northern blotting and RT-PCR (PLAGGE et al. 2004; XIE et al. 2006), 
including BAT (Figure 5.3 B), the stomach (Figure 5.4. C) and the heart (Figure 
5.4. D), XL-βGal expression was observed to be limited to the blood vessels and 
no XGal staining was seen in the cells of the tissues themselves. In adult tissue 
this blood vessel expression was completely down-regulated (Figure 5.6 C). 
To determine the localisation of the XL-βGal expression in the blood 
vessels double immunofluorescence was applied. This established that the 
expression of XL- Gal was limited to the alpha smooth muscle actin ( SMA) 
positive cells in the muscular walls of the blood vessels (Figure 5.7) and was not  
present  in the endothelial cells of the blood vessels, as indicated by the 
endothelial marker von Willebrand Factor (vWF) (Figure 5.8).  
5.3.5. ENDOGENOUS βGALACTOSIDASE-LIKE ACTIVITY WAS OBSERVED IN SOME 
TISSUES 
Using immunofluorescence, XL- Gal expression was observed in the 
growth plates of neonatal bones of CMV-Cre/+; +/XLlacZGT mice (Figure 5.9. A), 
however, control tissues (+/+; +/XLlacZGT mice) stained with the
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Figure 5.4. XGal staining of the various different muscles of neonatal Cre/+; +/XLlacZGT mice 
(A) The intercostal muscle tissue surrounding the ribs (green arrow) stains for the fusion protein. 
Staining was also seen in the rib bones (yellow arrow). 500 µm scale bar 
(B) Strong XL-βGal fusion protein staining in the muscle of the neonatal tongue (Staining performed 
by Stefan Krechowec). 1000 µm scale bar 
(C) In stomach tissue of neonatal CMV-Cre/+; +/XLlacZGT mice XL-βGal fusion protein was confined to 
the blood vessels (red arrow). No staining was observed in the tissue of the stomach itself (Picture 
taken by Stefan Krechowec). 500 µm scale bar 
(D) Neonatal heart in Nestin-Cre/+; +/XLlacZGT shows expression in the blood vessels (red arrows) 
but no staining in the muscle cells of the cardiac tissue. Counter-stained with Eosin. (Picture taken by 
Anna Newlaczyl). 50 µm scale bar; 7 µm paraffin section. 
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Figure 5.5. Muscle XGal staining in whole mount tissues of control +/+; +/XLlacZGT neonatal mice 
(A) Control staining in the intercostal muscle +/+; +/XLlacZGT mice. There is staining in the rib bones 
detected indicating that it is endogenous βGalactosidase-like activity (Yellow arrows). XGal precipitate 
was not observed in the muscles. 
(B) Whole mount staining of +/+; +/XLlacZGT neonatal tongue. None of the strong blue XGal precipitate is 
formed remains in this tissue. 
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Figure 5.6. Whole mount XGal staining of adult peripheral tissues in CMV-Cre/+; +/XLlacZGT mice 
(A)  The strong blue XGal precipitate seen in neonates in lost in adult CMV-Cre/+; +/XLlacZGT mice. The 
endogenous Galactosidase-like activity seen in bones is still observed (yellow arrows). 
(B) XGal staining in the tongue of adult CMV-Cre/+; +/XLlacZGT mice showed no XL-βGal fusion protein 
expression 
(C) XGal staining in whole mount stomach tissue indicated that XL-βGal fusion protein expression is lost in 
the blood vessels in adult CMV-Cre/+; +/XLlacZGT mice.   
500 µm Scale bars 
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Figure 5.7. Confocal images of Colocalisation of XL-βGal fusion protein and alpha smooth muscle 
actin in neonatal blood vessels using immunofluorescence staining 
(A) XL-βGal fusion protein staining in blood vessels with the anti-βGalactosidase antibody  
(B) Alpha Smooth muscle actin staining in blood vessels with a directly labelled anti-alpha smooth muscle 
actin antibody 
(C) Merged image of XL-βGal fusion protein and alpha smooth muscle actin in (A) and (B) respectively 
showing high level of colocalisation between the two proteins 
50 µm scale bars; 14 µm cryostat sections  
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Figure 5.8. Confocal images of co-staining of XL-βGal fusion protein and von Willebrand Factor in 
neonatal blood vessels using immunofluorescence staining 
(A) XL-βGal fusion protein staining in neonatal blood vessels of muscles  
(B) von Willebrand Factor staining of neonatal blood vessels. This is a marker for endothelial cells in blood 
vessels. 
(C) Merged image of XL-βGal fusion protein and von Willebrand Factor showed there was no overlap 
between XL-βGal fusion protein and von Willebrand Factor 
50 µm scale bars; 14 µm cryostat sections 
Chapter 5. Gnasxl Expression Pattern II: Peripheral Tissues 
141 
Figure 5.9. Neonatal immunofluorescence staining in the growth plates of neonatal limb bones is 
βGalactosidase-like activity  
(A) βGalactosidase-like staining in the limb bones of CMV-Cre/+; +/XLlacZGT mice with the 
βGalactosidase antibody showed staining in the growth plates of neonatal mice 
(B) There is βGalactosidase staining in the growth plates of +/+; +/XLlacZGT mice. This means there is 
βGalactosidase –like activity in the growth plates of bones. 
500 µm scale bars; 25 µm cryostat sections 
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 anti- Galactosidase antibody showed the same pattern of staining with 
comparable strength (Figure 5.9. B). Negative controls showed little background 
staining could be attributed to the Dylight 594 secondary antibody. This 
endogenous βGalactosidase-like activity was also observed in bones of neonatal 
and adult mice using XGal staining (Figure 5.4. A; Figure 5.5. A; Figure 5.6. A) 
Endogenous Galactosidase-like activity was also observed in the adult kidney 
medulla in +/+; +/XLlacZGT mice, in the sphincter of the stomach and the upper 
intestine of neonatal and adult mice (Figure 5.10). 
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Figure 5.10. Whole mount control XGal staining in +/+; +/XLlacZGT adult mice showed endogenous 
βGalactosidase staining in some tissues 
(A) Endogenous βGalactosidase-like staining in the medulla of the adult kidney. 
(B) Endogenous βGalactosidase-like activity is seen in the sphincter of the stomach. The diffuse blue 
staining in the stomach is probably due to the gut flora of the mice  
 (C) In the upper gastrointestinal tract there was a diffuse staining in +/+; +/XLlacZGT mice which was 
attributed to the gut flora of mice. LacZ being a bacterial enzyme would result in a false positive staining 
in the gut. 
500 µm scale bars; Yellow arrows indicate endogenous staining; Purple arrows indicate false positive 
staining in the gut caused my micro-flora found in the rodent gastrointestinal tract 
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5.4. DISCUSSION 
5.4.1. PERIPHERAL GNASXL STAINING IN MUSCLES IS LIMITED TO NEONATES 
Analysis of XL-βGal expression in neonatal peripheral tissues was 
previously confined to analysis of mRNA with Northern blots and RT-PCR 
(PLAGGE et al. 2004; XIE et al. 2006). These data indicated that there was 
neonatal Gnasxl expression in the heart, stomach, WAT and BAT (PLAGGE et al. 
2004). Histology performed on these tissues in this project revealed that there 
was no XL-βGal expression in the cells of these tissue types and that the 
expression observed was from the blood vessels that ran through these tissues. 
Vascular tissue would have formed part of the Northern blot lysates previously 
analysed from these tissues but it would not have been possible to determine 
which cell types contributed to the detection of Gnasxl. 
Further analysis of the XL-βGal expression in the neonatal blood vessels 
established that it was limited to the SMA (as indicated by co-staining) in the 
muscular walls of the blood vessels. There was no staining in the endothelial 
cells of the vessels. This is consistent with other expression in the intercostal 
muscles and tongue. The very strong expression in the tongue of the neonates 
indicates it might be playing an important role in this area during development 
and this is obviously developing before birth. It is possible that the deletion of 
Gnasxl expression in these muscle tissues is a cause for the inertia observed in 
Gnasxl knock-out mouse pups (CATTANACH and KIRK 1985; KRECHOWEC and 
PLAGGE 2008; PLAGGE et al. 2004). 
Analysis of adult muscle indicates that there is no expression of Gnasxl in 
any muscle tissues including the tongue, the intercostal muscles, or the blood 
vessels. These data concur with previous findings in rats and mice (PASOLLI et al. 
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2000). It is possible that this transient muscle expression during the neonatal 
period could be an explanation for the recovery of correct feeding behaviour 
(tongue and facial muscles) and activity levels (skeletal muscles) in adult knock-
out mice (CATTANACH and KIRK 1985; KELLY et al. 2009; PLAGGE et al. 2004; XIE et 
al. 2006). 
5.4.2. XL-βGAL FUSION PROTEIN EXPRESSION IN OTHER PERIPHERAL TISSUES 
In the adrenal medulla and the pituitary XLαs expression had previously 
been identified with in situ hybridisation (PLAGGE et al. 2004). This data was 
replicated with XL-βGal staining and this expression pattern was maintained at 
adult stage. This is unsurprising as these tissues are derived from the neural 
tissues of the embryo and Gnasxl is highly expressed in neural tissues (PASOLLI 
and HUTTNER 2001).  
5.4.3. ENDOGENOUS βGALACTOSIDASE-LIKE STAINING ACTIVITY 
Endogenous Galactosidase-like activity also detected in adult kidney 
medulla and in the gastrointestinal tracts of both neonates and adults. Mice 
have a large population of naturally occurring gut flora and as lacZ is an E.Coli 
derived enzyme it is likely that this is the cause of the staining seen in the 
gastrointestinal tissues.  
The endogenous staining in all bones of neonatal and adult bones 
(regardless of genotype) might be due to staining in osteoclasts. This has been 
described previously (ODGREN et al. 2006). 
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6.1. INTRODUCTION 
6.1.1. XLLACZGT CARRIER MICE EXHIBIT AN UNEXPECTED PHENOTYPE 
Genotyping of the XLlacZGT pups from crosses of male gene trap carriers 
with female Cre-mice revealed that the genotypes were born in the expected 
Mendelian ratio. However, the phenotype of the +/+; +/XLlacZGT mice – which 
were expected to behave like and have the phenotype of wild type mice as the 
gene trap they carried would be inactive and should not have an effect on the 
expression of the XLαs protein – had the phenotype of CMV-Cre/+; +/XLlacZGT 
active gene trap carriers. In appearance they looked like Gnasxlm+/p- mice as well 
as showing the same neonatal mortality and growth retardation. In crosses of 
wild type females and XLlacZGT males, offspring showed the same phenotype 
when carrying the inactive gene trap. This unexpected phenotype of +/+; 
+/XLlacZGT pups led to the suspicion that Gnasxl expression might have become 
down-regulated by the insertion of the gene trap cassette in place of exon A20. 
Analysis of the expression levels by qPCR of Gnasxl in the Cre-negative gene trap 
carriers showed that there was a 90% reduction in expression levels of Gnasxl 
compared to wild type mice (KRECHOWEC et al. 2012). 
To elucidate the cause of this reduction in mRNA expression levels the 
+/+; +/XLlacZGT mice were analysed for their methylation pattern at the Nespas 
and Gnasxl promoter with the wild type mice. LacZ cassette insertions can cause 
disruption to methylation. It has also recently been observed that the Nespas-
Gnasxl DMR extends further along the locus than previously thought, and 
includes the A20 exon (SMALLWOOD and KELSEY 2011; TOMIZAWA et al. 2011). A 
gain of methylation on the paternal allele could cause silencing of the Gnasxl 
promoter. 
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6.1.2. AIMS 
The aim of this experiment was to elucidate the methylation pattern at 
the differentially methylated proximal Gnasxl promoter and Gnasxl exon in +/+; 
+/XLlacZGT and wild type littermates produced from Cre x XLlacZGT crosses. 
The expected DNA fragments for each genotype had to be established and then 
the DNA from each genotype was analysed by Southern blot. 
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6.2. MATERIALS AND METHODS 
6.2.1. TISSUE LYSIS FOR DNA EXTRACTION 
Tissues were placed in tail lysis buffer at 55°C for 12-48 hours depending 
on the size of the tissue. If the tissue piece was large it was necessary to 
precipitate the DNA with an equal volume of isopropanol, remove the lysate and 
resuspend the DNA pellet with 500 μL 1 x TE buffer before performing the 
phenol/chloroform extraction described below.  
6.2.2. GENOMIC DNA EXTRACTION AND PURIFICATION 
Under the fume hood, an equal volume of phenol: chloroform: isoamyl 
alcohol (25:24:1; Sigma) was added to each sample and the sample was shaken 
until the solution was mixed thoroughly. The samples were centrifuged for 30 
seconds and the aqueous layer was transferred to a fresh tube. It was important 
not to carry over any of the protein interphase layer. An equal volume of 
chloroform: isoamyl alcohol (24:1; Sigma) was added to the aqueous layer; the 
samples were mixed vigorously and then centrifuged for 30 seconds. The 
aqueous layer was again removed and transferred to a fresh tube. To this 0.1 
volumes of 3 M sodium acetate (pH 5.0) and 2.5 volumes of 100% EtOH were 
added and mixed until white strings of DNA were observed. The samples were 
centrifuged for 1 minute and the supernatant removed; care was taken not to 
touch the DNA pellets. The DNA pellets were then washed with 70% EtOH and 
centrifuged for 1 minute. The EtOH was removed and the pellets were allowed 
to air-dry at 37 C for 10 minutes. Dry pellets were resuspended in an 
appropriate volume of 1 x TE. 
6.2.3. RESTRICTION DIGESTS OF GENOMIC DNA 
10-20 µg genomic DNA was digested with restriction enzymes overnight 
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at 37°C in a total volume of 50 μL containing one unit of restriction enzyme and 
1 x concentration of restriction enzyme buffer. Digests were electrophoresed on 
0.8-1.2% agarose gels made with TAE buffer and containing ethidium bromide 
for visualisation.  
6.2.4. SOUTHERN BLOTTING AND DNA HYBRIDISATION 
6.2.4.1. DIG PCR DNA probe labelling kit (Roche) 
Primers were initially tested in Go Taq PCR reactions to make sure 
primer pairings produced bands of the expected size. 50 μL DIG-PCR reaction 
mix consisting of 160 ng/µl plasmid DNA; 1 x Buffer; 1 x DIG synthesis mix; 1 
mM forward primer; 1 mM reverse primer; 1 U DIG polymerase was run on the 
thermocycler. The program consisted of a continuously heated lid at 111°C and 
a 2 minute hot start at 95°C followed by 30 cycles of: 30 seconds denaturing at 
95°C, 30 seconds annealing at 56°C and 3 minutes extending at 72°C. The 30 
cycles were followed by a final extension time of 7 minutes at 72°C and cooling 
to 10°C. 2 μL of the PCR product was run on a 2% agarose gel containing 
ethidium bromide to establish that the reaction worked. The labelled probes 
produced in the PCR reactions were heat denatured for 10 minutes at 100 C and 
then added to an appropriate volume of hybridisation solution to be used as 
DNA probes in hybridisation of blotted membranes. 
6.2.4.2. Southern Blotting of Agarose Gels  
Restriction digests of genomic DNA were run on agarose gels (0.8 or 
1.2%) at a low voltage for several hours or overnight along with an appropriate 
DNA ladder. Gels were imaged in a gel dock along with a UV-sensitive ruler to 
allow confirmation of the band sizes detected on membranes after hybridisation 
and development. On completion of electrophoresis the gel was treated for 5 – 
10 minutes in 0.25 M HCl, twice for 15 minutes with denaturing solution (0.5 M 
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NaOH; 1.5 M NaCl) and twice for 15 minutes with neutral solution (1 M NH4 
acetate). Gels were blotted with the bottom side exposed to a nylon membrane 
(GE Healthcare) for 24 – 48 hours to ensure complete transfer of DNA to the 
membrane. After cross-linking with UV light using a Stratagene Cross-linker to 
permanently bind the DNA to the membrane, the membranes were pre-
hybridised with hybridisation buffer at 68°C for at least one hour. This solution 
was exchanged for the hybridisation buffer containing denatured DIG-labelled 
DNA probe and hybridised overnight at 68°C. Membranes were washed with 2 x 
SSC and 0.1% SDS, twice for 5 minutes at room temperature, then with two 
preheated stringent washes (0.2 x SSC and 0.1% SDS) for 20 minutes at 68°C. 
Equilibration was performed with DIG buffer 1 for several minutes prior to 
blocking the membrane with 1% blocking reagent (Roche) for 30 minutes at 
room temperature on a shaker. The membrane was incubated with 1% blocking 
reagent containing alkaline phosphatase-conjugated anti-DIG-Fab fragments 
(1:5000; Roche) for at least 30 minutes. Finally the membranes were washed 
twice for 15 minutes with DIG buffer 1 followed by equilibration in DIG buffer 3. 
6.2.4.3. Membrane Development 
A preparation of 45 μL NBT and 35 μL BCIP per 10 mL DIG buffer 3 was 
used for membrane development. The membrane was left floating in the 
development solution in the dark until a purple precipitate formed on the 
membrane (usually overnight) and the DNA fragments could be observed. 
Washing membranes in PBS stopped the reaction. Membranes were left to dry 
on Whatman™ 3MM paper in the dark, then stored in the dark. 
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6.3. RESULTS 
6.3.1. SELECTION OF RESTRICTION ENZYMES 
Using pDraw software, the Gnasxl promoter and exon were analysed for 
restriction site sequences of two types of restriction enzyme with specific 
properties. Firstly, a non-CpG methylation-sensitive enzyme was investigated; 
this needed to cut two or three times around the Nespas-Gnasxl DMR to create 
large DNA fragments, easily detectable by Southern blot, that could be cut into 
smaller fragments. The second enzyme was a methylation-sensitive restriction 
enzyme which would cut within the larger fragments created by the non-
methylation-sensitive restriction enzyme. The two enzymes selected were NsiI 
(non-methylation-sensitive) and EagI (methylation-sensitive); these enzymes 
cut in each genotype differently with the sizes indicated in Table 6.1. For 
restriction site sequences of the restriction enzymes see Appendix 5. 
6.3.2. DESIGN OF DIG-LABELLED DNA PROBES  
Two probes were created to analyse the whole of the methylation region 
covering the Gnasxl promoter and exon 1. The first probe was created using the 
XL DIG Probe F1 and XL DIG Probe R1 primers (XL Dig probe F1/R1; Appendix 
1). This would detect the methylation in the promoter and beginning of the 
Gnasxl exon (Figure 6.1). The second probe was created using the XL-F10 and 
XL-R5 primers (XL-F10/R5 probe; Appendix 1). This probe would detect the 
687 bp fragment at the end of the Gnasxl exon 1 (Figure 6.1). 
6.3.3. SOUTHERN BLOTTING OF DNA FROM XLLACZGT NEONATAL MICE 
Brain tissue, dissected on neonatal day 1 (see Chapter 3), was prepared 
for genomic DNA extraction. DNA was collected from a +/+; +/XLlacZGT mice 
along with wild type littermates.  
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Table 6.1. Fragments detected by Southern blot probes. Brackets indicate the fragment size if the 
paternal allele were to have unexpected methylation. 
 
 
+/+; 
+/XLlacZGT 
WT 
CMV-Cre/+; 
+/+ 
XL-DIG F1/R1 probe   
EagI/NsiI 
(EagI sites methylated) 
(8.8 kbp) 
5.8 kbp 
5.8 kbp 5.8 kbp 
EagI/NsiI 
(EagI sites unmethylated) 
3.4 kbp 3.4 kbp 3.4 kbp 
XL-F10/R5 Probe   
EagI/NsiI 
(EagI sites methylated) 
(8.8 kbp) 
5.8 kbp 
5.8 kbp 5.8 kbp 
EagI/NsiI 
(EagI sites unmethylated) 
1.1 kbp 687 bp 687 bp 
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Figure 6.1. Schematic of Restriction Digest Patterns for Southern blotting of DNA from offspring of a 
Cre x XLlacZGT cross 
(A) The maternal allele of each of the genotypes should be identical as it was inherited as a wild type allele 
from Cre-transgenic mice. As the maternal allele is methylated at the Gnasxl exon 1, it was expected that 
each probe would detect a 5.8 kbp DNA fragment. 
(B) Carriers of the paternally inherited non-active gene trap, in the inverted position were expected to 
produce one detectable fragment for each probe that was used. The XL DIG-F1/R1 probe would detect a 
fragment of ~3.4 kbp while the XL-F10/R5 probe would detect a 1.1 kbp fragment if the paternal allele 
remained unmethylated (8.8 kbp if the paternal allele was methylated). 
(C) Offspring that inherited a wild type paternal Gnasxl allele (with or without Cre) would produce the 
same size fragment as is detectable with the XL DIG-F1/R1 in gene trap carrying offspring of 3.4 kbp. The 
XL-F10/R5 would detect a 687 bp fragment. 
* indicates a fragment of ~300 bp that is too small to be detected by XL-F10/R5 probe, open circles 
indicate no methylation at that position; closed circles indicate the presence of methylation at that position. 
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Although the hybridised blot only produced weak signals and had strong 
background, the XL Dig F1/R1 probe detected the maternal wild type allele 
fragment, which was expected to be methylated and contained no gene trap, at 
5.8 kbp (Table 6.1; Figure 6.2). The paternal allele was also detected in all 
genotypes, producing a DNA fragment at 3.4 kb, which indicated an un-
methylated allele (Table 6.1; Figure 6.2).  
The XL-F10/R5 probe produced a different pattern of methylation 
depending on the genotype as these fragments were affected by an EagI 
restriction site within the lacZ cassette or the A20 exon (Table 6.1; Figure 6.1). 
The maternal wild type allele indicated that methylation was the same in all 
genotypes (5.8 kbp fragment; Figure 6.3). The paternal allele showed the 
expected 1.1 kbp fragment for the +/+; +/XLlacZGT DNA, and the 687 bp 
fragment for the wild type and CMV-Cre/+; +/+ (Figure 6.3).   
Although these blots were not ideal and were performed on a tight 
timescale towards the end of the PhD project they showed that the methylation 
pattern of the mice carrying the inactive gene trap was as expected and not 
altered by the addition of the gene trap. 
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Figure 6.2. Southern Blot of neonatal brain with XL Dig-F1/R1 probe  
(A) +/+; +/XLlacZGT DNA produced a fragment of 5.8 kbp this would be from the maternal allele and 3.4 
kbp – this would be from the paternal allele. There is no detection of a larger 8.8 kbp fragment that would 
occur if methylation was present on the paternal allele and no reduction of the 3.4 kbp band which would 
disappear (or be reduced) if methylation occurred unexpectedly. 
(B) The wild type DNA produces the same 5.8 kbp fragment from the maternal allele and a 3.4 kbp. 
fragment from the paternal allele.  
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Figure 6.3. Southern Blot of Cre/XLlacZGT neonatal brain with XL-F10/R5 probe 
(A) +/+; +/XLlacZGT, non-active gene trap carriers, produced the expected 5.8 kbp fragment from the 
maternal allele and the 1.1 kbp fragment that would be expected from the paternal allele if methylation 
was not present. This would suggest that the methylation is not altered. 
(B) The wild type DNA produced fragments as expected. The methylated maternal allele appeared as 
expected along with the 687 bp fragment from the paternal allele that was expected.  
(C) The CMV-Cre/+; +/+ mice appeared as wild type mice as expected. 
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6.4. DISCUSSION 
The analysis by Southern blot revealed that there was no change in the 
methylation using either of the two probes. The maternal allele was detected as 
expected, with methylation still maintained in all of the genotypes. No 
unexpected methylation occurred in the Gnasxl exon region of the paternal 
alleles of the different genotypes. Given more time it would have been 
preferable to improve the Southern blot analysis and perhaps analyse the 
methylation using a more quantitative method (e.g. qPCR).  
As there is no alteration in the methylation that could have been caused 
by the insertion of the gene trap, it is likely that inserting the gene trap in the 
position of exon A20 disrupted or deleted an important regulatory element, 
such as an enhancer. This would account for the reduced expression levels that 
are seen in both the Cre/+; +/XLlacZGT mice expressing the XL-βGal fusion 
protein and in the mice carrying the inactive gene trap (KRECHOWEC et al. 2012). 
A new gene trap mouse line is in development in the laboratory. The 
gene trap uses td-tomato red fluorescent protein as the reporter instead of lacZ. 
The gene trap has been inserted further into the Gnasxl intron in a non-
conserved region. This should not interfere with any enhancer elements that 
might be present around the exons. 
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CHAPTER 7. EXPLORATION OF POSSIBLE XL S 
INVOLVEMENT IN NEUROPEPTIDE SIGNALLING IN THE 
BRAIN 
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7.1. INTRODUCTION 
7.1.1. HYPOTHALAMIC REGULATION OF ENERGY HOMEOSTASIS  
The hypothalamus is an important centre for food intake regulation and 
energy metabolism as previously discussed in Chapter 4. In this region of the 
brain there are many signalling neuropeptides that have been implicated in the 
control of energy homeostasis. These fall into one of two categories. Firstly, 
orexigenic peptides – those that increase food intake – and secondly, 
anorexigenic peptides – those that decrease food intake. Their effects on energy 
expenditure can differ regardless of their effects on food intake. Adult 
Gnasxlm+/p- mice have increased energy expenditure as well as increased food 
intake (an unusual combination), as it is normal that neuropeptides which 
increase food intake would reduce energy expenditure – although this is not 
always the case. Gnasxlm+/p- mice also have an increased leptin-sensitivity 
(Frontera et al. in prep) and insulin-sensitivity (XIE et al. 2006). These aspects of 
signalling are controlled (partially) in the hypothalamus and thus it was 
important to establish which pathways might be affected by the lack of XLαs. 
7.1.2. OREXIN AND MELANIN-CONCENTRATING HORMONE INTERACT IN THE LH 
AND DMH TO REGULATE ENERGY HOMEOSTASIS 
Orexin is an orexigenic peptide found in the LH and DMH. It is derived 
from the precursor pre-pro-orexin, a 130-residue polypeptide (SAKURAI et al. 
1998). A product of a gene on mouse chromosome 2, the pre-pro-orexin amino 
acid sequence is conserved between species – human 83% identity to rat, 
mouse 95% identity to rat – with most of the differences between the sequences 
occurring in the C-terminal part of the precursor (DE LECEA et al. 1998; SAKURAI et 
al. 1998). This pre-pro-orexin gives rise to two separate peptides, orexin A and 
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orexin B, which show a large similarity to secretin (DE LECEA et al. 1998). 
Functional orexin appears in embryonic development and by the day of birth 
there are low levels expressed in the hypothalamus, reaching maximum 
expression by day 20 after birth (VAN DEN POL et al. 2001). 
Orexin A is 33 amino acids in length and is C-terminally amidated. This 
molecule is highly conserved between species with bovine, rat, mouse and 
human orexin A being identical (SAKURAI et al. 1998). Orexin B is a 28 amino acid 
peptide, which is 46% identical to orexin A. Although this molecule is conserved 
between mouse and rat (DE LECEA et al. 1998; SAKURAI et al. 1998) there are two 
amino acid substitutes in the human form compared to the rodent form (SAKURAI 
et al. 1998). It also induces a transient increase in intracellular calcium in 
CHO/OX1R cells in a dose dependent manner (DE LECEA et al. 1998; SAKURAI et al. 
1998). 
Two receptors have been discovered that can bind orexins: orexin 
receptor 1 (OX1R) and orexin receptor 2 (OX2R). These two G-protein-coupled 
receptors (GPCR) were discovered to have 64% identity and are more similar to 
each other than any other receptor (NAMBU et al. 1999; SAKURAI et al. 1998). 
They are conserved between species and are strongly expressed at neonatal 
stages. However, expression decreases towards adulthood (NAMBU et al. 1999; 
SAKURAI et al. 1998; VAN DEN POL et al. 2001).  
Medium-sized orexin neurons constitute one of two types of neurons 
located in the LH of the brain (ABIZAID et al. 2006; DE LECEA et al. 1998; SAKURAI et 
al. 1998; VAN DEN POL et al. 2001). Immunofluorescence has shown that orexin is 
found in the cytoplasm of neurons (SAKURAI et al. 1998). When orexin A is 
applied to the LH there is a three-fold increase in food consumption within one 
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hour (SAKURAI et al. 1998; VAN DEN POL et al. 2001). These data suggest that 
orexins play some role in feeding regulation. Neurons in other areas of the brain 
involved in energy homeostasis do not express either isoform of orexin (DE 
LECEA et al. 1998; SAKURAI et al. 1998). However, orexin axons have a far-
reaching effect with projections to the LDTg, NTS, the PVN, LC and the posterior 
hypothalamus (DE LECEA et al. 1998; NAMBU et al. 1999; VAN DEN POL et al. 2001). 
Withholding food for 48 hours results in a 2.4-fold increase in the production of 
pre-pro-orexin mRNA showing that orexin expression is responsive to 
nutritional status (SAKURAI et al. 1998). 
In human patients with narcolepsy, a disorder that causes excessive 
drowsiness and sleep attacks, there is a deficiency of orexin. These patients 
have a decreased food intake but their BMI increases (SAKURAI 2007). It was also 
discovered that mice lacking orexin were hypophagic and developed late onset 
obesity due to decreased energy expenditure (SAKURAI 2007). There is a dense 
projection of orexin neurons to the Arc where orexins might act on NPY neurons 
while inhibiting POMC neurons in the same region (SAKURAI 2007). Reciprocal 
connections have also been observed indicated by NPY receptors being 
expressed in orexin-positive neurons (STANLEY et al. 2005). It is possible that 
orexins act upstream of the NPY system to regulate feeding behaviour and 
energy metabolism (ABIZAID et al. 2006). Decreases in food intake occur when 
anti-orexin A antibodies or OX1R-selective antagonists are administered ICV 
(HAYNES et al. 2000; YAMADA et al. 2000) and when mice lack orexin (HARA et al. 
2001; WILLIE et al. 2001). Administration of an OX1R–selective antagonist 
decreases food intake in ob/ob leptin-deficient mice (HAYNES et al. 2002). 
Chronic administration of orexin A does not result in any change in body weight 
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(YAMANAKA et al. 1999).  
It is essential that animals remain alert during the time they must spend 
searching for food and orexin seems to be an important factor in this response. 
If there is a scarcity of food then there is usually an increased “awake” period in 
order to facilitate further food searching. If orexin is not present then mice do 
not have this response (SAKURAI 2007). It has also been observed that orexins 
promote and maintain food anticipatory activity (FAA) (SAKURAI 2007). Food can 
be restricted to a specific period, when mice do not normally feed. This results 
in c-fos (a marker for neuronal activity) expression in orexin neurons during the 
restricted period when food was available rather than when the mice normally 
feed. Hence orexin neurons are active at the time when food is available and not 
when mice normally feed. This change in neuronal activation is not present in 
mice lacking orexin (SAKURAI 2007). Projections occur from neurons in the SCh 
to neurons which stimulate orexin,  indicating an indirect role for orexin in 
circadian feeding behaviours (SAKURAI 2007). It may also provide a link between 
obesity and insomnia (ABIZAID et al. 2006). 
Orexin stimulates sympathetic outflow which could be a reason for the 
increase in BMI in the orexin-ablated mice (SAKURAI 2007). It is possible that a 
decrease in orexin may produce decreased sympathetic tone and a decrease in 
energy expenditure (SAKURAI 2007). Food-seeking behaviours are known to be 
reinstated when ventral tegmental area infusions of orexin are administered 
(SAKURAI 2007).  
ICV administration of orexin A strongly activates the CRH-expressing 
neurons in the limbic system, specifically in the central amygdala, and it would 
appear that there is a reciprocal activation (SAKURAI 2007). GABA, glucose, 5-HT, 
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NA and leptin are all known to inhibit orexin neurons while many peripheral 
humoral factors related to metabolism also influence them (SAKURAI 2007; 
STANLEY et al. 2005). Studies have also shown that orexin neurons are sensitive 
to the nutritional state of the body (BERTHOUD 2004; SAKURAI et al. 1998; 
YAMANAKA et al. 2003). In narcoleptic dogs it has been observed that food 
perception results in cataplexy (a sudden relaxation of muscle tone, often 
associated with an emotional state). This suggests that orexin is essential for the 
proper perception of food and some inadequacy in this system results in 
cataplexy (SAKURAI 2007). Orexin has been found to increase synaptic activity by 
increasing presynaptic release of glutamate and GABA (VAN DEN POL et al. 1998; 
VAN DEN POL et al. 2001). It has been established that orexin-expressing neurons 
act upon MCH neurons depolarising them and increasing synaptic transmission 
to these neurons (VAN DEN POL et al. 2004).  
MCH is a 19 amino acid cyclic neuropeptide (BITTENCOURT et al. 1992) 
expressed primarily in the LH and ZI of the brain and derived from the pmch 
gene. These neurons are confined to a separate population than those 
expressing orexin. It has been shown to increase food intake and decrease 
energy expenditure (COLL et al. 2007; FUNATO et al. 2009; SHIMADA et al. 1998). 
MCH-expressing neurons have projections to many areas of the brain important 
for integration of nutrient-sensing and feeding behaviour. This makes their 
placement in the LH ideal for their signalling involvement in feeding regulation 
and energy expenditure (BITTENCOURT et al. 1992). MCH neurons have also been 
shown to partially co-express CART in the LH (F. BRISCHOUX 2001). 
MCH-deficient mice have reduced body weight and are hypophagic 
despite having decreased plasma leptin levels and POMC mRNA,  as well as 
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having an increased metabolism  similar to the Gnasxlm+/p- mouse line (SHIMADA 
et al. 1998; XIE et al. 2006). Crosses of MCH knock-out mice with the leptin-
deficient ob/ob obese mice produced less obese ob/ob offspring. This suggests 
that MCH has some opposing effect to leptin working downstream of leptin to 
regulate energy expenditure plus locomotor activity, and plays a significant role 
in the maintenance of energy balance (SEGAL-LIEBERMAN et al. 2003). MCH has 
also been found to depress the synaptic activity of its target cells (glutamate and 
GABA neurons) in rat hypothalamus (GAO and VAN DEN POL 2001). 
MCH1R has been identified as a GPCR (originally discovered as an 
orphan GPCR and was named SLC-1 or GPR24) (LEMBO et al. 1999). MCH1R 
mRNA is localised to many areas of the brain, which also express XLαs including 
the Arc, Amy and DMH (SAITO et al. 2001). The MCH receptor 1 (MCH1R) knock-
out might have more relevance to the Gnasxlm+/p- as they display a lean, 
hyperactive and hyperphagic phenotype more similar to the phenotype 
observed for the Gnasxlm+/p- mice (CHEN et al. 2002; MARSH et al. 2002; XIE et al. 
2006).  
7.1.3. CORTICOTROPIN-RELEASING HORMONE 
CRH is a 41 amino-acid peptide. It is well described that CRH is located in 
the important SNS outflow centre, the PVN. CRH can also be found in the 
cerebral cortex, cerebellum and amygdalo-hippocampal complex (BITTENCOURT 
et al. 1999; SWANSON et al. 1983). It has other functions beside SNS mediation 
including neuroendocrine, autonomic and behavioural responses to stress as 
well as in controlling energy homeostasis. CRH has been shown to stimulate 
energy expenditure through BAT and reduce food intake (RICHARD et al. 2000). 
This neuropeptide has two known receptors: CRHR1 and CRHR2 (PERRIN 
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and VALE 1999). These are both GPCRs (DAUTZENBERG and HAUGER 2002) which 
are known to couple the Gs  subunit for signalling (DAUTZENBERG et al. 2000). 
This Gs  coupling is involved in the Ca2+ transduction mediated by CRH 
receptors (BISHOP et al. 2000; CHALMERS et al. 1996; GUTKNECHT et al. 2009).  
A deficiency of CRH is often related to neurodegenerative disorders such 
as Alzheimer’s, Parkinson’s and Huntingdon’s (BEHAN et al. 1995; DE SOUZA 
1995). If the opposite is induced (CRH is elevated) this has been associated with 
major depression (ARBORELIUS et al. 1999; MITCHELL 1998). CRH has also been 
implicated in eating disorders like anorexia nervosa.   
7.1.4. CATECHOLAMINES IN THE HYPOTHALAMUS 
Catecholamines are important neurotransmitters in the brain. XLαs is 
expressed in many regions of the brain which are catecholaminergic including 
the LC, the main noradrenergic centre in the brain. Tyrosine hydroxylase (TH) is 
the enzyme important in the production of catecholamines. It converts L-
tyrosine to L-dihydroxyphenylanine (DOPA) using tetrahydrobiopterin as a co-
enzyme and is the rate-limiting step in the production of noradrenaline and 
adrenaline. TH is found in the cytoplasm of catecholamine expressing cells 
(Figure 7.1).  
Dopamine plays a role in food intake control as well as locomotion and 
emotional behaviours. Dopamine’s control of energy homoeostasis is likely to be 
due to projections to the hypothalamus. Deficiency of the dopamine D2 receptor 
results in lean mice with decreased food intake. They have reduced plasma 
leptin with increased leptin sensitivity (KIM et al. 2010). It is thought that D2 
receptors might have a role in the control of food intake by controlling 
signalling to the arcuate nucleus through leptin signalling (KIM et al. 2010).  
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Figure 7.1. The production of Catecholamines. 
L-Tyrosine is converted to L-DOPA by tyrosine hydroxylase (TH). L-DOPA is then converted to dopamine 
by DOPA decarboxylase. Dopamine is converted to norepinephrine this in turn is converted to 
epinephrine by phenethanolamine N-methyltransferase. 
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7.1.5. LEPTIN AND INSULIN SIGNALLING IN THE HYPOTHALAMUS 
Leptin is secreted by adipocytes as a measure of adiposity and it is 
relayed to the brain to control food intake accordingly. The main centre for 
control of food intake and energy metabolism is in the hypothalamus. Here, the 
many signals that regulate energy homeostasis are integrated to regulate energy 
expenditure and food intake according to nutrient signals relayed from the 
peripheral tissues (i.e. the gut and adipose tissue). Leptin is known to increase 
energy expenditure and decrease food intake (CAMPFIELD et al. 1995; HALAAS et 
al. 1995; PELLEYMOUNTER et al. 1995; STEPHENS et al. 1995). Concurring with this 
finding, leptin-deficient ob/ob mice are obese and develop diabetes mellitus 
type 2 (INGALLS et al. 1950; ZHANG et al. 1994). The same effects are observed in 
mice (and humans) deficient in leptin receptor (LepR) (CLÉMENT et al. 1998; 
TARTAGLIA et al. 1995; ZHANG et al. 1994).  Leptin has also been associated with 
other metabolic processes in bone homeostasis, reproduction, mood and 
emotions (BLÜHER and MANTZOROS 2007; KARSENTY 2006; LAM and LU 2007; LU 
2007).  
Gnasxlm+/p- mice have decreased plasma insulin and leptin as well as 
being insulin-sensitive (XIE et al. 2006) and leptin-sensitive (Frontera et al. in 
prep). Weight-reducing properties of leptin result from its inhibitory effect on 
orexigenic NPY/AgRP-expressing neurons in the Arc and its stimulatory effect 
on anorexigenic POMC neurons, reducing food intake and increasing energy 
expenditure (ELIAS et al. 1999). The leptin knock-out mouse line (ob/ob) or the 
knock-out of the leptin receptor (db/db) are obese and have poor fertility 
(HUMMEL et al. 1966; INGALLS et al. 1950). These mice have activated NPY/AgRP 
neurons that inhibit POMC neurons, which results in increased food intake and 
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decreased energy expenditure (ELIAS et al. 1999). In the Arc there are different 
populations of neurons of interest. The orexigenic NPY/AgRP neurons and the 
anorexigenic pro-opiomelanocortin (POMC) neurons are known to have 
opposing effects on controlling energy metabolism through leptin signalling 
(HAHN et al. 1998). Leptin stimulates POMC neurons resulting in a decrease in 
food intake and an increase in energy expenditure while producing an 
inhibitory effect on NPY/AgRP neurons (ELIAS et al. 1999). When leptin 
signalling is reduced these NPY/AgRP neurons are no longer inhibited by leptin, 
food intake is increased and energy expenditure is decreased (ELIAS et al. 1999). 
These neurons have inhibitory projections to POMC neurons, further reducing 
the restrictions on food intake (Figure 7.2). Both of these groups of neurons in 
the Arc have projections that exert their respective effects on MCH and orexin 
neurons in the LH (ELIAS et al. 1999).  
POMC is the precursor for -melanin-stimulating hormone ( -MSH). This 
activates melanocortin-3 and melanocortin-4 receptors (MC3R and MC4R). 
Deleting either of these receptors results in obesity and leptin resistance, whilst 
deletion of both results in an obesity phenotype more severe than their 
individual deletions (CHEN et al. 2000).    
AgRP neurons release -aminobutyric acid (GABA). This release inhibits 
the neuronal activity of POMC neurons in the Arc (Figure 7.2) (COWLEY et al. 
2001). Conversely, increased leptin inhibits the release of GABA from AgRP 
neurons and thus the inhibition of POMC neurons by AgRP is reduced (ELIAS et 
al. 1999).  
When LepRs are restored in the Arc of LepR-deficient mice both 
hyperphagia and obesity are corrected (WALL et al. 2001). This indicates 
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Figure 7.2. Schematic of the integration of nutrient sensing signals in the hypothalamus.  
Leptin released from white adipose tissue inhibits neuropeptide Y expressing neurons which 
increase food intake and decrease energy expenditure and stimulates POMC neurons which 
decrease food intake and increase energy expenditure. NPY neurons inhibit POMC neurons by the 
release of GABA. NPY and POMC neurons have opposing effects on CRH in the PVN and on orexin 
and MCH in the DMH. 
Green arrows indicate a stimulatory pathway. Red arrows indicate inhibitory pathway. 
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that neurons in this nucleus are essential for correct leptin signalling controlling 
food intake. LepR is not only expressed in the Arc but in many other regions of 
the brain including the PVH, DMH, LH and NTS (MORRIS AND RUI 2009).There is 
evidence that LepR in these different areas might act in parallel or 
synergistically (DONATO et al. 2011). It has been found that leptin and insulin act 
in parallel in anorexigenic POMC neurons to activate the PI3K pathway. 
However, in AgRP neurons these two molecules have opposing effects (XU et al. 
2005). This implies that these two populations have different mechanisms for 
the mediation of these signals in the Arc (XU et al. 2005).  
The mTOR-S6K pathway is essential for appropriate nutrient sensing in 
the hypothalamus (COTA et al. 2006; MORRIS and RUI 2009). mTOR signalling 
relevant to metabolism is known to occur in POMC and NPY/AgRP neurons in 
the Arc (COTA et al. 2006).  This pathway is activated through signalling via the 
insulin receptor substrate (IRS). Both insulin and leptin are able to act via IRS, 
insulin directly and leptin in a triple complex with JAK2 and SH2B (Figure 7.3) 
(DUAN et al. 2004a; MORRIS and RUI 2009). SH2B is a ubiquitously expressed 
protein found in the cytoplasm of cells. It contains a pleckstrin homology (PH) 
and a src-homology-2 (SH2) domain along with many phosphorylation sites 
(RUI et al. 1997). SH2B has been shown to bind IRS and JAK2 at the same time 
resulting in leptin-stimulated PI3K signalling in cultured cells (DUAN et al. 
2004a). Mice lacking SH2B (SH2B-/-) have insulin resistance, glucose 
intolerance, leptin resistance, hyperphagia and obesity (DUAN et al. 2004b; REN 
et al. 2005). They also have increased energy expenditure gaining less weight 
than pair-fed wild type littermates despite hyperphagia, suggesting SH2B is 
involved in the control of both food intake and energy expenditure but could
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Figure 7.3. Schematic of insulin and leptin receptor signalling via the mTOR-S6K1 pathway.  
Binding of insulin to the insulin receptor (InsR) results in activation of the insulin receptor substrate 
(IRS). This in turn activates the PI3K pathway, forming PIP3 activating PDK1 and Akt. Akt is an inhibitor 
of the tuberous sclerosis (TSC) protein 1/2 complex which in turn is an inhibitor of the mTORC1 complex. 
mTORC1 activates S6K1, resulting in the production of active S6 and the inhibition of IRS. This 
desensitises the receptor signalling and can cause insulin resistance. 
It is also possible for leptin to activate this pathway. Leptin binds to the leptin receptor (LepR) this can 
activate IRS by the formation of a triple complex of Janus kinase 2 (JAK2), SH2B and IRS which can be 
bound by the leptin receptor and results in the activation of the PI3K pathway which continues as above. 
It is possible for AMPK to stimulate the TSC complex which results in the inhibition of the mTOR-S6K 
pathway. 
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regulate them via separate neuronal pathways (REN et al. 2005).  Interestingly, 
neuron-specific restoration of SH2B improves hyperphagia and reduces energy 
expenditure (REN et al. 2007). 
Binding of IRS results in signalling via the mTOR-S6K1 pathway, after 
activation of the PI3K-Akt pathway. The activation of Akt results in the 
inhibition of the TSC1/TSC2 complex. This removes the inhibition that the 
TSC1/TSC2 complex imposes on mTOR and allows the activation of mTOR and 
S6K1. S6K1 is a major physiological substrate of mTOR in the hypothalamus 
(Figure 7.3) (CHENG et al. 2002). The activation of S6K1 results in a negative 
feedback loop onto IRS. This inhibits the whole pathway (Figure 7.3) (POLAK and 
HALL 2009). S6K1 activation produces active ribosomal protein S6 (rpS6) 
(Figure 7.3). This is a good histological marker for activation of the mTOR-S6K1 
pathway.  
Interestingly, the S6K1 knock-out mice are small with increased food 
intake, lypolysis, energy expenditure and insulin sensitivity with reduced body 
weight and adiposity, which is similar to the metabolic phenotype of the 
Gnasxlm+/p- mice (SHIMA et al. 1998; UM et al. 2004; XIE et al. 2006).  
The leptin-mediated activation of mTOR signalling has important 
implications for weight management. It has also been shown that leptin induces 
a time- and dose-dependent phosphorylation of S6K1 in macrophages (MAYA-
MONTEIRO et al. 2008).  
7.1.6. GABAERGIC SIGNALLING IN THE HYPOTHALAMUS 
GABAA neurons are central to the control of feeding behaviours (MIÑANO 
et al. 1992). It is thought that there are two opposing GABA-sensitive feeding 
centres that are present in the hypothalamus. If muscimol, the GABAA receptor 
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selective agonist, is applied to the medial nucleus of the hypothalamus then 
feeding is stimulated. However, if the same is applied to the lateral region of the 
hypothalamus then feeding is suppressed (MIÑANO et al. 1992).  
Glutamate decarboxylase 67 kDa (Gad67) is a catalyst for the conversion 
of glutamate to GABA. Many GABA-expressing neurons act upon other neurons 
in an inhibitory manner (WATANABE et al. 2002). NPY neurons inhibit POMC 
through GABA release (Figure 7.2). XLαs has been shown to colocalise with NPY 
but not POMC neurons (Frontera et al. in prep).  
A recent mouse line showed a very similar expression pattern of the 
vesicular GABA transporter (VGAT) in the brain to that of the Gnasxl expression 
identified in Chapter 4 (VONG et al. 2011). 
7.1.7. GHRELIN  
Ghrelin is a hunger hormone that is produced in the stomach and signals 
via the vagal nerve to the NTS (COLL et al. 2007). Its signalling increases food 
intake (COLL et al. 2007). Analysis of plasma from Gnasxlm+/p- mice has shown 
that there is a two-fold increase in plasma ghrelin in these mice (KRECHOWEC et 
al. 2012). This evidence supports another observation that injections of ghrelin 
in Gnasxlm+/p- mice produce a blunted response (i.e. a smaller increase in 
feeding) compared to wild type counterparts (Frontera et al. in prep).  
It was discovered that ghrelin is the substrate for the previously known 
growth hormone secretagogue receptor (GHSR) (KOJIMA and KANGAWA 2008). 
There are ghrelin receptors on neurons in the Arc as well as in the brain stem. 
By binding to GHSR, ghrelin initiates a cascade of events culminating in the 
phosphorylation of AMPK (pAMPKα) which results is the inactivation of ACC 
(pACC) and thus a decreased production of malonlyl CoA which increases fatty 
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acid oxidation (Figure 7.4). AMPK is an activator of the TSC1/TSC2 complex 
which inhibits the mTOR-S6K1 pathway (Figure 7.3) (LAGE et al. 2008).  
7.1.8. AIMS  
The aim of this work was to investigate which pathways might be affected by 
the loss of XLαs. Pathways involved in the control of energy homeostasis were 
of particular interest, including the orexigenic peptides and pathways mediated 
by ghrelin and leptin signalling. This was analysed by immunofluorescence, 
immunohistochemistry and Western blotting. 
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Figure 7.4. Ghrelin’s Activation of AMPK. 
Binding of ghrelin to the G-protein coupled growth hormone secretagogue receptor (GHSR) results in a 
cascade of events which finally results in the phosphorylation and activation of AMPK (pAMPK). This 
activation in turn results in the phosphorylation and inactivation of acetyl coenzyme A (ACC). The 
inactivation of ACC stops the conversion acetyl CoA into Malonyl CoA. A decrease in malonyl CoA results 
in the increased oxidation of cellular fatty acids. 
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7.2 MATERIALS AND METHODS 
7.2.1. MICE AND TISSUE COLLECTION 
Brains were collected from adult wild type and Gnasxlm+/p- mice. Tissues 
were collected and sectioned as in Chapter 4 for histology. Tissues to be used for 
Western blot analysis were collected by schedule one procedure, dissected out 
and frozen at -80°C until required for protein lysate preparation. 
7.2.2 ANTIBODIES 
7.2.2.1. Immunohistochemistry 
The following primary antibodies were used: goat anti-XLαs (M14) 
(Santa Cruz; sc-18993; 1:200) and rabbit anti-MCH (Phoenix Pharmaceuticals; 
H-070-47; 1:500). Secondary antibodies used were: Vectastain Elite biotin-
conjugated rabbit anti-goat (Vector laboratories; PK6105; 1:200), Vectastain 
Elite biotin-conjugated goat anti-rabbit (Vector laboratories; PK6101; 1:200), 
AffiniPure™ goat anti-rabbit HRP-conjugated (Jackson ImmunoResearch 
Laboratories; 703-035-155; 1:1000) and Affinipure  donkey anti-goat Biotin 
conjugated (Jackson ImmunoResearch Laboratories; 705-065-147; 1:3000). 
7.2.2.2. Immunofluorescence 
The following primary antibodies were used: goat anti-XLαs (M14) 
(Santa Cruz; sc-18993; 1:200), rabbit anti-βGalactosidase (Cappel; 55976; 
1:2000), rabbit anti-orexin A (Phoenix Pharmaceuticals; H-003-30; 1:500), 
rabbit anti-TH (Millipore; AB152; 1:200), rabbit anti-DBH (Santa Cruz; sc-
15318; 1:100) and rabbit anti-pS6 (Cell Signalling Technology; #2211; 1:200). 
The following secondary antibodies were used: DAPI (Invitrogen; 1:1000), 
donkey anti-rabbit AF594 (Invitrogen; A21207; 1:1000) and donkey anti-goat 
AF488 (Invitrogen; A11055; 1:1000).  
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7.2.2.3. Primary antibodies tested and found to be unspecific in histology 
Primary antibodies tested and found to be non-specific or that produced 
no staining included: rabbit anti-CRH (Abcam; ab8901), rabbit anti-CRH 
(Phoenix Pharmaceuticals; H-019-06) and rabbit anti-CRH (Lifespan 
Biosciences; LS-C50244). 
7.2.2.4. Western blotting 
Primary antibody concentrations used were: rabbit anti-pAMPKα (Cell 
Signaling Technology; #4188; 1:2000), rabbit anti-AMPKα (Cell Signaling 
Technology; #2603; 1:1000), rabbit anti-pACC (Cell Signaling Technology; 
1:1000), rabbit anti-ACC (Cell Signaling Technology; #3662; 1:1000), 
monoclonal rabbit anti-pS6 (Cell Signalling Technology; #2211; 1:1000), 
monoclonal rabbit anti-S6 (Cell Signaling Technology; #2217; 1:1000), goat 
anti-XLαs (M14) (Santa Cruz; sc-18993; 1:500) and rabbit anti-GAPDH (Santa 
Cruz; sc-25778; 1:2000). Secondary antibodies were used in the following 
dilutions: AffiniPure™ donkey anti-goat horse radish peroxidase-(HRP-) 
conjugated (Jackson ImmunoResearch Laboratories; 703-035-147; 1:5000), 
AffiniPure™ goat anti-rabbit HRP-conjugated (Jackson ImmunoResearch 
Laboratories; 703-035-155; 1:10000). 
7.2.3. IMMUNOHISTOCHEMISTRY DOUBLE STAINING 
IHC was performed for XLαs as in the protocol described in Chapter 3. 
However, after incubation with the first colour substrate and washes, a 20 
minute post-fix step with 4% PFA was applied, and the staining procedure was 
repeated as above using a different colour substrate (DAB without nickel 
chloride).  
7.2.4. FLUORESCENCE ANALYSIS 
Neuronal fluorescence intensity data for pS6 were analysed using ImageJ 
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software (RASBAND 1997-2011) on epifluorescence images. Individual cells were 
encircled. Their pixel intensity was measured and corrected for background 
intensity of the image from an average of nine 16 μm x 16 μm squares (100 x 
100 pixels). Analysis of colocalisation was collected live on the epifluorescence 
microscope. Individual cells were deemed to be XLαs positive if they showed 
clear plasma membrane-associated staining. Staining of axons and punctuate 
non-specific staining were not included in cell counts. 
7.2.5. WESTERN BLOTTING 
7.2.5.1. Protein Lysate preparation 
Individual hypothalami were homogenized and sonicated in 400 μL RIPA 
lysis buffer containing protease inhibitor cocktail (Sigma), PMSF (Sigma) and 
PhoSTOP (Roche). The first two inhibit the ability of proteases to break down 
proteins, and the latter protects against de-phosphorylation of proteins. 
Sonication disrupts the high molecular weight DNA. These samples were kept 
on ice then spun down for 10 minutes at 12000 g. Lysate supernatants were 
split into 100 μL aliquots and kept at -80°C allowing samples to be used for 
many experiments without fear of repeated freeze and thaw cycles damaging 
the proteins of interest. Protein concentration was determined using a Pierce® 
BCA Protein Assay kit (Thermo Scientific; 23227) following the manufacturer’s 
directions.  
7.2.5.2. Protein concentration analysis with Pierce® BCA Protein Assay kit 
BSA protein standards were diluted from stocks provided with the kit 
and according to the manufacturer’s instructions. Protein samples were diluted 
1:10, then 100 μL of each sample and standard were pipetted into separate test 
tubes. Standards and samples were analysed in duplicate. To each test tube 2 
mL working reagent was added and then incubated at 37°C for 30 minutes. The 
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tubes were allowed to cool to room temperature and then the OD562 measured 
for each. Average absorbencies of duplicate BSA standards produced a standard 
curve of protein concentration for the analysis. Protein lysate samples were 
compared to the standard curve and then the original 1:10 dilution was 
accounted for.  
7.2.5.3. PAGE GELS 
Gel cassettes (Sigma) were assembled and a resolving gel (see buffer list 
for composition) was poured into the cassette. The gel was overlayed with 
isobutanol and allowed to polymerise for 30 minutes. Polymerisation of the 
acrylamide was tested by checking that left over acrylamide had set in a 15 mL 
falcon. After polymerisation of this gel was complete the isobutanol was 
discarded and the gel front rinsed with ddH2O. The gel front was dried carefully 
and the stacking gel (see buffer list for composition) was poured into the 
cassette, the comb inserted and the gel polymerised for 30 minutes. 20 µg of 
each lysate was mixed 1:1 with 2x Lamelli protein loading buffer (National 
Diagnostics) in a small volume, heat denatured for 3 minutes then loaded into 
the acrylamide gel along with a broad spectrum protein ladder (Fermentas). 
Any spare lanes were loaded with 1 x Lamelli protein loading buffer. The gel 
cassette was placed in the electrophoresis tank containing Tris-glycine running 
buffer and run at 10 mA through stacking gel then at 15 mA through the 
resolving gel until the bromphenol blue dye reached the bottom of the gel. It 
was important to keep the current constant to ensure expected migration of 
ions through the gel. The gel was removed from the glass plates and soaked for 
10 minutes in transfer buffer ready to be placed in the blotting sandwich. Other 
components of the blot sandwich were prepared. Firstly, the sponge was soaked 
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in transfer buffer until any air bubbles trapped in it were removed. Then the 
Amersham Hybond™-P PVDF membrane (GE Healthcare) was soaked in MeOH 
for 10 seconds. The membrane was then soaked in ddH2O for 5 minutes and in 
transfer buffer for 10 minutes. The Whatman-type™ 3MM filter paper was 
soaked for 20 minutes in transfer buffer. These components were layered onto 
the Western blot sandwich cassette, ensuring removal of any air bubbles 
between layers as they would disrupt transfer. Next the sponge was positioned 
in the cassette, then the gel (highest molecular weight bands towards the 
hinges), followed by the PVDF membrane and finally the filter paper. The 
cassette could then be folded over, clamped shut and placed into the transfer 
chamber with pre-cooled transfer buffer.  This was allowed to equilibrate for 10 
minutes with the magnetic stirrer before running the transfer at 30 V, 75 mA 
overnight. Transfer to the membrane was determined by checking for either the 
transfer of the coloured protein ladder to the membrane or by Ponceau staining.  
7.2.5.4. Ponceau Staining:  
To check that the transfer of the protein to the membrane had worked 
efficiently the membrane was submerged in Ponceau S solution for 5 minutes, 
destained in ddH2O for 2 minutes then visualised. To completely destain the 
membrane for probing with antibodies it was washed in fresh ddH2O for a 
further 10 minutes or until the red Ponceau S staining had disappeared.  
7.2.5.5. Membrane Detection of Proteins:  
Membranes were blocked with blocking solution (5% non-fat dried milk 
powder; 0.1% Tween20; TBS) for 1 hour at room temperature. They were then 
incubated with primary antibodies diluted in blocking solution overnight at 4°C. 
Membranes were washed four times for 10 minutes in TTBS and incubated with 
secondary antibodies diluted in blocking solution before being washed four 
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times with TTBS and incubated with Amersham™ ECL Plus Western Blotting 
Detection System (GE Healthcare), and exposed to film (Kodak). Films were 
developed in the dark and transferred through developer solution (Sigma) for 1 
minute until bands of interest appeared, washed briefly in water and fixed for 1 
minute in fixative solution (Sigma). Films were air-dried and stored at room 
temperature.  
7.2.6. STATISTICAL ANALYSIS 
pS6 intensity levels and Western blot data were analysed using ImageJ. 
Statistical tests were performed using MINITAB™ software. For pS6 
fluorescence intensity data as well as Western blot analysis of pAMPKα, pACC 
and pS6, Student’s t-tests were applied to the data. Cell counts for pS6 in the Arc 
were analysed by the non-parametric Wilcoxon matched-pairs signed-ranks 
test.  
  
Chapter 7. XLαs and Neuropeptide pathways  
183 
7.3. RESULTS 
7.3.1. XLαS LOCALISATION IN THE LATERAL AND DORSOMEDIAL HYPOTHALAMIC 
AREAS  
In the LH/DMH region of the brain are neurons expressing the orexigenic 
peptides orexin A and MCH. This area highly expresses XLαs as shown in 
Chapter 4. To assess the localisation of XLαs in comparison to orexin A, serial 14 
μm, cryostat sections covering the entirety of the LH/DMH region of the brain 
were analysed in three rounds of staining (a total of 18 sections) to gain a 
representative overview of colocalisation for the two brains analysed. The data 
from sections across the whole area were pooled for each round of staining to 
achieve an average cell count for each individual. The percentage of colocalised 
cells was determined by dividing the number of colocalised cells by the number 
of orexin A positive cells or XLαs positive cells and standard error of the mean 
(SEM) was calculated. 23% of orexin A positive neurons in the DMH and LH 
coexpressed XLαs (n=2; 23.1  5.22 %; Figure 7.5). 12 % of XLαs positive 
neurons also expressed orexin A (n=2; 11.7  0.79 %; Figure 7.5).  
A second population of neurons in the LH/DMH region of the 
hypothalamus, which is positive for MCH and separate from orexin A, did not 
express XLαs (Figure 7.6). Immunohistochemistry staining clearly indicated 
singly stained cells for each protein with no overlap of the two populations. 
7.3.2. DOPAMINERGIC A12 NEURONS IN THE ARC CO-EXPRESS XLαS  
There are dopaminergic neuron populations in the Arc (A12 group) and 
the ZI (A13 group), in the hypothalamic region of the brain. Both of these 
regions also express XLαs as shown in Chapter 4. To identify if the dopaminergic 
neurons are coexpressed with XLαs-expressing neurons in these areas 
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Figure 7.5. Immunofluorescence analysis of XLαs coexpression with orexin A in the lateral and 
dorsomedial hypothalami of adult wild type mice 
(A) XLαs in the LH and DMH of adult wild type mice. This shows clear plasma membrane bound 
expression of this alternative G-protein alpha subunit. There is also clear fluorescent labelling of axonal 
projections from these neurons and throughout the tissue. An AF488-conjugated secondary antibody 
was used.  
(B) Orexin A in the LH and DMH of adult wild type mice show that this food intake stimulating 
neuropeptide is located in the cytoplasm of neurons in these regions. An AF594-conjugated secondary 
antibody was used.   
(C) A merge of the XLαs (green) and orexin A (red) images in (A) and (B) indicate that there is some 
colocalisation of the two proteins in this area. Nuclei are labelled with DAPI.    
(D) Graphical representation of percentage colocalisation of orexin A positive neurons that also express 
XLαs (n=2; 23  5.22 %) and XLαs positive neurons that also express orexin A (n=2; 12  0.79 %). Cells 
expressing XLαs and/or orexin A were counted on an epifluorescence microscope.  
White arrows indicate a double-labelled XLαs/orexin A labelled neuron, red arrows indicate an orexin A 
labelled neuron without XLαs and green arrows indicate a XLαs labelled neurons not expressing orexin 
A. Sections 14 μm; scale bars 20 μm. 
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Figure 7.6. MCH localisation in the lateral and dorsomedial hypothalami does not overlap with 
XLαs staining in these areas. 
(A) Double immunohistochemistry staining to analyse XLαs (purple) and MCH (brown) localisation in 
the LH and DMH indicates that the two proteins are expressed in different populations of neurons in 
these regions of the hypothalamus. 
Sections 14 μm; scale bar 20 μm.  
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immunofluorescence was performed. TH is known to mediate the first step in 
the production of dopamine, norepinephrine and epinephrine. A TH antibody 
would only indicate that the neurons are catecholaminergic, thus it was 
necessary to determine if the neurons were dopaminergic or noradrenergic. 
DBH is an enzyme further down the adrenaline production pathway (Figure 7.1) 
and an antibody against this was used to distinguish between the types of 
neurons expressing XLαs in the Arc. 
TH-expressing neurons showed some colocalisation with XLαs-positive 
neurons in the Arc. Interestingly colocalisation was confined to the A12 neurons 
in this region of the hypothalamus. Areas positive for TH in the dorsal regions 
(A13 population) were singly stained for TH (Figure 7.7). Arc colocalisation of 
TH-positive neurons also expressing XLαs was ~65% (n=2; 65  17.2 %; Figure 
7.7), while XLαs expressing neurons were also positive for TH in ~41% of 
counted cells (n=2; 41  10.9 %; Figure 7.7).  
  Immunofluorescence staining in serial sections across the Arc indicated 
that the TH positive neurons seen in the A12/Arc region could only be defined 
as dopaminergic due to the lack of DBH positive neurons (Figure 7.8 A-C). 
Specificity of the second DBH antibody was tested in the LC, an area known to 
be noradrenergic, which clearly contained positive staining for DBH (Figure 7.8 
D and E).  
7.3.3. XLαS DOES NOT COLOCALISE WITH CRH IN THE PVN 
In the PVN – a nucleus important for sympathetic outflow – CRH is 
expressed in many neurons. Initially double antibody staining was attempted, 
with IF and IHC. The antibodies available for CRH were found to be non-specific 
(see methods for tested antibodies). A double staining for CRH and XLαs was 
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Figure 7.7. XLαs colocalisation with Tyrosine Hydroxylase (TH) in the Arc in adult wild type tissue 
(A) Overview of XLαs and TH double staining in the hypothalamus. TH is observed in the Arc colocalised 
with XLαs (A12 neurons) but is not colocalised with XLαs in the A13 dopaminergic neurons of the ZI and 
XLαs stains the LH and DMH without TH. 
(B) Staining of XLαs in the Arc of adult wild type mice show clear plasma membrane bound expression of 
this alternative G-protein alpha subunit. There is also clear fluorescent labelling of axonal projections from 
these cells. An AF488-conjugated secondary antibody was used.  
(C) Staining of TH in the Arc of adult wild type mice shows that the neuropeptide is located in the 
cytoplasm of neurons in this area. An AF594-conjugated secondary antibody was used.   
(D) A merge of the XLαs and TH images in (B) and (C) indicate that there is some colocalisation of the two 
proteins in this area. Nuclei are labelled with DAPI.  
(E) Graphical representation of percentage colocalisation of TH positive neurons that also express XLαs 
(n=2 mice; 65  17.2%) and XLαs positive neurons that also express TH (n=2 mice; 41  10.9%) as counted 
on an epifluorescent microscope. 
The white arrow indicates a double-labelled XLαs/TH area/neuron; the red arrow indicates a TH-labelled 
area without XLαs expression and the green arrow indicates an XLαs-labelled area/neuron not expressing 
TH. Sections 14 μm; (A) scale bar 200 μm; (B-D) scale bars 20 μm. 
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Figure 7.8. XLαs expressing neurons in the Arc do not co-express the norepinephrine marker, DBH 
(A) XLαs expression in the Arc shows clear plasma membrane-bound staining of this alternative G-
protein alpha subunit.  
(B) DBH staining in the Arc. There is no clear staining that differs from background staining, indicating 
that they are dopaminergic not noradrenergic neurons in this region of the hypothalamus. 
(C) Merged image of XLαs (A) and DBH (B) localisation in the Arc, there is no coexpression of XLαs and 
DBH in these cells. 
(D) High magnification image of control DBH staining in the LC. 
(E) Overview control staining of DBH in the LC shows the antibody is specific. There is no staining in 
other areas of the pons. 
(A-D) Sections 14 μm thick; scale bars 20 μm 
(E) Sections 14 µm thick; Scale bar 100 µm  
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attempted with an in situ hybridisation (ISH) for CRH mRNA, followed by an IHC 
staining for XLαs protein. Primers specific for CRH were used in RT-PCR to 
create a CRH specific cDNA. This was cloned into pSuperscript II SK plasmid 
using a ligation reaction. The plasmid was linearised and used in an in vitro 
transcription reaction to create a DIG-labelled RNA probe.   This approach again 
proved unsuccessful. The ISH protocol detected the CRH mRNA in the PVN. 
Although the anti-XLαs antibody required a short heated antigen retrieval step, 
it was not possible to detect the XLαs protein after the overnight high 
temperature steps of the ISH protocol. In order to determine whether CRH 
might colocalise with XLαs in the PVN, ISH and IF protocols were carried out on 
adjacent sections from adult brain tissue. By staining separately for CRH and 
XLαs in this way it was possible to see that CRH positive cells were located in 
the centre of the PVN (Figure 7.9), while XLαs expressing cells were located 
around the periphery of the nucleus (Figure 7.9). This indicated that the XLαs 
was unlikely to co-localise with CRH in this region. 
7.3.4. ANALYSIS OF mTOR-S6K ACTIVITY IN THE ARC IN GNASXLM+/P- AND WILD 
TYPE SIBLING MICE 
The mTOR-S6K pathway is important in insulin and leptin signalling. Its 
negative feedback loop onto IRS would result in sensitivity to both leptin and 
insulin. To assess changes in the mTOR-S6K pathway in the adult mouse Arc 
three aspects were investigated: colocalisation, pS6 positive cell number and 
pS6 fluorescence intensity. Colocalisation and cell number/fluorescence data 
were collected separately. 
To assess colocalisation, two adult wild type mouse brains were 
cryosectioned at 14 M and assessed for colocalisation of pS6 (a histological 
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Figure 7.9. XLαs and CRH are located in different populations of neurons in the 
Paraventricular nucleus of the hypothalamus. 
(A) In situ hybridisation probe for CRH in the paraventricular nucleus of the hypothalamus showing 
localisation to the central part of this nucleus. 
(B) Immunofluorescence staining of XLαs in the peripheral neurons of the paraventricular nucleus 
of the hypothalamus, suggesting that XLαs and CRH do not colocalise in this nucleus of the brain. 
Scale bars 200 μm; 14 μm sections 
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marker for mTOR-S6K activity) with XLαs. Analysis was carried out in three 
rounds of staining with pS6 and XLαs antibodies, on a range of serial cryostat 
sections across the Arc (18 sections). Data were pooled as for previous co-
staining experiments and an average gained for each mouse. These pooled data 
were used in analysis allowing an overview to be obtained of the colocalisation 
across the entire nucleus. pS6 was found to colocalise with XLαs in the Arc. 
Approximately 19% of pS6 neurons expressed XLαs (n=2; 19  7.4 %; Figure 
7.10) and ~32% of XLαs neurons were also pS6 positive (n=2; 32  8.9 %; 
Figure 7.10).  
Analysis of cell number and fluorescence intensity of pS6-positive cells in 
the Arc was carried out in six wild type and six Gnasxlm+/p- mice. These were 
assessed as pairs of littermates that were perfused on the same day at 
approximately three months old. 14 μm cryostat brain sections from littermate 
pairs were stained simultaneously and images were taken at the same time to 
avoid differences in degradation in fluorescent secondaries over time.  
pS6-positive cell number assessment in six wild type/Gnasxlm+/p- 
littermate pairs of mice indicated a decrease in the number of pS6-positive cells 
in Gnasxlm+/p- mice compared to their wild type siblings (n=6 per genotype; 
p=0.036; Figure 7.11). 
Analysis of the fluorescence intensity of individual neurons in the Arc 
indicated there was no change in the pS6 protein expression level in neurons 
between wild type and Gnasxlm+/p- mice (n=6 per genotype; p=0.156; Figure 
7.11), although a trend towards lower fluorescence intensity in the Arc of 
Gnasxlm+/p- mice was recognisable.  
Analysis of whole hypothalamus protein lysates, using Western blotting 
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  Figure 7.10. XLαs colocalisation with pS6 in the Arc of adult wild type mice 
(A) XLαs in the Arc of adult wild type mice again shows clear plasma membrane bound expression of 
this alternative G-protein alpha subunit in this region. An AF488-conjugated secondary antibody was 
used to label these neurons.  
(B) pS6 in the Arc in adult wild type mice show that this ribosomal protein is located in the 
cytoplasm of neurons in this area. An AF594-conjugated secondary antibody was used to label these 
neurons.   
(C) A merge of the XLαs and pS6 images indicate that there is some colocalisation of the two proteins 
in this area. Nuclei are labelled with DAPI (blue).  
(D) Graphical representation of percentage colocalisation of pS6 positive neurons that also express 
XLαs (n=2; 19  7.4%) and XLαs positive neurons that also express pS6 (n=2; 32  8.9%). 
White arrows indicate an XLαs/pS6 double-labelled neuron, red arrows indicate a pS6-labelled 
neuron without XLαs expression and green arrows indicate a XLαs-labelled neurons not expressing 
pS6. Sections 14 μm, scale bars 20 μm, magnification x400. 
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Figure 7.11. Comparison of pS6 expression in wild type and Gnasxlm+/p- mice 
(A) Representative image of adult wild type expression of pS6 in the Arc. Mice used in this staining 
were approximately 2 months old. 
(B) Representative image of pS6 in the Arc of Gnasxlm+/p- mice. This mouse was an littermate of the 
wild type in (A). They were stained at the same time for pS6 and imaged on the same day. 
(C) Graphical representation of pS6-positive neuron number in wild type and Gnasxlm+/p- mice. Data 
was analysed from sibling pairs. There were significantly less neurons expressing pS6 in Gnasxlm+/p- 
mice compared to their wild type siblings (n=6; p=0.036).  
(D) Graphical representation of fluorescent intensity of pS6 in wild type and Gnasxlm+/p- mice. Data 
was analysed from sibling pairings but was not significantly different (n= 6; p=0.157).  
(A) and (B) Scale bar 20 μm; 14 μm section. 
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for pS6 in wild type and Gnasxlm+/p- mice, revealed no significant difference in 
phosphorylation levels between genotypes (n=6 WT; n=8 Gnasxlm+/p-; p=0.54; 
Figure 7.12). This could be due to the dilution of any changes in pS6 expression 
in specific areas of the hypothalamus (e.g. Arc) due to the use of whole 
hypothalamus lysates. 
7.3.5. MARKERS FOR GHRELIN SIGNALLING DO NOT APPEAR TO CHANGE IN 
GNASXLM+/P- MICE. 
The AMPK signalling pathway is an indicator of the activity in the ghrelin 
pathway. As plasma ghrelin was increased in Gnasxlm+/p- mice it was thought 
that perhaps an increase in ghrelin would result in an increase in AMPK activity 
and that it might be a cause of the increased food intake observed in Gnasxlm+/p- 
mice. Hypothalamic lysates from six wild type and eight Gnasxlm+/p- mice were 
prepared for protein detection by western blotting. pAMPKα was analysed in 
the context of the increased plasma ghrelin detected in the Gnasxlm+/p- mice   
(n=6 WT; n=8 KO; p=0.98; Figure 7.13) and as a second enzyme in the ghrelin 
pathway pACC (n=4 WT; n=5 KO; p=0.82; Figure 7.14) – these again proved to 
be non-significant between genotypes. Any changes seen would indicate the 
disregulation of the AMPK pathway and ghrelin signalling (LAGE et al. 2008). 
Again, similar to the pS6 data, the lack of significance of the data might be due to 
the whole hypothalamus lysate diluting the changes of AMPK and ACC in a 
specific region of the hypothalamus. 
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Figure 7.12. pS6/ S6 relative expression analysis by Western blot 
(A)Western blots of phosphorylated S6 (pS6) were compared to total S6 (S6) from hypothalamic 
lysates of wild type (WT) and Gnasxlm+/p- (KO) littermate pairs. The membrane was probed for pS6 
then stripped and reprobed with a total S6 antibody and then stripped again to probe for GAPDH. 
GAPDH was used as a house-keeper to have a second loading control. Mice were collected at 2 months 
of age for tissue extraction. 
(B) Graphical representation of the quantitative analysis of the western blots showing no significant 
difference between the phosphorylated and total S6. Students t-test p=0.54. 
WT n=6; KO n=8 
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Figure 7.13. pAMPKα/AMPK relative expression analysis 
(A)Western blots of phosphorylated AMPK (pAMPKα) were compared to total AMPK  (AMPK) from 
hypothalamic lysates from wild type (WT) and Gnasxlm+/p- (KO) age-matched sibling pairs. Mice were 
collected at 2 months of age for tissue extraction. GAPDH was used as a house-keeper to have a second 
loading control. Membranes were initially probed using an anti-pAMPKα antibody. These were then 
stripped and reprobed using an anti-total AMPK  antibody. GAPDH could be probed separately as there 
is large difference in the size of the GAPDH and AMPK proteins 
(B) Graphical representation of the quantitative data analysed from the western blots showing no 
significant difference between the phosphorylated and total AMPK. Students t-test p=0.98. 
WT n=6; KO n=8 
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Figure 7.14. pACC/ACC relative expression. 
(A) Western blots of phosphorylated ACC (pACC) were compared to total ACC (ACC) from hypothalamic 
lysates from wild type (WT) and Gnasxlm+/p- (KO) littermate pairs. Mice were collected at 2 months of age 
for tissue extraction. The house-keeper protein GAPDH was used as a second loading control for samples. 
(B) Graphical representation of the data analysed from the western blots showing no significant 
difference between the phosphorylated and total ACC. Students t-test p=0.82. 
WT n=4; KO n=5 
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7.4. DISCUSSION 
7.4.1. XLΑS IN OREXIGENIC PEPTIDE-EXPRESSING NEURONS 
XLαs was found to co-express in a proportion of orexin A-positive 
neurons in the DMH. Orexin A, a peptide that increases energy expenditure and 
food intake, is also known to be involved in sleep and wakefulness (SAKURAI 
2007; SAKURAI et al. 1998). If XLαs acts as an inhibitor of neuronal activity in 
these cells, then removal of XLαs in the Gnasxlm+/p- mice might cause an over-
activity in these orexin cells, which could give rise to the increased food intake 
and energy expenditure that is seen in these mice (FUNATO et al. 2009; XIE et al. 
2006). It is also possible that orexin, when disinhibited in these colocalised cells, 
is in part responsible for the increased energy expenditure in the XLαs-deficient 
mice.  It would be interesting to investigate whether there is any change in the 
orexin expression in Gnasxlm+/p- mice with immunohistochemistry. Given that 
MCH and orexin have opposing effects on energy expenditure, it is unsurprising 
that XLαs is only found in one population.   
7.4.2. CATECHOLAMINERGIC COLOCALISATION WITH XLΑS 
XLαs expression pattern overlaps with TH in a very specific way in the 
brain. XLαs is found in the LC (a noradrenergic nucleus) in the pons, where TH 
is highly expressed, but not in the substantia nigra or the ventral tegmental area 
(dopaminergic nuclei). The colocalisation in the hypothalamus was limited to 
the A12 dopaminergic neurons in the Arc with no colocalisation present in the 
A13 dopaminergic neurons. The A12 neurons are important for the production 
of prolactin from the pituitary gland (PHELPS 2004). 
A D2-knock-out mouse line is hypermetabolic and lean, similar to the 
phenotype in Gnasxlm+/p- mice. They are also leptin sensitive. It is possible that 
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the dopamine-D2 receptors might play a role in controlling food intake in the 
arcuate nucleus through the control of leptin signalling (KIM et al. 2010). 
7.4.3. MTOR-S6K PATHWAY   
Gnasxlm+/p- mice exhibit a metabolic phenotype similar to that of a fasting 
state (hypoglycaemia, hypoinsulinaemia; hypoleptinaemia) and it has been 
shown that the mTOR-S6K pathway has reduced activity in mice under fasting 
conditions. The Gnasxlm+/p- mice also exhibit increased insulin and leptin 
sensitivity (Frontera et al. in prep) (XIE et al. 2006). mTOR-S6K negative 
feedback can desensitise the PI3K-Akt signalling pathway by inhibiting IRS with 
possible effects on hormone resistance (Figure 7.3).  
The similarity between XLαs and S6K1 knock-out is interesting. These 
mouse models are both lean, hypermetabolic, and have increased food intake, 
lypolysis and insulin sensitivity (SHIMA et al. 1998; UM et al. 2004; XIE et al. 
2006). It would be interesting to see if the loss or reduction of pS6-positive 
neurons specifically occurs in the neurons that have lost XLαs in the Gnasxlm+/p- 
mice.  This could not be achieved with the current conditional knock-out due to 
the decreased expression levels of the XL-βGal fusion protein in the Arc, but it 
might be possible with the new targeting construct that is being prepared to 
create a new mouse line. 
The full role of the mTOR-S6K pathway in the XLαs-deficient mice has yet 
to be elucidated. It is possible that alterations in this pathway may be a 
secondary factor, caused by the metabolic phenotype which is the result of some 
other disregulation from the ablation of XLαs. In order to confirm the reduction 
in expression of pS6 in the arcuate nucleus it would be necessary to perform 
Western blots on lysates created specifically from the Arc. 
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7.4.4. PHOSPHORYLATED PROTEIN CHANGES MIGHT BE MASKED IN WHOLE 
HYPOTHALAMIC LYSATES 
The use of whole hypothalamic lysates for western blotting of S6, AMPK 
and ACC might be a reason for the lack of difference between wild type and 
Gnasxlm+/p- phosphorylated proteins. If there was a difference in a specific 
region of the hypothalamus, for example the Arc, but no difference in other 
regions, this might mask the difference in the small Arc region. This could be 
overcome by having a more specific dissection of the hypothalamic tissue. There 
is reason to believe that there would be a difference because the pS6 analysis by 
IF revealed a lower number of cells in the Gnasxlm+/p- mice compared to their 
wild type siblings.  
It is also possible that the increased plasma ghrelin, previously observed 
(KRECHOWEC et al. 2012), might be a secondary effect of the leanness described 
in the Gnasxlm+/p- mice (XIE et al. 2006). 
In order to fully analyse the changes in the arcuate nucleus of the 
hypothalamus it would be necessary to perform dissection of specific areas of 
the hypothalamus and use lysates from these to analyse the relative levels of 
expression of AMPK and ACC.  
7.4.5. ANTIBODY SPECIFICITY PROBLEMS 
The specificity of antibodies is a problem that has been repeatedly 
encountered during these analyses. MCH1R, GHSR and Gad67 as well as the CRH 
antibodies that were purchased were found to be unspecific. The Gad67 
antibody has now been replaced and this analysis is ongoing. The CRH problem 
with antibodies was overcome by using in situ hybridisation. It was not possible 
to perform co-localisation with XLαs and CRH but the individual ISH and IF 
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stainings for CRH and XLαs, respectively, indicated that the two did not 
colocalise. It might be an option to use double IF-ISH in cases where antibodies 
are not specific.  
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8.1. FINAL SUMMARY OF RESULTS 
8.1.1. EXON A20 SPLICING IN GNASXL TRANSCRIPTS 
Data collected for alternative splicing of Gnasxl transcripts revealed that 
in the XLN1 truncated protein the exon A20 is regularly spliced into the protein 
and Exon 3 is always spliced. In the full-length XLαs protein exon A20 was 
rarely detected. It was also found that inclusion of the exon A20 in splicing 
resulted in a frame-shift with a premature stop-codon in mice. This concurred 
with data that had previously described human splicing (HAYWARD et al. 1998a). 
8.1.2. XLΑS EXPRESSION PATTERN CHANGES FROM NEONATAL AND ADULT 
STAGES 
Changes in the expression pattern of XLαs between neonatal and adult 
phases of development were observed using wild type and Cre/+; +/XLlacZGT 
mice (Table 4.1). The orofacial motor nuclei had a reduced expression of 
XLαs/XL- Gal towards adulthood, however the LDTg could not be detected with 
XGal staining or immunohistochemistry in adults. The changes observed in the 
orofacial motor nuclei and the LDTg could explain the neonatal-specific 
phenotype of lethargy and reduced suckling. The expression in skeletal muscles, 
which was confined to neonatal stages, could also be a contributing factor to the 
lethargic phenotype in Gnasxlm+/p- neonatal mice that is recovered in adults 
when muscle expression is no longer observed.  
8.1.3. MAINTAINED AND EXPANDED XLΑS EXPRESSION IN THE BRAIN 
The XLαs expression pattern, which is maintained from neonatal to adult 
phases of development, was in areas relevant for food intake (LH/DMH, Arc, 
PVN). These areas are unlikely to contribute to the suckling phenotype of the 
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neonates since hypothalamic circuits only become fully functional during the 
late postnatal period. The phenotype of poor suckling also persists beyond day 4 
when the hypothalamic nuclei strongly express XLαs in neonates (KRECHOWEC et 
al. 2012). 
8.1.4. MUSCLE EXPRESSION OF GNASXL IS OBSERVED IN NEONATAL TISSUE BUT 
NOT ADULT 
Blood vessel staining was found in many tissues, which had previously 
been associated with Gnasxl expression by Northern blotting (PLAGGE et al. 
2004), including the heart, stomach and BAT. This expression was confined to 
alpha smooth muscle actin-expressing cells and was lost in adult tissue. 
Muscle expression of XLαs varied. The neonatal tongue contained strong 
XLαs expression which was completely lost in adult mice. Other muscle staining 
in intercostal muscles were also strongly stained in neonates while limb skeletal 
muscle had weaker expression (KRECHOWEC et al. 2012). In both cases 
expression was lost in adults. The loss of XLαs expression in muscle tissue could 
contribute to the poor suckling ability of neonatal Gnasxlm+/p- mice as well as the 
lethargy which has been observed (CATTANACH and KIRK 1985). 
8.1.5. GNASXL EXPRESSION IS MAINTAINED IN TISSUES DERIVED FROM NEURAL 
TISSUE 
In the intermediate layer of the pituitary gland and in the adrenal 
medulla Gnasxl expression was found in both neonates and adults, confirming 
previous data (PLAGGE et al. 2004). These layers are derived from neural tissue 
and are considered to be part of the SNS. Both are important for secretion of 
hormones. This expression is unlikely to contribute to the changing phenotype 
between neonatal and adult stages of development as it is maintained 
Chapter 8. Final Results and Discussion 
205 
throughout life. 
8.1.6. POSSIBLE IMPLICATIONS OF GNASXL REMOVAL IN SIGNALLING PATHWAYS 
INVOLVED IN ENERGY HOMEOSTASIS 
XLαs was found to partially co-express with orexigenic peptides in the 
hypothalamus (orexin A). This concurred with the NPY co-expression with XLαs 
in other work (Frontera et al. in prep). XLαs did not appear to co-localise with 
either CRH or MCH. Other antibodies for markers of energy homeostasis in the 
hypothalamus were not specific and this work is being continued in the 
laboratory to further analyse markers in the brain, including Gad67, which is of 
particular interest following recent reports showing that GABA has an 
expression pattern similar to XLαs (VONG et al. 2011).  
The partial colocalisation of pS6 with XLαs in the Arc of wild type mice, 
along with the reduced number of pS6-expressing cells in the Arc of Gnasxlm+/p- 
mice suggest a role of the mTOR-S6K pathway in the Gnasxlm+/p- phenotype. The 
similarity of the S6K1-deficient mouse line, which is lean and hypermetabolic, to 
the Gnasxlm+/p- supports this suggestion (UM et al. 2004). 
The involvement of this pathway in leptin and insulin signalling could be 
a possible cause of the leptin and insulin sensitivity observed in the XLαs-
deficient mice (Frontera et al. in prep; (XIE et al. 2006)). 
The increased plasma ghrelin levels (KRECHOWEC et al. 2012) prompted 
an investigation into the pathways ghrelin might influence. AMPK and ACC are 
under the influence of this system. No changes were observed but this might be 
due to whole hypothalamic lysates masking any differences which could be 
occurring in specific regions of the hypothalamus, such as the Arc. This could be 
further investigated by using punch dissection of specific regions or by laser 
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dissection, both of which are difficult to perform in the mouse brain. 
8.1.7. METHYLATION ANALYSIS 
Analysis of the expression levels of Gnasxl in the genotypes produced 
from the Cre crosses with the XLlacZGT mouse line showed that mice containing 
the inactive gene trap had an unexpected reduction in Gnasxl expression, 
leaving only 10% of normal full-length expression (KRECHOWEC et al. 2012). This 
could not be attributed to a change in methylation over the Gnasxl promoter and 
first exon (Figure 1.2). It is possible that an unknown enhancer or other 
important expression element was deleted with the placement of the gene trap 
cassette.  
To address this problem a new gene trap construct has been developed. 
This will allow the testing of the specific deletion of XLαs in neuron populations 
(e.g. NPY/AgRP, POMC) and/or tissue types (e.g. muscle). 
8.2. SPECULATIVE DISCUSSION 
It is interesting that the facial muscles that control the mouth and tongue, 
and the areas of the brain which control these muscles (7N, 12N, Mo5) both 
express XLαs at the neonatal stage of development. All of these tissues lose their 
expression of XLαs in adult mice. 
Given that XLαs is expressed only from the paternal allele (being 
imprinted on the maternal allele) it would suggest that XLαs is important for the 
acquisition of nutrients from the mother during the period when the mother is 
the sole provider of resources. However, once the offspring are weaned and 
they no longer require resources from the mother it would appear that the 
expression of XLαs is lost in the aforementioned regions of the brain and the 
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muscles of the face. This is the time-point in development that the paternal 
genome would no longer need to influence nutrient acquisition. 
These data fit the idea of parental-conflict theory. It would be necessary 
to determine the exact time-point in development when XLαs expression is lost 
in these regions. This would require further histological analysis of the 
expression pattern of XLαs in brain and muscle tissue in pre-weaning mice at 
several time-points in development. 
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APPENDIX .1. OLIGONUCLEOTIDES 
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Oligo Name Sequence 
XL-FL1 5’-GGAAGCTGCTTCGGTCTATC-3’ 
XLN1-R6 5’-TCTAGTGGGGGTACTAGACT-3’ 
A20-F1 5’-AGCGACACTGAGGGTCGTTA-3’ 
Nesp2-F1 5’-GACTCCGTCCAGATTCTCCT-3’ 
Exon5-R1 5’-GTAGTCCACTCTGAACTT-3’ 
XL-F10 5’- GGAGCCAGGTCACTCTCAGC -3’ 
XL-R5 5’- CAGAAGCTGCCGCATTACCT-3’ 
XL DIG Probe-F1 5’- CGAGCAAGAACCTTTGGAAG-3’ 
XL Dig Probe-R1 5’-ATCCATTGCTTCAGGCTGG-3’ 
lacZ-F4 5’-TACGCCAATGTCGTTATCCA-3’ 
lacZ-R4 5’-GCGAATACCTGTTCCGTCAT-3’ 
Crh-F1A 5’-CCAAGGGAGGAGAAGAGAGC-3’ 
Crh-R1A 5’- AAGCGCAACATTTCATTTCC-3’ 
lacZ-R2 5’- TCGGGATAGTTTTCTTGC-3’ 
Cre-F1 5’- CATTTGGGCCAGCTAAACAT-3’ 
Cre-R1 5’- CCCGGCAAAACAGGTAGTTA-3’ 
 
Appendix Table 1. Oligonucleuotide primers used in PCR with their sequences 
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APPENDIX 2. CLONING VECTORS 
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PBLUESCRIPT SK  
 
  
Appendix Figure 1. pBluescript SK vector schematic.  
This indicates the layout of the pBluescript plasmid vector showing the resctriction sites and 
promoters. 
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pCR 2.1 CLONING VECTOR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Appendix Figure 2. pCRTOPO cloning vector 
The TOPO cloning vector used in the analysis of A20 alternative splicing. Showing at where the PCR product 
is inserted into the vector. This vector can only be sequenced in one direction using the T7.  
Appendices 
214 
APPENDIX 3. LOX VARIANTS 
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Appendix Table 2. Lox variants used in the production of the novel Gnasxl gene-targeting strategy 
in the XLlacZGT mouse line 
 
Lox Variant Sequence 
LoxP ATAACTTCGTATA GCATACAT TATACGAAGTTAT 
Lox2272 ATAACTTCGTATA GGATACTT TATACGAAGTTAT 
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APPENDIX 4. VECTASTAIN ELITE KIT STAINING PRINCIPLE 
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Appendix Figure 3.Vectastain  Process 
(A) The primary antibody is applied to the tissue section and binds to the antigen.  
(B) After the excess primary antibody is washed off the biotinylated secondary is applied to the tissue 
and incubated. The biotin on the secondary allows more than one avidin molecule to bind to the 
primary antibody in the next step 
(C) After the incubation with the secondary antibody and washing the avidin-biotin complex is applied 
to the tissue section. 
(D) Finally the DAB:Ni colour substrate is added to the section. 
A B 
C D 
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APPENDIX 5. RESTRICTION ENZYMES 
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Restriction Enzyme Cut Sequence 
NsiI ATGCA^T 
EagI C^GGCCG 
EcoRI G^AATTC 
EcoRV GAT^ATC 
 
Appendix Table 3. Restriction enzymes used in all experiments indicating cut recognition sequence. 
Underlining indicates sensitivity to CpG methylation. 
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APPENDIX 6. ABSTRACTS AND PUBLICATIONS FROM THIS 
WORK 
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PUBLICATIONS 
Krechowec, S. O., K. L. Burton, A. U. Newlaczyl, N. Nunn, N. Vlatkovic et al., 2012 
Postnatal changes in the expression pattern of the imprinted signalling protein 
XLalphas underlie the changing phenotype of deficient mice. PLoS ONE 
[Electronic Resource] 7: e29753 
 
POSTERS 
1. A. Plagge, K. Burton, S. Krechowec, N. Nunn, A. Newlaczyl, R. Barrett-Jolley. 
Postnatal changes in the expression pattern of Gnasxl correlate with 
changes in the phenotype of knock-out mice, hyperactivity of the 
sympathetic nervous system and elevated cardiovascular parameters. 
Barcelona Imprinting Conference (2011). 
2. A. Plagge, S. Krechowec, K. Burton, A. Newlaczyl, N. Nunn, R. Barrett-Jolley. 
Postnatal changes in the expression pattern of the genomically 
imprinted Gnasxl transcript underlie the KO phenotype of neonatal 
failure-to-thrive and adult sympathetic nervous system hyperactivity. 
GfG Conference (2011). 
3. K. Burton, S. Krechowec, A. Newlaczyl and A. Plagge. Expression pattern 
and signalling pathway alterations in the brain concur with the 
hypermetabolic phenotype of mice lacking Gnasxl/XLαs. First author 
and presenter of a poster at the Physiological society main meeting, Oxford 
(11-14 July 2011). 
4. K. Burton, N. Nunn, S. Krechowec, R. Barrett-Jolley and A. Plagge. 
Hypothalamic expression pattern and molecular and physiological 
markers indicate elevated sympathetic stimulation of metabolism in 
XL s-deficient mice. Co-Author and co-presenter of a poster presented at 
the Physiological Society meeting for Metabolism and Endocrinology (24-26 
March 2010). 
5. K.L. Burton and A. Plagge Comparative characterisation of Gnasxl (XLαs) 
expression in postnatal and adult mouse brain. EMBO World Workshop 
‘Genomic Imprinting’ Abstract and Poster (2008). 
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